










The handle http://hdl.handle.net/1887/20257 holds various files of this Leiden University 
dissertation. 
 
Author: Fredriksson, Lisa Emilia 
Title: TNFalpha-signaling in drug-induced liver injury 
Issue Date: 2012-12-06 

Stellingen
behorende bij het proefschrift
TNFα-signaling in drug-induced liver injury
1.	 Chemicals	that	show	strong	Nrf2	activation	as	well	as	a	perturbation	of	NF-κB	signaling	have	
a	significant	drug-cytokine	cytotoxic	synergy,	which	is	predictive	for	DILI	(this thesis).
2.	 Enhanced	 drug-induced	 translation	 processes	 initiate	 PERK-mediated	 CHOP	 signaling,	
thereby	sensitizing	towards	caspase-8-dependent	TNFα-induced	apoptosis	(this thesis).











7.	 The	 liver	 injury	 induced	 by	 drug/LPS	 co-exposure	 can	 be	 reproduced	 by	 substituting	
TNFα	administration	for	LPS,	which	supports	the	critical	importance	of	this	cytokine	in	the	
pathogenesis	(Shaw	et al,	Journal	of	Pharmacology	and	Experimental	Therapeutics,	2009).
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1Intracellular signaling in drug-induced liver injury





1. ADVERSE DRUG REACTIONS
Adverse drug reactions (ADRs) constitute an important issue both in clinic and for 
the drug-industry. 5% of the hospital admissions in Europe are due to adverse drug 
reactions and in 2008 this was estimated to cost the society a total of €79 billion (source: 
Annex 2 of the report on the impact assessment of strengthening and rationalizing EU 
Pharmacovigilance, 2008). 
 Some decades ago, the major reasons for drug attrition were based on poor 
pharmacokinetic and bioavailability. While these drug development problems were 
tackled, 10 years ago this had shifted towards increased issues with clinical safety and 
toxicology, which was the underlying reason for ~30% of the compound withdrawals (1). 
 The development of a new drug is estimated to cost about 1 billion dollars (2), 
the cost for the society is significant if adverse drug reactions lead to hospitalization and, 
even more importantly, the ADRs cause a lot of suffering for the individuals affected. 
Therefore it is of outmost importance to improve our understanding of the underlying 
mechanisms of adverse drug reactions and integrate this knowledge in pre-clinical safety 
testing strategies of new medicines. 
 The most common type of adverse drug reactions, and the most common cause 
of drug withdrawal is drug-induced liver injury (DILI) (3,4). Moreover, DILI is the leading 
cause of acute liver failure in the Unites States with paracetamol (acetaminophen) 
accounting for about 50% of those cases and other adverse drug reactions (mostly 
idiosyncratic; see below) accounting for another 10% (5). This thesis will focus on 
mechanisms of DILI. 
2. DRUG-INDUCED LIVER INJURY (DILI)
The reason why the liver is a critical target organ for adverse drug reactions is not 
surprising. The liver has the highest exposure to oxygen and nutrient rich blood, it is 
equipped with highest drug metabolizing capacity in the body to enhance excretion 
of xenobiotics. The first-pass effect ensures that the liver is the first organ exposed to 
anything that is ingested. 
 In addition to the drug metabolism capacity, the liver is an essential organ for 
clearance of circulating pathogens and products thereof. Thus, the liver contains the 
largest amount of resident macrophages (in the liver called Kupffer cells) and natural killer 
cells, which upon activation can produce large amounts of cytokines and chemokines (6) 
to activate the systemic immune systems. As a consequence the liver cells may also 
be exposed to not only toxic drug metabolites but also inflammatory cytokines, which 
potentially could act synergistically to increase the risk for the DILI. 
 DILI can roughly be classified into two types, intrinsic and idiosyncratic. Intrinsic 
DILI is generally dose-dependent, predictable and related to the pharmacological action 




a minority of the clinically associated DILIs is dose-dependent and predictable. In a 
pharmacological and toxicological context ‘’idiosyncratic’’ DILI (iDILI) means that the 
adverse reaction to a drug is particular to a certain individual, involving risk factors such 
as gender, age, concomitant disease and genetic background (4). In concrete terms 
this means that the adverse drug reaction in question is unexplainable, rare (about 1 in 
10,000-100,000 people who take the drug), occurring with variable times of onset and 
that it is typically non-related to the dose, although this can be discussed since drugs 
with a dosing of more than 50 mg/day is related to a higher incidence of iDILI (7-9). For 
the drug-industry iDILI is extremely difficult to foresee and prevent. The rarity and the 
unpredictability often lead to the adverse reactions only being recognized after the release 
of the drug to the market when many patients have been exposed. This commonly results 
in the withdrawal of the product or a restricted use. This causes both financial harm to the 
industry and unmet needs for patients that would otherwise benefit from this medication 
(7). Examples of drugs that induce iDILI are carbamazepine, diclofenac, ketoconazole 
and nefazodone (3,10). The mechanisms behind idiosyncratic DILI are incompletely 
understood but there are however, several hypotheses behind their incidence.
3. MECHANISTIC WORKING MODELS FOR IDILI
The formation of reactive intermediates during drug metabolism on the one hand and 
the activation of the immune system (innate and/or adaptive) on the other, are thought to 
represent the two most critical events in the pathogenesis of DILI (4,9,11). The hapten, 
danger and pharmacologic interaction (p-i) hypothesis has long been described as the 
primary working models for iDILI. These working models for iDILI will be discussed below 
also taking additional cellular stress responses and inflammatory stress conditions into 
consideration. 
3.1 Adaptive immunity – allergic hepatotoxicity
3.1.1 Hapten hypothesis
Small molecules with a mass of less than 1,000 daltons are unable to induce an immune 
response unless they are bound to macromolecules, including proteins. Landsteiner 
already proposed this in 1935 (12) and it forms the basis of the hapten hypothesis to 
describe the occurrence of iDILI. This hypothesis also has its foundation in the fact 
that some DILIs are presented with an allergic response including fever, rash and the 
presence of circulating autoantibodies (3). 
 In the context of DILI, reactive drug metabolites formed in the liver can bind to 
cellular proteins that can subsequently act as haptens causing initiation of an adaptive 
immune response. In a first exposure, the immune system recognizes such a hapten and 
becomes sensitized towards it. Upon re-challenge, the hapten-exposing tissue is attacked 




of target cells to for example reactive oxygen species (ROS), cytotoxic cytokines and 
proteases, thereby causing severe tissue damage (11).  A classical example is the allergic 
reaction to penicillin. The penicillin molecule contains a reactive group that can bind to 
proteins and in some patients this result in an immune response against the penicillin-
protein complex (11,13). 
 Idiosyncratic DILIs, such as the one caused by diclofenac and carbamazepine, 
have also been associated with T-cell activation and production of antibodies against 
drug-adducted proteins, which would support the role of haptenization and activation of 
the adaptive immune system in iDILI (11,14-16). As individuals may vary in the way they 
develop an adaptive immune response to a specific antigen this could explain the rarity 
of iDILI, and make the adaptive immune system an attractive target to understand iDILI.
3.1.2 P-i concept
The p-i concept (direct pharmacological interaction of drugs with immune receptors) is an 
alternative to the hapten hypothesis. According to this theory, iDILI is the result of a drug’s 
ability to stimulate the T-cell receptor without hapten-protein formation and subsequent 
antigen presentation by antigen presenting cells (APCs) (17). The p-i concept was first 
developed after the observation that T-cells from sulfamethoxazole-sensitive patients, 
recognized the drug itself and not a protein adducted by the drug (18). Nowadays more 
drugs have been associated with this hypothesis, including carbamazepine (19). In some 
cases, the immunological evidence can not be explained by drug metabolism and the 
hapten model (20). The p-i concept then favors a iDILI working model whereby drugs do 
not require drug metabolism followed by covalent modification of target proteins to cause 
an immune response. 
3.1.3 Danger hypothesis
The danger hypothesis is a modified version of the hapten hypothesis and it was first 
described by Matzinger in 1994 (21). It proposes that the major determinant whether 
an immune response is elicited against a drug or not is if this drug induces some type 
of cell damage by itself already (22). The fundamental step leading to an adaptive 
immune response is recognition by T-cells of processed antigens presented on the 
major histocompatibility complex (MHC; in humans human leukocyte antigen [HLA]) of 
APCs, for example macrophages. In addition to this first signal, a second one is needed 
for a fulminant immune response. If this is not presented, the result is tolerance to the 
presented antigen. 
 Activation of APCs leads to up-regulation of co-stimulatory molecules that would 
induce this second, activating signal. The activation of APCs can occur via several 
mechanisms but the most attractive one, in this context, is indeed that injured cells (by 
drugs and drug metabolites) provide the APCs a “danger signal”. This danger signal could 
include the secretion of heatshock proteins, the nuclear protein high mobility group box 
1 (HMGB1) and the calcium binding S100 proteins (23-25). However, other examples of 




infections, or secreted cytokines (26). This type of allergic hepatotoxicity is for example 
more common in HIV patients (27) and especially in patients with concomitant hepatitis 
B or C infection (28), which would further support the need for a danger signal in the 
induction of DILI as well as generally supporting the hypothesis that an activated immune 
system might affect the drug toxicity (9).
 Due to frequent exposure to circulating and absorbed antigens in the liver, and the 
large amount of immune cells present in this organ, adaptation is crucial to avoid a hyper-
activated immune system. Importantly, the response in the liver is usually adaptation 
(4,6). Yet, failure of an adaptation response could be another susceptibility factor for the 
development of iDILI. It is likely that cytokines play an important role in the balance of 
either promoting a tolerogenic or a pathogenic response to drug-protein adducts (26). 
3.2 Mitochondrial dysfunction hypothesis
The mitochondria can be the direct intracellular target of drug toxicity as well as the reason 
for patient susceptibility to DILI (29). Gradual accumulating mitochondrial damage could 
explain the temporal onset of iDILI; it might happen faster in certain individuals than in 
others due to genetic or acquired mitochondrial abnormalities (30). Moreover, mutations 
in mitochondrial DNA seem associated with DILI caused by certain drugs (9,29).
 As an example, superoxide dismutase (SOD2) is a protein that is located in 
the mitochondria where it plays a critical role in detoxifying superoxide anion radicals 
that are constantly being formed during electron transport in the respiratory chain, an 
essential step for cellular energy production. Heterozygous SOD2+/- mice exhibit a similar 
phenotype to susceptible humans in the sense that the “mutation” goes unnoticed until 
there is a drug exposure leading to mitochondrial damage by enhanced mitochondrial 
oxidative stress. Troglitazone-induced hepatotoxicity, which goes typically unnoticed in 
“normal” animal models, has been shown to involve mitochondrial damage in this mouse-
model and drug exposure led to a late onset of hepatic necrosis, mimicking a human iDILI 
process (31). 
 For mitochondria to get fatally damaged, certain thresholds need to be reached at 
multiple levels. For example inhibition of the different complexes in the electron transport 
chain needs to reach more than 50% to affect the ATP production, and about 60% of the 
mitochondrial DNA must be deleted before this has an overt effect (30). This is called 
the mitochondrial threshold effect and might also explain the lag time of iDILI since it will 
likely take a long time for the critical thresholds to be reached after drug exposure. The 
results obtained with the SOD+/- mice described above represents an interesting model 
for studying the role of the threshold effect in iDILI. 
3.3 Inflammatory stress hypothesis
Inflammatory infiltrates are common in patients suffering from iDILI. This raised the 




inflammation (32,33). Conditions associated with inflammation include arthritis, 
atherosclerosis, infection by bacteria and virus, immune responses to certain antigens 
etc.  However, activation of the innate immune response could also be elicited by 
apoptotic and necrotic hepatocytes and their release of so-called damage-associated 
molecular pattern molecules such as heat shock proteins (4), as described above in the 
section about the danger hypothesis, and thereby lead to inflammatory stress. 
 The underlying mechanism of sensitization to DILI by viral infections remains 
unknown. Possibly the mechanism includes activation of the innate immune system, 
whereby secreted cytokines and chemokines are important components of an anti-viral 
response (34). These cytokines might then modulate the extent of inflammation and, 
thereby, control the levels of injury (26).
  The balance between the secretion of protective cytokines like IL-6 and IL-10 
and injurious ones like TNFα, FasL, IL-1β and IFN-γ have also been implicated in the 
development of iDILI and genetic circumstances that could make the balance tip one way 
or the other could be detrimental (3,4). 
 Another source of innate immune system activation are bacterial endotoxins 
released from the intestines into the circulation. The magnitude of such endotoxin release 
may vary depending on different factors such as diet and alcohol consumption (33). This 
could also explain the random temporal onset of iDILI as well as the rare incidence. 
Animal models have been developed to simulate this scenario using the Gram-negative 
bacterial endotoxin lipopolysaccharide (LPS). Injection of LPS to animals in this model 
has rendered an otherwise non-toxic dose of a drug known to cause iDILI in humans, toxic 
(7). This LPS co-exposure model is also the first animal model to mimic the pronounced 
liver injury seen in patients with iDILI (7). Examples of drugs that have been used and 
proven toxic in such a model include diclofenac, amiodarone, sulindac and trovafloxacin 
(35-38). Importantly, the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) 
has been determined the most important mediator of the toxicities observed. Inhibition of 
TNFα transcription significantly reduced trovafloxacin/LPS induced liver injury indicating 
that the hepatotoxicity is largely TNFα dependent (38) and the same was shown for 
sulindac using a soluble TNFα-receptor  to inactivate the cytokine, etanercept (37), 
emphasizing the important role for cytokines and cytokine-induced signaling in iDILI.
3.4 Multiple-determinant hypothesis
The above hypotheses are not mutually exclusive.  It is more likely that they are all 
individual parts of a complex puzzle that provides a complete mechanistic understanding 
of human iDILI. A combination of many factors would support the sporadic occurrence of 
iDILI, and provide a condition whereby the risk of developing iDILI would be the product 
of all the different mechanistic risk factors taken together (3,34). As a summary of this 
we foresee an overall working model whereby the main susceptibility determinants for 
the development of iDILI include the biochemical properties of the drug, environmental 




 Potential genetic factors include for example polymorphisms in drug-metabolizing 
enzymes and mutations that determine sensitivity to mitochondrial damage and to 
inflammatory stresses. Environmental factors could include exposures to inducers of 
drug metabolism and viral/bacterial products (7). 
 Because of their rarity and unpredictability, iDILIs are thought to depend largely 
on genetic variation (9). The most apparent example is provided by the highly variable 
human leukocyte antigen (HLA) system. This plays a key role in delayed immune-mediated 
adverse drug reactions, including DILI, since it is involved in the T-cell recognition of the 
drug-induced antigen (9,39,40). For some reactions, for example abacavir hypersensitivity, 
one single gene locus (HLA-B*5701) can provide adequate predictive accuracy to allow 
the gene to be used in a clinical setting as a biomarker for the risk of idiosyncratic adverse 
drug reactions (41,42). A correlation with HLA polymorphism has also been found for 
more drugs, including the antibiotics amoxicillin-clavulanate and flucloxacillin (40). For 
most other drugs there are likely correlations between polymorphisms in single gene 
and specific adverse drug reactions. Yet, it seems more plausible that such individual 
gene polymorphism are insufficient to significantly increase the susceptibility for ADR, but 
rather would act in combination with other genes (43). 
4. INTRACELLULAR STRESS SIGNALING IN IDILI
Since both drug metabolism-dependent cell injury responses as well as immune-
mediated responses are critical components of iDILI, a cross-talk between drug-induced 
and cytokine-induced intracellular signaling events that enhances the drug-toxicity in 
certain individuals is likely to occur. In the following paragraphs these two responses and 
their cellular consequences will be described.
4.1 Drug-induced intracellular stress signaling
4.1.1 The role of drug-metabolism
Drugs are generally designed as hydrophobic molecules to allow proper absorption 
into the body after oral intake. Biotransformation reactions are essential to metabolize 
these molecules into more hydrophilic compounds that can easily be eliminated via the 
urine or the bile. Most of this xenobiotic metabolism occurs in the liver. The primary 
biotransformation of drugs involves the cytochrome P450 (CYP450) oxidase system, 
consisting of over 100 different family members (44). Typically, drug metabolism leads 
to their inactivation and ultimate elimination. But alternatively it leads to the formation 
of reactive moieties that can then covalently bind to cellular macromolecules, and as a 
consequence disturb the intracellular homeostasis or induce oxidative stress and thereby 
cause cellular damage (3,45).
 Drugs that are being metabolized have a significantly higher risk of causing iDILI 
(46) and the formation of harmful reactive metabolites is an anticipated main mechanism 




enzymes are related to increased incidence of this type of adverse drug reactions (9,48). 
Further support for biotransformation as a mechanism is based on the association of 
iDILI with dosages higher than 50 mg/day, which would result in higher absolute levels 
of metabolites formed than with a lower daily dosing. However, importantly, inability to 
metabolize can also lead to toxicity as this most likely leads to decreased elimination, and 
thereby the possibility for enhanced, toxic, levels of the parent drug (47).
 Not only oxidative metabolism by CYP450s has been shown to form reactive 
intermediates, but also conjugation reactions (phase II metabolism). Thus, acyl-
glucuronide formation has been linked to DILI (45,49). Diclofenac is a good example here 
since the acyl-glucuronides and not the CYP produced hydroxyl-metabolites are linked 
to diclofenac-induced iDILI (15,49). In addition, a genetic variant of the enzyme that 
produces the diclofenac acyl-glucuronide, uridine diphosphate glucuronosyl-transferase 
2B7 (UGT2B7), has been shown to significantly contribute to the risk of developing 
diclofenac-induced DILI (50).
 Many drugs are being metabolized into reactive species, however, clearly not 
all of them cause hepatotoxicity. The reason for this is the tight association between 
bioactivation and detoxifying enzyme systems. Examples of inactivation systems are 
glutathione S-transferases (GSTs) and their conjugation of glutathione (GSH) to reactive 
molecules as well as other reactive oxygen species (ROS) involved in downstream 
hepatotoxic mechanisms. Interestingly, double mutations in two relevant GSTs (GSTT1 
and GSTM1) have been linked to troglitazone hepatotoxicity in Japanese patients (51). In 
the case of reactive metabolite formation cytotoxicity will only occur when the (adaptive) 
detoxifying defense systems are saturated or fail (45). 
 Formation of protein adducts is implicated in the toxicity of many drugs including 
paracetamol. Moreover, protein adduct formation seems correlated with higher incidence 
of iDILI (52). If the adducts are formed on proteins critical for certain cellular functions 
and signaling pathways, it increases the likelihood of inhibiting/activating critical cellular 
functions eventually resulting in cytotoxicity (45,53). Additionally, if adduct formation 
occurs on proteins that are subsequently presented to the immune system, an adaptive 
immune response can be elicited (see above). However, protein adduction does not per 
se mean enhanced toxicity. A good example of this is the difference observed between 
paracetamol and its regioisomer 3’-hydroxyacetanilide (AMAP). Parecetamol is liver 
toxic while AMAP is not, but interestingly, both drugs cause similar levels of total cellular 
protein adduction. However, paracetamol causes mitochondrial protein adduct formation, 
while AMAP does not, which possibly explains their difference in toxicity (54). This 
underlines the critical requirement of gaining more mechanistic information about the 
exact cellular targets modified by covalent binding (45) and the resulting cellular injury 
such as mitochondrial damage or oxidative stress (4). Although, it might be tempting to 
completely abandon the chemical entities in (candidate) drugs that show covalent binding, 
this will not always offer a solution since some drugs, like penicillins and omeprazole, are 
dependent on covalent binding for their efficacy (45). 




fruitful in identifying the structures of reactive intermediates that are formed in the course 
of drug metabolism and their intrinsic potential to cause hepatotoxicity (55). In addition, 
identifying critical residues within proteins that become adducted and that leads to protein 
inactivation, as well as which proteins become adducted, adds another importance to 
these types of studies (45,56,57).
4.1.2 Mitochondrial damage
The role of mitochondria in hepatocellular death can be either direct by drug accumulation, 
inhibition of electron transport or depletion of antioxidant defense mechanisms, or indirect 
by the activation of different signaling pathway that affect the mitochondrial integrity and, 
thereby, the cell survival outcome (30). 
 Hepatocytes have many mitochondria that besides taking care of the energy 
supply of the cell ensuring cell survival, play a role in the control of cell death. Mitochondria 
are unique organelles involved in the control of both apoptosis and necrosis. For example 
high pH, pro-oxidants and activation of the pro-apoptotic Bcl-2 family member Bax can 
lead a so-called mitochondrial membrane permeability transition (mPT) (30). 
 The induction of mPT leads to loss of the transmembrane potential, which is 
essential for ATP production. Moreover, mPT makes the mitochondria release a large 
pool of mitochondrial free calcium resulting in cellular calcium-overload and related 
cytotoxicity (58). The direct toxic targeting of all mitochondria followed by the induction 
of mPT is in general believed to lead to necrosis as a result of loss of cellular energy. 
On the contrary, more subtle mitochondrial perturbation, as described in the following 
paragraph, would most likely favor apoptosis (3). 
 Selective permeabilization of the outer mitochondrial membrane, MOMP, is 
induced by translocation and binding of the two pro-apoptotic Bcl-2 family members 
Bax and Bak to the membrane pore, leading to the release of pro-apoptotic factors that 
are normally located in the inter-membrane space, such as cytochrome c, apoptosis-
inducing factor (AIF) and Smac/Diablo, (29,59-61). The release of cytochrome c from the 
mitochondrial inner membrane space leads to activation of pro-caspase-9 via formation 
of the so called apoptosome, which includes cytochrome c and apoptosis protease-
activating factor 1 (APAF1) (62). Caspase-9 subsequently activates the effector capase-3 
which cleaves several cytosolic and nuclear proteins to trigger apoptosis (63). Importantly, 
for the cell to undergo apoptosis the mitochondrial membrane potential needs to be 
retained thus ensuring enough energy for the active apoptotic process to proceed. The 
two factors that determine if the cell will undergo apoptosis or necrosis, is the amount of 
mitochondria affected and the extent of ATP depletion. 
 The integrity of the mitochondrial membrane is thus in large parts determined 
by the Bcl-2 family members. This family of proteins is composed of both pro- and anti-
apoptotic members, with the former group including the already introduced Bax and 
Bak, and the latter for example Bcl-2 itself and Bcl-xL. The anti-apoptotic Bcl-2 family 
members act by binding to the pro-apoptotic ones and thereby inhibiting the release of 




the control of life or death.
 Oxidant stress is a crucial regulator of mitochondria-mediated cell death. Under 
normal conditions the large amount of antioxidant systems in the mitochondria will 
prevent any damage, but if this protective system is compromised due to genetic defects 
or for example drug exposure, the cellular organelles and substructures will get damaged 
(29). Oxidant stress can also lead to damage of the mitochondrial DNA. Since this DNA 
encodes specific subunits of the electron transport chain, long term problems here may 
involve further increased production of ROS and additional cellular damage, thus causing 
a vicious cycle (29). In addition, mutations in mitochondrial DNA are not uncommon in 
the population, although this normally does not result in damage since there are so many 
mitochondria present in one cell. However, under particular stress conditions, as after 
drug exposure, this might change if the drug of interest also targets the mitochondria 
(29).
 Many hepatotoxic drugs, or the metabolites thereof, can interfere with the 
mitochondrial function (58) and this is also common with drugs associated with iDILI. 
Interestingly, in a study by Xu and colleagues (64), 50-60% of the 300 drugs associated 
with iDILI showed mitochondrial changes while 0-5% of the negative controls did 
not. Moreover, drugs like carbamazepine, known to cause iDILI, interferes with the 
mitochondrial respiration, mitochondrial membrane potential and ATP synthesis (10). 
Diclofenac on the other hand, is known to cause mitochondrial damage by for example 
the uncoupling of the oxidative phosphorylation and inhibition of complex I/III which leads 
to an increased mitochondrial-derived oxidative stress due to enhanced superoxide 
formation (29,65,66) 
 Mitochondrial inhibition is most likely not by itself the cause of cellular injury, 
however it might increase the susceptibility to other damaging factors. This includes for 
example depletion of the reduced glutathione (GSH) storage (34) or by stress kinases 
increased susceptibility of the mitochondria to induction of cell death (30). It is likely that 
underlying defects in mitochondrial function, possibly genetic, amplify the risk of iDILI 
development in certain susceptible individuals. 
4.1.3 Oxidative stress
Formation of reactive oxygen species (ROS) is one of the most commonly cited cell 
death mechanisms in organ toxicity, including DILI (59). The most apparent sources 
of intracellular ROS are the electron transport chain in the mitochondria, the drug 
metabolizing CYP450 system, and intracellular oxidases (59). In addition, reactive 
metabolites originating from drug metabolism can by themselves induce oxidative stress 
(45). This either directly through redox cycling, or indirectly through glutathione depletion, 
increases the amount of reactive oxygen species as observed with APAP and diclofenac 
exposure (45,49,67).
 Extensive ROS formation bares a problem to the cells since it increases the 
damage to macromolecules through protein oxidation, lipid peroxidation and DNA damage 




electron transport chain. Alternatively, drug metabolism can result in superoxide formation 
through the development of unstable radicals by P450 reductases, which then reacts with 
molecular oxygen (30). 
 Because of the damage that can be caused by oxidative stress, the cell has a 
well-developed system to deal with ROS. Superoxide dismutases (SOD1 and SOD2) are 
responsible for detoxifying superoxides, and glutathione peroxidases (GPXs) take care 
of reducing hydrogen peroxides, where the isoform GPX4 is specialized in reducing fatty 
acid hydroperoxides (59). In addition, small antioxidant molecules such as glutathione 
(GSH) constitute a very important anti-oxidant defense system by scavenging different 
types of ROS (59). Emphasizing the importance of this small molecule, the toxicity of 
drugs such as paracetamol and nevirapine can be diminished by supplementing with the 
glutathione precursor N-acetyl-cysteine (68). The mitochondria have their own separate 
GSH pool and especially depletion of this one upon drug exposure has been linked to 
enhanced toxicity (69). The reason for this is enhanced reactive metabolite-mediated 
impairment of the electron transport chain, or by other means enhanced ROS generation 
by mitochondria since GSH is especially important in hydrogen peroxide detoxification as 
a conjugation molecule for GPX (70). 
 Another consequence of reduced GSH levels is alterations of the protein redox 
status, possibly leading to altered protein function (71). However, such post-translational 
redox modifications of proteins can also be an important mechanism for activating or 
inactivating signaling pathways in hepatocytes following drug exposure. As an example, 
ROS can lead to inhibition of JNK phosphatases crucial for the inactivation of this pro-
apoptotic stress-kinase (72). Yet, ROS also activates the anti-oxidant adaptive response 
through the activation of the transcription factor nuclear factor-erythroid 2 (NF-E2)-related 
factor 2 (Nrf2).
 Factors that influence drug metabolism and detoxification are likely all critical 
components in iDILI. A major pathway regulating both of these processes is Nrf2-signaling. 
Nrf2 initiates transcription of both drug metabolizing enzymes, detoxifying enzymes and 
molecules, such as sulfiredoxin (SRXN1), GSTs and GSH (73,74), and is as such the 
most important transcription factor in the anti-oxidant response system. Under non-
stressed conditions, Nrf2 is kept in the cytosol by its endogenous inhibitor Kelch-like 
ECH-associated protein 1 (Keap1) and thereby guided to proteasomal degradation as 
Keap1 acts as a substrate adaptor for the ubiquitination complex responsible for the 
polyubiquitination of Nrf2 (75). Many reactive drug metabolites and intermediates as well 
as ROS activate the Nrf2 response by reacting with the many critical cysteine residues 
on Keap1 (74,76-78) and thereby allowing newly synthesized Nrf2 to translocate to the 
nucleus. In the nucleus Nrf2 heterodimerizes with small Maf proteins and subsequently 
binds with high affinity to the so-called antioxidant response elements (ARE) in the 
promoter region of antioxidant genes (79). In support of the Keap1/Nrf2 system in the 
control of DILI, Nrf2-/- mice have been shown to be more susceptible towards paracetamol 





 Although overwhelming oxidative stress and mitochondrial dysfunction due 
to reactive metabolite formation can lead to hepatocyte death, ROS can also initiate 
cell injury by (in)activation of intracellular (stress) signaling (30,81,82). Whether the 
hepatocyte survives or dies, either by controlled apoptosis or by necrosis, is in great 
part determined by the balance between pro-death and pro-survival signaling pathways 
activated (81). 
 ROS has been shown to induce JNK activation, and when sustained, this activity 
causes cell death (82,83). Inhibition or knockdown of JNK showed protection against 
paracetamol-induced hepatotoxicity in mice (84) and troglitazone-induced apoptosis in 
cultured hepatocytes (HepG2) (85). JNK can actively promote hepatocyte cell death 
by translocating to the mitochondria and there promote membrane permeabilization 
resulting in the release of pro-apoptotic factors (30,81,86) (see above). However, active 
JNK does not per se induce mitochondrial permeabilization and cell death; most likely 
the mitochondria must first suffer redox-related damage (30,81). In addition, the exact 
mechanism by which JNK induces mitochondrial membrane permeabilisation has not 
been determined, but JNK has been shown to translocate to the mitochondria, and 
there anti-apoptotic Bcl-xL and pro-apoptotic Bax are known downstream targets of JNK 
(30,84,87).
 Supportive for the role of extensive ROS production in iDILI is the genotypic 
variation in SOD2 and GPX1 in humans suffering from this drug-induced damage 
(48,88). This would lead to enhanced production/reduced detoxification of ROS within 
the mitochondria upon drug exposure leading to enhanced mitochondrial damage. In 
addition to this, combined deficiency of GSTT1 and GSTM1, enzymes important for 
catalyzing the conjugation of GSH to ROS and reactive metabolites, has been linked to 
troglitazone hepatotoxicity and other iDILI-inducing compounds in humans (51,89,90).
 In addition to mitochondrial effects of oxidative stress, the activity of heat shock 
proteins (HSPs) is also enhanced after this type of stress induction. Pre-treatment with 
hyperthermia, which up-regulates heat shock proteins, has been shown to protect against 
paracetamol-induced hepatotoxicity while HSP70 knockout induced it (91), illustrating the 
role of these proteins in drug-induced toxicity. Heat shock proteins are chaperones that 
ensure proper folding of proteins, which is likely altered as a consequence of covalent 
binding and redox changes after drug exposure. A central organelle in which protein 
folding is continuously taking place is the endoplasmic reticulum.
4.1.4 Endoplasmic reticulum stress
The endoplasmic reticulum (ER) is mostly recognized for its role in protein synthesis 
and folding and as intracellular calcium storage. However the endoplasmic reticulum is 
also involved in many processes that are important in drug-induced toxicity. It is in the 
membrane of this organelle that the P450 enzymes, the UDP-glucuronosyltransferases 
(UGTs) and some GSTs that are so important in drug metabolism reside (92,93). 
Furthermore, the ER is now recognized as a target of reactive intermediate-mediated 




involved in the signaling induced after such damage determining the fate of the affected 
cell (94).
 The ER lumen has two unique properties that are relevant to drug toxicity (94). 
Firstly, it has an oxidizing environment relative to the cytosol, something that is critical 
in the oxidative protein folding but that can also contribute to the generation of oxidative 
stress (95). Secondly, the ER contains a much higher concentration of calcium and 
thereby serves as a storage for calcium which is needed for intracellular signaling (96). 
Severe ER stress can lead to calcium release, thereby increasing cytosolic calcium levels 
which enters the mitochondria to trigger mPT and MOMP and thereby cell death (97).
     The ER lumen also contains proteins that are involved in ER function. The most 
prominent protein, which is also important in the sensing of ER stress, is the glucose-
regulated protein 78 (GRP78; a heat shock protein family member also known as BiP) 
(98,99). This stress protein is expressed under normal conditions but the expression 
is enhanced by insults that disrupts ER-function and causes accumulation of unfolded 
proteins. GRP78 plays a crucial role in initiation of the so called unfolded protein response 
(UPR) in ER stress (99).
 The UPR functions to counteract the ER stress in three major ways: 1) by 
decreasing protein synthesis to decrease the protein load in the ER (100); 2) by up-
regulating chaperones (such as GRP78) to enhance the protein folding capacity (100); 
and 3) by increasing the activity of ER-associated degradation pathways to remove 
unfolded proteins (101). The initiating step to the UPR is the binding of GRP78 to the 
unfolded proteins in the lumen of the ER. This releases and thereby activates the signaling 
molecules that then transmit the intracellular signals of the UPR (102). 
 The UPR signaling is transduced by three ER resident proteins, which are 
inhibited by GRP78 in a non-stressed state; protein kinase R-like ER kinase (PERK), 
inositol-requiring enzyme 1-alpha (IRE-1α) and activating transcription factor 6 (ATF6). 
The reduction in protein synthesis is mediated by PERK-induced eIF2α phosphorylation 
(103). This attenuates global translation but favors translation of activating transcription 
factor 4 (ATF4) that induces production of proteins involved in amino acid transport and 
protection against oxidative stress, but most importantly, also C/EBP-homologous protein 
(CHOP; also known as GADD153 and DDIT3) which is an important transcription factor in 
ER-stress dependent apoptosis (104). The transcriptional up-regulation of genes involved 
in the protein processing is mediated by activation of the other ER-resident kinase and 
endonuclease, IRE-1α (105). Once activated IRE-1α splices X-box binding protein 1 
(XBP1) mRNA yielding a mature mRNA that encodes the required transcription factor 
(106). The last ER stress signal transducing protein that resides in the ER membrane 
is ATF6. After translocating to the Golgi apparatus where it gets cleaved, ATF6 induces 
genes involved in for example quality control in the ER (107). These three pathways of the 
UPR are critical for the cell to be able to withstand disruption of normal ER homeostasis. 
However, if the stress is too immense the apoptotic program will be initiated.
 The mitochondrial death pathway mediates ER stress-induced apoptosis, and 




CHOP overexpression by itself does not cause apoptosis (108). However, CHOP 
sensitizes mitochondria to pro-apoptotic signals by inhibiting the transcription of anti-
apoptotic Bcl-2 (108), by transcribing pro-apoptotic Bim (109) and by disturbing the cellular 
redox state including depletion of cellular GSH (108). The activity of IRE-1α has also 
been implicated in the apoptosis induction downstream of ER-stress-induction. However, 
the importance of this pathway is less clear than that of CHOP (110), although it has been 
shown to involve the activation of JNK which results in apoptosis (111). More importantly, 
XBP1 splicing and protein levels decline with time of ER stress, which is associated 
with enhanced apoptosis, and reconstitution of IRE-1α protects against cytotoxicity (112). 
Also ATF6 was shown to have a protective effect, while prolonged activation of PERK 
including CHOP expression is what caused the ER-stress-induced apoptosis (112).
 Since drugs are being metabolized and potentially bioactivated by P450 enzymes 
in the ER, the ER-resident proteins also serve a high risk of getting covalently adducted 
by these metabolites. This has been reported for both CYP-enzymes themselves, but 
also for other ER-related proteins such as UGTs (94,113). This binding has also been 
shown associated to the formation of antibodies targeting ER proteins suggesting a 
resulting immune related response (94).
4.2. Cytokine-induced intracellular stress signaling
Cytokines are small soluble messenger molecules that can be secreted by all types of 
cells in the body, although they are mainly used by the immune system and the main 
function of the cytokines is to regulate inflammatory responses (26). The liver can 
produce both hepatotoxic and -protective cytokines in response to injury and it is believed 
that the balance between these is what affects an individual’s susceptibility to DILI. The 
secretion of cytokines has even been proposed as potential biomarkers of DILI, although 
an increased understanding of their role in the actual damage induction is required before 
this can be implemented (114,115).
4.2.1 The role of TNFa in DILI
TNFα is a cytokine that is mainly secreted by monocytes and activated macrophages but 
also T-cells (26), and in hepatic inflammation, TNFα release is one of the earliest events 
observed. Moreover, TNFα is secreted by the liver stationary macrophages, Kupffer 
cells, after contact with bacterial factors absorbed via the gastrointestinal tract to activate 
an immunological response as a defense mechanism (6). Interestingly, polymorphisms 
within the promoter region of the gene encoding this cytokine has been linked to the 
severity of inflammatory reactions in humans (116) although this has so far not been 
shown to correlate with the risk of developing DILI (117).
 TNFα has been implicated in liver injuries induced by several types of drugs 
including paracetamol (118), trovafloxacin (38), ranitidine (119) and sulindac (37) and 
its role in DILI has been demonstrated using neutralizing antibodies (38,119). Other 




against IFNγ as well as IFNγ-/- mice protected against paracetamol-induced toxicity (120). 
However, the proposed mechanism underlying this observation was down-regulation of 
other cytokines including TNFα, which further emphasizes the role of the latter cytokine 
in DILI.
 TNFα is especially interesting in the context of toxicity due to the nature of its 
receptor, which can induce both direct pro-apoptotic signaling via its death domain and 
pro-survival signaling via activation of the nuclear factor kappa B (NF-κB) pathway. These 
two signaling pathways will be further discussed in the following paragraphs.  
4.2.2 NF-kB signaling
Hepatocytes, like most cells are resistant to TNFα exposure due to their activation of NF-
κB. NF-κB is an important transcription factor that promotes expression of anti-apoptotic 
genes such as Bcl-xL, cellular FLICE inhibitory protein (cFLIP) and inhibitor of apoptosis 
proteins (IAPs), although it is mostly recognized as a master regulator of the immune 
response due to its transcription of for example cytokines and adhesion molecules (121). 
 The NF-κB proteins are dimeric transcription factors composed of five different 
subunits, p65 (RelA), RelB, cRel, p50 and p52 (121,122).  Under normal conditions the 
transcription factor is kept in the cytoplasm through masking of its nuclear localization 
sequence by the inhibitor of kappa B (IκB) proteins. There are two routes through which 
NF-κB can be activated, the classical or canonical activation route and the alternative, 
non-canonical route. After TNFα binding to its receptor, it is the canonical pathway that 
gets activated, and therefore this pathway will be in focus here. An overview of the 
signaling pathway can be seen in Figure 1.
 After TNFα binding to its receptor, the adaptor protein TNF receptor-associated 
death domain (TRADD) connects with the cytoplasmic tail of the receptor, and so does 
the kinase receptor-interacting protein 1 (RIP1) (122,123). This leads to the recruitment 
of the TNF receptor associated factor 2 (TRAF2) adaptor protein (124), which in turn 
promotes cellular (c) IAP1 and cIAP2 association to the complex. This is an essential 
event for the IκB kinase (IKK) activation since this promotes the K63-linked ubiquitination 
of RIP1 (125) needed for IKK and TGF-β-activated kinase-1 (TAK1)/ TAK1 binding 
protein (TAB) complex recruitment (126). In the canonical pathway, the IKK complex 
consist of the catalytic subunits IKKβ (IKK2 or IKBKB), IKKα (IKK1 or CHUK) and the 
regulatory component IKKγ (NEMO or IKBKG). The latter is important for the binding to 
the K63 ubiquitin chain on RIP1 needed for activation (127). This subsequently leads to 
the rate-limiting and crucial step of (IKK) complex activation (128) via TAK1-mediated or 
auto-phosphorylation of IKK (126). The activated IKK complex then phosphorylates IκB 
proteins, for the canonical p65/p50 dimer the IκB-protein IκBα, resulting in its K48-linked 
polyubiquitination and proteasomal degradation, which subsequently leads to the nuclear 
translocation of NF-κB (126).
 The activation of the NF-κB pathway is clearly tightly regulated by different 
post-translational modification steps, as illustrated above. However, this pathway is 




target genes of NF-κB and constitutes the most important inhibitory protein of NF-κB 
signaling: the newly synthesized IκBα protein transports NF-κB from the nucleus back 
into the cytoplasm (129). A20 is another NF-κB target gene and an important regulator 
of NF-κB activation by its effect on RIP1 ubiquitination (130). A20 deubiquitinates the 
K63-linked activating ubiquitin chains on RIP1 and it also promotes K48-linked poly-
ubiquitinations that targets the protein for proteasomal degradation, resulting in inhibited 
NF-κB activation (131). 
 NF-κB and the proteins involved in NF-κB activation all contain critical cysteine 
residues that are important for proper function. Non-hepatotoxic doses of APAP alter 
the redox environment of hepatocytes which lead to the inhibition of NF-κB activation, 
sensitizing primary hepatocytes to TNFα-induced apoptosis (132). Also other compounds, 
such as hydrogen peroxide and antimycin, that affect the redox status of cells, cause 
hepatocyte sensitization to TNFα (133). Additionally, glutathione depletion has been 
linked to inhibition of NF-κB activation (134,135).
 The reason why inhibition of NF-κB renders TNFα-exposure cytotoxic is due 
to the dual role of the TNF receptor 1. The pro-apoptotic role of this receptor will be 































Figure 1. NF-κB signaling down-
stream of TNFR1. Upon TNFα 
binding to its receptor a complex 
sequence of protein recruitment 
and posttranslational modification 
events is initiated, ultimately 
leading to the rate-limiting step 
of IKK-complex activation by 
phosphorylation. The activated 
IKKβ then phosphorylates the 
inhibitor of NF-κB, IκBα, which is 
followed by its polyubiquitination 
and proteasomal degradation. 
This unmasks the nuclear 
localization signal in NF-κB, 
allowing nuclear translocation 
of the transcription factor and 
transcription of genes involved 
in for example inflammation, 
suppression of apoptosis and, 
importantly, the inhibitors of NF-




4.2.2 Pro-apoptotic death receptor signaling
There are six TNF receptor (TNFR) family death receptors, including TNFR1, and they 
are characterized by the presence of a death domain (DD) in their cytosolic segments 
(136). Under normal conditions, the pro-apoptotic signaling is not induced by TNFα 
exposure as the NF-κB-mediated activation of gene transcription leads to production of 
proteins that inhibit this pathway, such as cIAP1/2 and cFLIP (121).  
 RIP1 is essential for the activation of NF-κB and it is hypothesized that when 
RIP1 gets degraded, or not ubiquitinated by cIAP1/2 (137), this results in activation of 
the pro-apoptotic pathway. However, this hypothesis has not fully been proven and it is 
still a mystery how and when TNFα-induced signaling switches from pro-survival to pro-
apoptotic (138). 
 What is known, though, is the basic compilation of proteins leading to the 
formation of the pro-apoptotic complex (see Fig. 2). Upon induction of pro-apoptotic 
TNFR1 signaling the TRADD adaptor protein, which is also essential for activation of 
the NF-κB pathway, recruits Fas-associated death domain (FADD) together with pro-
caspase-8 to form the cytoplasmic pro-apoptotic complex. In the case of functional NF-
κB signaling, cFLIP is also present in this complex inhibiting the activation of caspase-8 
(139). Although caspase-8 can lead to direct activation of caspase-3 (140) the apoptotic 
signal usually needs amplification. This is achieved by caspase-8 mediated cleavage of 
the Bcl-2 family member Bid (141). tBid then promotes the disruption of the mitochondrial 
membrane integrity by  Bax and Bak oligomerization (see above in the section about the 













Figure 2. Pro-apoptotic signaling 
downstream of TNFR1. Unless 
inhibited by NF-κB transcribed 
genes, such as cIAPs and 
cFLIP, intracellular signaling 
induced by TNFα also leads to 
apoptosis. This event is initiated 
by TRADD dissociation from 
the receptor leading to FADD 
and pro-caspase-8 recruitment. 
This is followed by activation 
of caspase-8, which can then 
induce apoptosis either directly 
by caspase-3 cleavage or by 
involvement of the mitochondrial 
death pathway via activation of 




5. METHODS TO STUDY CROSS-TALK BETWEEN DRUG- AND CYTOKINE-
INDUCED SIGNALING IN LIVER INJURY
As already mentioned in the beginning of this chapter, it is of outmost importance to 
integrate a complete molecular mechanistic understanding of iDILI in advanced pre-
clinical cell and animal models to identify candidate drugs that are at high risk to induce 
DILI. Of course relevant models to uncover these molecular mechanisms are essential 
to bring this project forward. 
5.1 Existing in vivo and in vitro models
It has been suggested that only animal models should be able to model the complexities 
that iDILIs constitute (7). However, as iDILI is expected to be as rare in animal models 
as in humans, not any animal model would be sufficient to get a complete mechanistic 
understanding of these rare but serious adverse drug reactions. Most likely, a first step 
is to move away from healthy animal models towards more intrinsically stressed ones, 
especially since humans on drug treatment have at least one condition, their illness, 
that potentially makes them more susceptible to adverse drug reactions (142). Two 
animal models have received special attention in this aspect, the SOD2+/- heterozygous 
mice, used to study the role of latent mitochondrial susceptibility (143), and the LPS co-
exposure model, to address the role of inflammatory stress in iDILI (7). 
 As animals cannot be used for drug safety screening campaigns, there is also a 
need for in vitro mechanism based high throughput tests that could be used in an even 
earlier preclinical toxicity testing phase (7). Cosgrove and colleagues presented such a 
model, which is analogous to the in vivo LPS co-exposure model developed by Roth and 
Ganey (144). By exposing different cell types (HepG2 cell line and primary rat as well as 
human hepatocytes) to known hepatotoxicants and their non-toxic counterparts, together 
with pro-inflammatory cytokines, they demonstrated that primarily drugs known to cause 
idiosyncratic DILI, displayed synergism in cytotoxicity when combined with cytokines. 
Important in the context of the studies presented in this thesis, TNFα was one of the 
cytokines that contributed most to the observed toxicity. 
5.2 High content imaging
High content cellular imaging techniques provides an in vitro platform to investigate 
the toxicity-inducing potential of many drugs and it provides an outstanding method 
to determine the mechanisms behind such toxicity. The most beneficial aspects is the 
possibility to see what is happening to the cells in time after drug exposure in a non-
invasive way that does not require many sample preparation steps which could result in 
the outcome deviating more than necessary to reality. 




mediated fluorescence staining in combination of automated imaging (145). This method 
does not only provide the amount of apoptosis induced as an end-point, but can also 
provide information on the kinetics of the apoptosis induced, something that could 
potentially provide a more mechanistic insight. 
 The use of fluorescent fusion proteins has opened up a whole new field of 
mechanistic research as it makes it possible to for example follow the translocation of 
crucial transcription factors from the cytoplasm to the nucleus in real time, or the induction 
of certain stresses by following the induction of typical target genes such as SRXN1 that 
is induced upon oxidative stress and the activation of Nrf2 (146).    
 Another way to follow the induction cytotoxic stress, such as glutathione depletion 
and mitochondrial damage proven important for the induction of idiosyncratic DILI (see 
above), is by the use of fluorescent probes indicative of the particular damage. Using this 
technique Xu and colleagues were able to develop an in vitro screening method, with 
a true-positive rate of 50-60% and a false-positive rate of 0-5%, for the identification of 
hepatotoxicants (64). This technique gives a good example of how high content imaging 
can prove very useful, not only for mechanistic insight, but also for the pre-clinical 
screening of novel compounds in pharmaceutical companies.
5.3 Pharmacogenetics
As genetic variations are important determining factors for the development of iDILI, 
pharmacogenetics constitutes an important method in the study of these adverse drug 
reactions.
 The most common way of studying relationships between genes and adverse 
events is by a targeted candidate gene association studies (CGAS) (40). However as 
it, due to the low incidence of iDILI, is rather unlikely to find a one-gene-association, 
genome wide association studies (GWAS) is a better approach as they are more likely to 
identify a combination of genetic risk factors associated to one adverse drug reaction (40). 
However, important for both the CGAS and the GWAS approach, is a more mechanistic 
insights to the iDILI in question. It is a prerequisite for the targeted CGAS study but it 
has also been proven more fruitful for GWAS studies as this helps to narrow down the 
target genes by only focusing on certain functional areas (40). This approach was nicely 
demonstrated when identifying genetic variation of the glucuronidation enzyme UGT2B7 
as a risk factor for diclofenac induced DILI (50). 
 Apart from the use of pharmacogenetics in identifying single or small groups of 
genes that can be linked to the development of iDILI, gene expression analysis is an 
important method to identify signaling pathways that are activated in the cellular stress 
response to a toxic insult (147). To achieve this, the development of dedicated and 
commercially available pathway analysis software such as Ingenuity Pathway Analysis® 
and MetacoreTM has been a major accomplishment (148,149).
 Although informative in the search for transcriptionally regulated genes, 




differentially expressed. Furthermore, transcriptional up-or down-regulation does not per 
se mean a functional change relevant for the phenotype studied. Small interfering RNAs 
(siRNAs) were first discovered in the early 2000s and they constitute an outstanding 
method for targeted silencing of individual genes for the study of their function (150). siRNA 
screening is now widely used by both academia and drug-industry for the discovery of 
novel drug targets affecting a certain intracellular system or for example for fundamental 
studies of mechanisms behind certain cellular processes (151,152). In addition, siRNA 
technology comprises an invaluable resource for the study of the functional roles of 




6. AIM AND SCOPE OF THIS THESIS
It has been anticipated that in vitro studies of idiosyncratic drug reactions cannot simply 
mimic all the complex interactions that occur in vivo (22). Rather, animal models could be 
better used to support hypothesis coming from clinical observations. However, in depth 
mechanistic in vitro studies at the molecular level are still essential to gain more detailed 
insight. Where appropriate the gathered knowledge could be integrated in improved pre-
clinical in vitro toxicity screening. 
 In this thesis I used an in vitro approach for the mechanistic studies of DILI 
by investigating the hypothesis that cross–talk between drug (metabolite)-induced and 
cytokine-induced intracellular stress signaling is a likely critical event that leads to an 
enhanced toxic response in susceptible individuals (Fig. 3). This hypothesis does not 
exclude either the innate or the adaptive immune system activation, as cytokines are 
the mediators of both. The focus is here on TNFα since this is a major mediator of 
inflammation-induced toxicity.
 Diclofenac-induced liver injury has been termed a “paradigm of idiosyncratic 
drug toxicity” (49). In chapter 2 I first used this drug in combination with a non-toxic 
dose of TNFα to provide a proof-of-concept for our working hypothesis. The apoptotic 
mechanism behind the enhanced drug-induced toxicity seen with the addition of TNFα 
was further studied using siRNA-screening technology and high-content imaging of 
apoptosis as described above. Using this methodology, the enhanced apoptosis was 
shown to originate from the TNF receptor, suggesting that diclofenac enhances the pro-
apoptotic properties of TNFα and not the other way around. Furthermore, I showed that 
this enhanced toxicity is related to diclofenac’s ability to inhibit the oscillatory pattern of 
NF-κB translocation. This is in line with the observation that TNFα can only be cytotoxic 
in the case of NF-κB inhibition.
 In chapter 3 the concept of TNFα enhancing the apoptotic outcome of drugs 
associated with idiosyncratic DILI was further investigated using a panel of 15 drugs, 
involving drugs linked to iDILI, DILI without an inflammatory component as well as non-
liver-toxic compounds. Here I show that the synergistic response with TNFα addition is 
not only linked to the inhibition of NF-κB as this could also be observed following the 
exposure to non-toxic compounds as well, but also dependent on induction of oxidative 
stress by the drug. The kinetics of oxidative stress induction was determined using high 
content imaging of Srxn1-GFP, a reporter for the activation of Nrf2-mediated oxidative 
stress response. I anticipate that the use of these three high content imaging methods 
can be used as a part of a toxicity-screening panel for the identification of compounds in 
a pre-clinical setting with a potential risk for human iDILI.
 In chapter 4 the mechanism behind the synergistic apoptotic response seen with 
certain drugs and TNFα addition was further investigated using a transcriptomics and 
subsequent functional genomics approach. In addition to diclofenac, carbamazepine was 
shown, both in this chapter and in chapter 2, to have a clear apoptotic synergism with TNFα. 




stress and ER stress pathways were shown to be significantly regulated with diclofenac 
and carbamazepine, but not with the non-toxic drug methotrexate. The involvement of 
these pathways could be confirmed using RNA interference. Moreover, a critical role for 
translation initiation mediated by RNA helicase EIF4A1 was shown for diclofenac/TNFα- 
and carbamazepine/TNFα-induced apoptosis. Potentially this gene could be used as a 
susceptibility marker to identify individual with a higher risk of developing iDILI. 
 As the nuclear translocation of NF-κB was found important for the toxic outcome 
of drug/TNFα exposure, the role of individual proteins involved in post-translational 
modifications in this response was investigated in chapter 5 using an siRNA screening 
approach and high content imaging of GFP-p65 translocation following TNFα exposure. 
Knockdown of genes that resulted in a faster, slower or blocked translocation response 
were identified. Further attention was given to the knockdowns that stopped the TNFα 
response and unexpectedly this was related to a protective response in a drug/TNFα 
exposure condition. Interestingly, both the translocation and the apoptosis outcomes 
were related to enhanced expression of the (de)ubiquitinase A20, a critical component in 
the NF-κB feedback loop, by the knockdowns themselves.
 Finally, chapter 6 provides a summary and a general discussion on the findings 











































e.g. viral and bacterial products
Figure 3. Summary of the hypothesized interplay between drug- and cytokine-induced stress signaling in the 
hepatocyte. A drug, when taken up by the hepatocyte, may induce intracellular stress either by itself or by the 
formation of reactive metabolites. This can alter the intracellular signaling pattern or cause organelle damage 
resulting in increased susceptibility of the cell. The hepatocyte damage, or external factors such as exposure 
to bacterial or vial products, can lead to activation of the innate and/or adaptive immune system. These exert 
their response by secretion of cytokines and chemokines, which either allow repair and survival of the already 
susceptible hepatocyte in the case of protective cytokines, or enhanced cellular injury and ultimately cell death 
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ABSTRACT
Drug-induced liver injury (DILI) is an important clinical problem. It involves a crosstalk 
between drug toxicity and the immune system, but the exact mechanism at the cellular 
hepatocyte level is not well understood. Here we studied the mechanism of crosstalk 
in hepatocyte apoptosis caused by diclofenac and the pro-inflammatory cytokine tumor 
necrosis factor α (TNFα). HepG2 cells were treated with diclofenac followed by TNFα 
challenge and subsequent evaluation of necrosis and apoptosis. Diclofenac caused 
a mild apoptosis of HepG2 cells, which was strongly potentiated by TNFα. A focused 
apoptosis machinery short interference RNA (siRNA) library screen identified that this 
TNFα-mediated enhancement involved activation of caspase-3 through a caspase-8/Bid/
APAF1 pathway. Diclofenac itself induced sustained activation of c-Jun N-terminal kinase 
(JNK) and inhibition of JNK decreased both diclofenac and diclofenac/TNFα-induced 
apoptosis. Live cell imaging of GFPp65/RelA showed that diclofenac dampened the 
TNFα-mediated nuclear NF-κB translocation oscillation in association with reduced NF-
κB transcriptional activity. This was associated with inhibition by diclofenac of the TNFα-
induced phosphorylation of the inhibitor of nuclear factor κB (NF-κB) alpha (IκBα). Finally, 
inhibition of IκB kinase β (IKKβ) with BMS-345541 as well as stable lentiviral short hairpin 
RNA (shRNA)-based knockdown of p65/RelA sensitized hepatocytes towards diclofenac/
TNFα-induced cytotoxicity.  Conclusion: Together our data suggest a model whereby 
diclofenac-mediated stress signaling suppresses TNFα-induced survival signaling routes 
and sensitizes cells to apoptosis. 
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INTRODUCTION
Adverse drug reactions are an important cause of morbidity and mortality in humans and 
drug-induced liver injuries (DILIs) are the leading cause of acute liver failure (1). In addition, 
DILI accounts for most of the drug attritions (2) and more than 10 % of the occurring liver 
failures happen due to idiosyncratic DILIs (1). We propose that the crosstalk between 
drug reactive metabolite-mediated stress responses and cytokine-mediated pro- and 
anti-apoptotic signaling is an important component in the pathophysiology of DILI.
 Diclofenac is one of the most commonly used drugs causing idiosyncratic DILI (3). 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) widely prescribed to treat 
for example pain and rheumatoid arthritis. Although the most frequently occurring ADR 
associated with use of diclofenac is gastrointestinal ulceration (4), severe idiosyncratic 
liver injuries are reported and due to the drug’s frequent clinical use, the total number of 
affected patients is significant (3).
 The underlying cellular mechanisms that determine the susceptibility towards 
developing DILI are incompletely understood. Due to their relatively rare occurrence, it 
is expected that multiple factors are involved. Increasing evidence points towards a role 
for the formation of reactive metabolites and the (innate) immune system (2, 5, 6).  In 
the liver, diclofenac is metabolized into three main metabolites, 4’-OH-diclofenac, 5-OH-
diclofenac and diclofenac acylglucuronide, that are reactive towards protein thiol-groups, 
associated with formation of reactive oxygen species (ROS) and causally related to 
DILI (7). Covalent protein modifications and ROS cause cellular injury and activation of 
different stress signaling pathways, including c-Jun N-terminal kinase (JNK) (8).
 The largest pool of stationary immune cells in the liver is the liver-specific 
macrophages, the Kupffer cells. Through intercellular communication between hepatocytes 
and Kupffer cells or due to direct endotoxin exposure from the intestine, Kupffer cells 
secrete pro-inflammatory cytokines, of which tumor necrosis factor-α (TNFα) is the major 
component (9). TNFα severely enhances liver damage caused by different xenobiotics 
(10-12). Although an involvement of the immune system in diclofenac hepatotoxicity is 
clear from an in vivo rat model (13), the exact role of cytokine signaling and the molecular 
mechanism of such an interaction are poorly defined. 
 TNFα induces both pro- and anti-apoptotic signaling. By formation of the 
complex I signalosome after TNFα binding to its receptor (TNFR-1), the transcription 
factor nuclear factor kappa-B (NF-κB) is activated (14). Nuclear translocation of NF-κB 
occur in an oscillatory manner following degradation of the inhibitor of NF-κB, IκBα, to 
induce transcription of its target genes which primarily encode survival  proteins, e.g. 
cellular FLICE-like inhibitory protein (c-FLIP) and inhibitor of apoptosis proteins (IAPs), 
and proteins that negatively regulate the activation of complex I, e.g. A20 and IκBα (15). 
Depending on the cellular signaling context, from complex I an apoptosis activating 
complex II can be formed, which results in activation of caspase-8 and induction of 
the apoptotic pathway (15, 16). In addition to activation of transcription factor NF-κB, 
signaling from complex I can lead to activation of mitogen activated protein kinases 
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(MAPKs). Activation of c-Jun N-terminal kinase (JNK) can either lead to survival or 
apoptosis, depending on whether the activation is transient or prolonged (17). Activation 
of caspases and prolonged JNK signaling are under normal conditions antagonized by 
different NF-κB target genes (16, 18). 
 Here we used a human HepG2 cell-based model to study the diclofenac/cytokine 
interaction. We show that the concentration-dependent toxicity of diclofenac is enhanced 
in the presence of the cytokine TNFα, which is dependent on the activation of JNK1. 
Consistent with signaling from the TNFR-I downstream pro-apoptotic response, using an 
RNA interference approach targeting all apoptotic machinery components, we identified 
a key role for the capase-8/Bid/APAF1 route in the diclofenac/TNFα-induced apoptosis. 
TNFα-induced IκBα phosphorylation was inhibited by diclofenac in association with 
attenuation of the nuclear translocation of NF-κB. Inhibition of IKKβ or RNA interference-
based silencing of the NF-κB subunit p65/RelA further sensitized cells to diclofenac/
TNFα-induced apoptosis. Our findings support a model whereby diclofenac perturbs pro-
survival NF-κB responses during periods of inflammation, which favours pro-apoptotic 
signaling via capase-8 and JNK upon cytokine exposure, ultimately increasing the 




Diclofenac sodium, naproxen sodium and the selective IKK2-inhibitor BMS-345541 were 
obtained from Sigma (Zwijndrecht, the Netherlands). Human and mouse recombinant 
TNFα were acquired from R&D Systems (Abingdon, United Kingdom). The selective JNK-
inhibitor SP600125 was from Enzo Life Sciences (Zandhoven, Belgium). The irreversible 
pan-caspase inhibitor z-VAD-fmk was from Bachem (Weil am Rhein, Germany). The 
irreversible inhibitors of caspases z-DEVD-fmk (caspase-3), z-IETD-fmk (caspase-8) and 
z-LEHD-fmk (caspase-9) were from Calbiochem (Merck KGaA, Darmstadt, Germany). 
AnnexinV-Alexa633 was made as previously described (19). The antibodies against 
active caspase-3 and phospho-specific JNK antibody were from New England Biolabs 
(Leusden, the Netherlands). The antibodies against caspase-8, caspase-9, cleaved 
PARP, JNK1/2, IκBα and the phospho-specific cJun and IκBα antibodies were from Cell 
Signaling (Bioké, Leiden, Netherlands). The antibody against tubulin was from Sigma 
and the antibody against NF-κB (p65) was from Santa Cruz (Tebu-Bio, Heerhugowaard, 
the Netherlands).
Cell lines 
Human hepatoma HepG2 cells and mouse hepatoma Hepa1c1c7 cells were obtained 
from American Type Culture Collection (ATCC, Wesel, Germany), cultured in DMEM 
supplemented with 10% (v/v) FBS, 25 U/mL penicillin and 25 µg/mL streptomycin and 
used for experiments between passage 5 and 20. 
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RNA interference
Stable HepG2 cell lines with p65/RelA knocked down were produced using 
lenti-viral  shRNA vectors (Sigma-Aldrich, collaboration with dr. Hoeben, 
Leiden University Medical Centre, the Netherlands) and selection with 
puromycin (2.5 µg/mL). The sequence for the non-targeting control shRNA was 
CCGGTCCGCAGGTATGCACGCGTGAATTC and the shRelA sequence was 
CCGGCACCATCAACTATGATGAGTTCTCGAGAACTCATCATAGTTGATGGTGTTTTT. 
Transient knockdowns of individual target genes were achieved using siGENOME 
SMARTpool siRNA reagents in the primary screen or single siRNA sequences in the 
secondary deconvolution screen (50 nM; Dharmacon Thermo Fisher Scientific, Landsmeer, 
the Netherlands). The negative control was siGENOME non-targeting pool #1. HepG2 
cells were transfected using INTERFERin™ siRNA transfection reagent according to the 
manufacturer’s procedures (Polyplus transfection, Leusden, the Netherlands) and left for 
72 hours to achieve maximal knockdown before treatment. 
Cell death analysis assays
Apoptosis was determined by cell cycle analysis using 4’,6-diamidino-2-phenylindole 
(DAPI) and flow cytometry (FACSCanto II; Becton Dickinson, Erembodegem, Belgium). 
The amount of cells in sub G0/G1 was calculated using the BD FACSDiva software 
(Becton Dickinson). Overall cell death (loss of membrane integrity) was determined by 
lactate dehydrogenase (LDH) release in the medium in essentially the same manner as 
previously described (20). Induction of apoptosis in real time was quantified using a live 
cell apoptosis assay previously described (19). Briefly, binding of annexin V-Alexa633 
conjugate to phosphatidyl serine on the membranes of apoptotic cells was followed in 
time by imaging every 30 minutes after drug exposure with a BD PathwayTM 855 imager 
(Becton Dickinson). The total fluorescent intensity per image or the relative fluorescence 
intensity per cell area was quantified using Image ProTM (Media Cybernetics, Bethesda, 
MD, USA). Caspase-3 activity was determined as previously described (21). 
Western blot analysis and immunofluorescence
Western blot analysis and immunofluorescent staining were essentially performed as 
previously described (20). For the immunofluorescence, cells were stained for NF-κB 
p65 followed by goat anti-mouse Alexa488- (Molecular probes, Breda, the Netherlands) 
or Cy3-labeled (Jackson, Amsterdam, the Netherlands) secondary antibodies. Hoechst 
33258 (2 µg/ml) was used to visualize the nuclei. Cells were imaged using a BD 
PathwayTM 855 imager (Becton Dickinson) and the NF-κB translocation was quantified 
as an intensity-ratio of NF-κB (nucleus): NF-κB (cytoplasm) using the AttoVisionTM 
software (Becton Dickinson). Images were processed in Adobe Photoshop CS2 (Adobe, 
Amsterdam, the Netherlands). 
Live cell imaging of GFPp65 in HepG2 cells
HepG2 cells stably expressing GFPp65 (NF-κB subunit) were created by 400 mg/
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mL G418 selection upon pEGFP-C1-p65 transfection using LipofectamineTM 2000 
(Invitrogen, Breda, the Netherlands). Prior to imaging, nuclei were stained with 100 ng/ml 
Hoechst 33342 in complete DMEM. The GFPp65 nuclear translocation response upon 
10 ng/mL human TNFα challenge was followed for a period of 6 hours, by automated 
confocal imaging (Nikon TiE2000, Nikon, Amstelveen, the Netherlands). Quantification of 
the nuclear/cytoplasmic ratio of GFPp65 intensity in individual cells was performed using 
an algorithm for ImageJ (Di et al, submitted).
Luciferase reporter assay 
To determine the effect of diclofenac exposure and RelA inhibition/knockdown on TNFα-
induced NF-κB transcriptional activity, HepG2 cells were transiently transfected with an 
NF-κB promoter-luciferase reporter plasmid (Clontech, Saint-Germain-en-Laye, France) 
using LipofectamineTM 2000 reagent according to the manufacturer’s procedures 
(Invitrogen, Breda, the Netherlands) and incubated for 16-18 hours. The Dual-Luciferase® 
luciferase assay kit (Promega, Leiden, the Netherlands) and a microplate luminometer 
(Centro XS3 LB960, Berthold Technologies) was used to monitor luciferase activity. 
Statistical analysis
All numerical results are expressed as the mean ± standard error of the mean (S.E.M.) 
and represent data from three independent experiments, unless otherwise stated. 
Calculations were made using GraphPad Prism 4.00 (GraphPad software, La Jolla, USA). 
Significance levels were calculated using unpaired student’s t-test or 2-way ANOVA in 
the case of multiple comparisons, * = P < .05, ** = P < .01, *** = P < .0001.
 
RESULTS
TNFa enhances diclofenac induced cell death in hepatocytes
To investigate a role for TNFα signaling in enhancement of diclofenac-induced 
hepatotoxicity, we first pre-treated human hepatoma HepG2 cells with increasing 
concentrations of diclofenac for 8 hours to allow formation of  reactive metabolites 
(supplementary data S1), followed by treatment with TNFα (10 ng/mL). Importantly, 
during this 8-hour period diclofenac was metabolized into both acylglucuronide and 
hydroxymetabolites (Supporting Data S1) which further accumulated in time. After 24 
hours, cells were collected to determine cell death. Diclofenac alone induced a mild 
concentration dependent increase in cell death and while no apoptosis was observed by 
TNFα alone, in combination with diclofenac, TNFα-addition resulted in a two-fold increase 
of apoptosis (Fig. 1 A).  This enhancement effect could be abrogated by co-treatment 
with the pan-caspase inhibitor z-VAD-fmk (50 μM), indicating that the TNFα-enhanced 
diclofenac-induced DNA-fragmentation is a caspase-executed apoptotic process (Fig. 
1 A). A structurally different non-steroid anti-inflammatory compound, naproxen, did not
lead to concentration-dependent induction of apoptosis after 24 hours of exposure, even 
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Figure 1. TNFα enhances diclofenac-induced apoptosis in hepatocytes. Treatment with diclofenac (A), but 
not the structurally different non-steroidal anti-inflammatory drug naproxen (B), induces apoptosis in HepG2 
cells after 24 hours, which is significantly enhanced by addition of tumour necrosis factor α (TNFα; 10 ng/mL) 
after 8 hours of drug exposure. The apoptosis was determined by cell cycle analysis (A and B) or followed in 
time using AnnexinV (AnxV)-Alexa633 staining and automated imaging (500 µM diclofenac; C and D). Lactate 
dehydrogenase (LDH) activity in the medium after 24 hours of diclofenac exposure +/- TNFα was used as a 
measurement of overall cytotoxicity in human (E) and mouse hepatocytes (F; 1 ng/mL TNFα added after 8 
hours). The data are presented as means of at least three independent experiments +/- S.E.M. The percentage 
of total LDH-activity under control conditions is <5 % and z-VAD-fmk (50 µM) was included where indicated. *** 
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in presence of TNFα (Fig. 1 B). This indicates that the diclofenac/TNFα induced apoptosis 
is independent from cyclooxygenase inhibition. 
 To gain insight in the temporal onset of the TNFα-enhanced diclofenac-induced 
apoptosis, we applied a live apoptosis microscopy assay, based on Alexa633-labeled 
annexin V (AnxV) binding to cells that present phosphatidyl-serine in the outer layer 
of their plasma-membrane (19). The diclofenac/TNFα-induced apoptotic response was 
initiated 4 hours after addition of TNFα (Fig. 1 D). This enhanced accumulation of AnxV 
positive cells correlated with enhanced release of lactate dehydrogenase (LDH) in the 
medium, which was prevented by z-VAD-fmk treatment (Fig. 1 E), supporting a model 
whereby TNFα promotes diclofenac-exposed HepG2 cell-killing by primarily apoptosis, 
followed later by secondary necrosis. Importantly, the apoptosis-inducing synergism 
between diclofenac and TNFα was not restricted to HepG2 cells, since the mouse 
hepatoma cell line Hepa1c1c7 was also susceptible to the combined treatment (Fig. 1 F). 
The induced apoptosis by TNFa in diclofenac treated HepG2 cells is dependent on the ex-
trinsic apoptotic pathway
Diclofenac alone can induce apoptosis in hepatocytes via the intrinsic, mitochondrial, 
apoptotic pathway involving caspase-9 (22). However, TNFα is well known to induce 
the apoptotic cascade via the extrinsic, death receptor-mediated pathway involving 
caspase-8 (16). To investigate which initial apoptotic process dominates in diclofenac/
TNFα co-exposed HepG2 cells, we assessed the activation of initiator caspases -8, -9 and 
effector caspase-3. Diclofenac-induced apoptosis involved activation of caspase-8 which 
started at 16 hours after drug exposure. Activation of caspase-8 by TNFα co-exposure 
was already observed between 10 and 12 hours after drug treatment (Fig. 2 A). However, 
whereas enhanced initiation of caspase-8 cleavage correlated with caspase-3 activation 
and cleavage of the endogenous caspase-3 substrate poly (ADP-ribose) polymerase 
(PARP), caspase-9 activation was not significantly affected. Caspase-inhibition by z-VAD-
fmk blocked activation of caspase-3 and PARP cleavage (Fig. 2 A) as well as caspase-3 
activity (Ac-DEVD-AMC cleavage) (Fig. 2 B). Caspase-8 and caspase-9 cleavage was 
also partially inhibited by z-VAD-fmk and diclofenac/TNFα co-exposure (Fig. 2 A, right 
panel). Together these data indicate that under diclofenac conditions, TNFα induces 
direct cleavage of caspase-8, which is the essential step in promoting the diclofenac-
induced apoptotic response. 
 To further determine the individual roles of caspase-8, -9 and -3, we exposed 
HepG2 cells with selective irreversible inhibitors (z-IETD-fmk, z-LEHD-fmk and z-DEVD-
fmk, respectively) and measured the onset of apoptosis by AnxV-Alexa633 live cell 
imaging (Fig. 2 C). All three caspase-inhibitors delayed the initiation of the diclofenac/
TNFα-induced apoptotic process (Fig. 2 D). At the 24-hour timepoint, the inhibition of 
caspase-3 and caspase-8 significantly reduced the apoptotic response to diclofenac/
TNFα treatment, while the capase-9 inhibitor z-LEHD-fmk did not (Fig. 2 E). 
 To get further insight into which players in the apoptotic pathways have important 
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roles in the induction of diclofenac/TNFα-induced apoptosis, we created a siRNA 
SMARTpool library containing 50 siRNAs against known pro- and anti-apoptotic genes 
(Supporting Data S2). Following knockdown in three independent experiments, as a 
primary screen, HepG2 cells were treated with diclofenac/TNFα, and onset of apoptosis 
was analyzed by live cell imaging. Candidate gene knockdown resulting in a >2.0 fold 
Figure 2. Diclofenac/TNFα-induced apoptosis is dependent on caspase-8 and -3 activities. (A) Expression levels 
of the active forms of caspase-8, -9, and -3 and the cleavage of poly (ADP-ribose) polymerase (PARP) after 500 
μM diclofenac exposure +/- TNFα (10 ng/mL) were measured by Western blot analysis. “C” : controls exposed 
to vehicle for 24 hours +/- TNFα after 8 hours. (B) Activity of effector caspase-3 after exposure to diclofenac +/- 
TNFα (10 ng/mL), was measured by Ac-DEVD-AMC cleavage assay. The activity is presented as fold of control 
where the control activity is ~1 pmol AMC/min/mg protein. (C, D and E) The effect of specific caspase inhibitors 
on apoptosis induced by 500 μM diclofenac +/- TNFα (10 ng/mL) was investigated by following AnxV-Alexa633 
binding to apoptotic cells in time using automated imaging. (C) Images, representative of three independent 
experiments (see supplementary information for complete movies M1-M7); IETD = caspase-8 inhibitor z-IETD-
fmk, LEHD = caspase-9 inhibitor z-LEHD-fmk, DEVD = caspase-3 inhibitor z-DEVD-fmk. (D) Quantification 
of the fluorescent AnxV-Alexa633 labelled apoptotic cells. (E) The difference in % increase in AnxV-Alexa633 
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reduction in apoptosis after 24 hours of diclofenac/TNFα exposure were defined as 
target genes involved in the onset of diclofenac/TNFα-induced apoptosis (Fig. 3 A and 
Supporting Data S2); knockdown resulting in a >2.0 fold increase in apoptosis were 
defined as apoptosis suppressors (Fig. 3 B and Supporting Data S2). Knockdown of 
caspase-8, Bid, p53 up-regulated modulator of apoptosis (PUMA), apoptosis inducing 
factor (AIF) and apoptotic protease activating factor 1 (APAF1) inhibited diclofenac/TNFα-
induced apoptosis; knockdown of cellular FLICE-like inhibitory protein (c-FLIP), Bcl10, 
Bcl-B and RIP-associated protein with a death domain (RAIDD) enhanced the apoptosis. 
Knockdown of caspase-9 and -3 partially inhibited apoptosis (Supporting Data S2). To 






Figure 3. siRNA-mediated 
knockdown of central apoptotic 
machinery components. 
siRNAs targeting 50 apoptotic 
machinery genes were used to 
investigate their individual roles 
in diclofenac/TNFα-induced 
apoptosis (500 µM/10 ng/
mL). AnxV-Alexa633 staining 
was followed in time using 
automated imaging. (A) Genes 
defined as pro-apoptotic 
regulators of diclofenac/TNFα 
based on the average > 2.0-
fold decrease compared to 
siControl transfected cells in 
the primary screen and 2 out 
of 4 single siRNA sequences 
showing the phenotype in 
the secondary deconvolution 
screen. (B) Genes defined as 
anti-apoptotic components 
of diclofenac/TNFα-induced 
apoptosis based on average 
> 2.0-fold increase compared 
to siControl transfected 
cells in the primary screen 
and 2 out of 4 single siRNA 
sequences showing the 
phenotype in the secondary 
deconvolution screen. For 
both (A) and (B), the tables 
present the fold-change 
induction of apoptosis in the 
primary screen compared to 
siControl transfected HepG2 
cells from three independent 
experiments as well as from 
averages of all three and 
the number of constructs in 
the secondary screen that 
resulted in the expected phenotype. The graphs present the average time-dependent diclofenac/TNFα-induced 
apoptosis as well as the averages of the 24 hour timepoints for the hits from the primary screen that could also 
be validated in the secondary deconvolution screen. Data are the means of three independent experiments 
+/- S.E.M. ** P < .01, * P < .05
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further validate the effect of the knockdown of the mentioned genes, a deconvolution 
secondary screen was performed with the four individual siRNA sequences that were 
present in the siRNA SMARTpool mix used in the primary screen. Deconvolution analysis 
of caspase-3 and -9 were also included, to verify the mitochondrial-dependent APAF1-
mediated apoptosome formation resulting in caspase-3 activation. Knockdown that 
resulted in a >1.5 fold increase or decrease in apoptosis compared to siControl transfected 
cells after 24 hours exposure of diclofenac/TNFα in at least 2 out of  4 individual siRNA 
sequences were considered as true mediators of diclofenac/TNFα-induced apoptosis 
(Fig. 3 A and B; Supporting Data S3).  These included caspases-8, -3 and -9, Bid, APAF1 
and PUMA. The caspase-8 inhibitory protein c-FLIP was indentified as a reducer of 
diclofenac/TNFα apoptosis.
 Altogether these data indicate that the route of apoptosis-induction after 
diclofenac/TNFα exposure is dependent on the extrinsic apoptotic pathway involving 
caspase-8. In addition, the siRNA screen revealed that the apoptosis was dependent on 
the mitochondrial apoptotic pathway initiated by the activation of Bid and including the 
release of APAF1-dependent activation of caspase-9 and -3.
Diclofenac and diclofenac/TNFa co-exposure leads to JNK-activation in HepG2 cells
Diclofenac-induced small intestinal injury is dependent on JNK-activation (23). In addition, 
TNFα-induced apoptosis can result from sustained JNK activation (24). Therefore 
we determined the activation status of JNK after diclofenac and diclofenac/TNFα 
treatment. Both diclofenac alone and diclofenac/TNFα co-exposure caused sustained 
JNK phosphorylation although only little sustained activation was seen with TNFα alone 
(Fig. 4 A). The diclofenac/TNFα-induced JNK activity was associated with increased 
phosphorylation of c-Jun, an important downstream target of JNK (Fig. 4 A). Inhibition of 
JNK-activation by a specific inhibitor of JNK, SP600125, almost completely inhibited the 
onset of diclofenac/TNFα-induced apoptosis (Fig. 4 B-D). 
 TNFα-induced apoptosis is associated with prolonged activation of JNK1 (25). 
However, other studies demonstrated a role for JNK2 as well (26, 27). We performed 
knockdown of the two major JNK isoforms, JNK1 and JNK2. Knockdown was verified by 
Western blotting (Supporting Data S2). Live cell imaging of the apoptosis onset identified 
JNK1 as the main JNK isoform involved in diclofenac/TNFα-induced apoptosis (Fig. 4 
E-F). Altogether these data suggest an important role for JNK1 activation by diclofenac in 
sensitizing HepG2 cells towards enhanced cell injury induced by TNFα.
Diclofenac inhibits TNFa-induced NF-kB signaling
Under normal physiological conditions hepatocytes are resistant to TNFα-induced 
apoptosis due to NF-κB mediated transcriptional regulation of anti-apoptotic target 
genes such as c-FLIP, thereby suppressing TNF-R-mediated caspase-8 activation (16). 
Activation of the IKK-complex by TNFα causes phosphorylation of the inhibitor of NF-κB, 
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IκBα, followed by its degradation by the proteasome allowing translocation of NF-κB to 
the nucleus. Since caspase-8 was central in diclofenac/TNFα-induced apoptosis (see 
Fig. 2 and Fig. 3), we next investigated whether the NF-κB signaling induced by TNFα 
was affected by diclofenac. Diclofenac caused a concentration dependent disturbance 
of the TNFα-induced NF-κB signaling (Fig. 5). Diclofenac both decreased and delayed 
IκBα phosphorylation in association with an inhibition of its degradation (Fig. 5 A, top 
and middle panel respectively). The delay in IκBα degradation was associated with a 
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Figure 4. Diclofenac/TNFα-induced apoptosis is dependent on JNK activity. (A) JNK activation in time after 
diclofenac exposure +/- TNFα was assessed by Western blot analysis. Tubulin was used as loading control. 
“C”: controls exposed to vehicle for 24 hours +/- TNFα after 8 hours. The ratios represent the fold increase of 
phosphorylated protein expression over total protein compared to C (-TNFα). (B, C and D) Cells were treated 
with the cJun N-terminal kinase (JNK)-specific inhibitor SP-600125 (20 µM) and its effect on apoptosis induced 
by 500 μM diclofenac +/- TNFα was followed by AnxV-Alexa633 staining and automated imaging (B) and by 
cell cycle analysis after 24 h drug exposure (D). End-point quantification of the AnxV-Alexa633 signal increase 
after 24 hours of drug exposure in the live apoptosis assay (B) is shown in (C). (E) Effect of siRNA-mediated 
knockdown of the individual isoforms JNK1 and JNK2 on apoptosis induction by diclofenac/TNFα was followed 
by AnxV-Alexa633 staining and automated imaging. Data are the means of three independent experiments +/- 
S.E.M. *** P < .001, ** P < .01, * P < .05
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TNFα exposure (min)
0 5 15 30 60 90 120
1      17.5    2.0    12.4   12.0    8.9     13.2        FC of 0 min
Control
FC of 0 min 1     14.3    4.1     7.5      9.1     6.4      8.2        
500 μM
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500 μM
























































































Figure 5. Diclofenac inhibits NF-κB signalling induced by TNFα. (A) HepG2 cells were pre-exposed to diclofenac 
for 8 hours before adding TNFα (10 ng/mL). The phosphorylation status of inhibitor of NF-κB (IκBα) and the 
subsequent degradation of the IκBα protein, were determined by Western blot analysis. Tubulin staining was 
used as loading control. Results are representative of three independent experiments and the fold changes 
(FC) represent the tubulin-normalized FC in protein expression compared to 0 minutes of TNFα exposure. (B) 
The effect of 8 hours diclofenac exposure on nuclear factor κB (NF-κB) (p65) translocation into the nucleus 
was investigated in time by immunofluorescence staining of p65 (green). The nuclei were stained with Hoechst 
33258 (blue). The cells were imaged using a BD PathwayTM 855 imager. The results are representative for 
three independent experiments. (C) The nuclear translocation pattern of NF-κB was determined using the BD 
AttoVisionTM software. The graphs represent the means of three independent experiments +/- S.E.M. (D and 
E) HepG2 GFPp65 cells were used to follow the translocation of NF-κB after TNFα exposure live +/- diclofenac 
pre-treatment using automated confocal imaging with pictures taken every 6 minutes. (E) The graph represents 
the quantification of the GFPp65 nuclear/cytoplasmic intensity ratio normalized to the highest intensity/cell. 
(F) NF-κB transcriptional activity was investigated using a NF-κB luciferase reporter construct. The luciferase 
activity was measured after 12 hours drug exposure +/- 10 ng/mL TNFα for the last 4 hours. Results are 
expressed as ratios of the luciferase activity measured after TNFα exposure in non-pre-exposed cells over 
diclofenac pre-exposed cells and represent the means from three independent experiments +/- S.E.M. * P < .05
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wildtype HepG2 cells and live cell imaging of HepG2 cells stably expressing the NF-κB 
subunit p65 coupled to GFP (GFPp65) (Fig. 5 B and D). Automated image quantification 
of the p65 signal intensity ratio of nucleus/cytoplasm, showed that diclofenac delays the 
onset of the second nuclear entry of NF-κB (Fig. 5 C and E). This diclofenac-induced 
reduction of the TNFα-induced NF-κB nuclear translocation response was associated 
with a decrease in the transcriptional NF-κB activity after TNFα treatment (Fig. 5 F). 
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Figure 6. Inhibition of IKKβ prevents nuclear NF-κB 
translocation and enhances diclofenac/TNFα-induced 
apoptosis. (A) Immunofluorescence staining of HepG2 
cells for NF-κB (red) and Hoechst (blue) after exposure 
to 10 ng/mL TNFα. Pre-exposing the HepG2 cells to 2 µM 
of the IκB kinase (IKK)-inhibitor BMS-345541 for 6 hours, 
but not 1 hour successfully inhibits the NF-κB nuclear 
translocation. (B) HepG2 cells transiently expressing a 
NF-κB luciferase reporter, were pre-treated for 6 hours 
with 2 μM BMS-345541 followed by 10 ng/mL TNFα for 
4 hours before measuring luciferase activity. The graph 
shows the average of five independent experiments +/- 
S.E.M. (C) HepG2 cells were pre-exposed to diclofenac 
and IKK-inhibitor BMS-345541 before adding TNFα (10 
ng/mL). After 24 h of drug exposure cells were collected 
for cell cycle analysis by FACS. The graph shows the 
means from three independent experiments +/- S.E.M. 
*** P < .001, ** P < .01, * P < .05
NF-kB signaling is essential to prevent TNFa-mediated enhancement of diclofenac-
induced apoptosis
We anticipated that interference of the NF-κB signalling pathway is causally associated 
with diclofenac/TNFα-induced apoptosis. To inhibit NF-κB activation we used an inhibitor 
of IKKβ, BMS-345541 (BMS, 2 µM).  Pre-treatment with BMS for 6 hours prevented the 
TNFα-induced nuclear entry of NF-κB (Fig. 6 A) in association with decreased NF-κB 
transcriptional activity (Fig. 6 B). Under these conditions, BMS strongly sensitized the 
HepG2 cells for diclofenac/TNFα-induced apoptosis (Fig. 6 C).  
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 Next we determined whether knockdown of the NF-κB subunit p65 affected 
diclofenac/TNFα cell killing. Lentiviral shRNA-based stable knockdown of p65/RelA 
reduced the levels of p65 as determined by immunofluorescence and Western blotting 
NF-κB (Fig. 7 A and B). Moreover, importantly, TNFα-induced activation of a NF-κB-
luciferase reporter construct was inhibited in shRelA-HepG2 cells to approximately the 
same extent as pre-exposure to the IKKβ inhibitor BMS (compare Fig. 6 B and Fig. 7 C). 
Knockdown of p65/RelA did not affect the basic level of apoptosis under both control and 
TNFα conditions (Fig. 7 D and E, respectively). Next, we exposed the different cell lines 
to a concentration range of diclofenac for 8 hours followed by TNFα treatment. Loss of 
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Figure 7.  Knockdown of p65 sensitizes HepG2 cells for TNFα-enhanced diclofenac-induced apoptosis.  (A) 
Immunofluorescence staining of NF-κB (green) on untreated wild-type (Wt) HepG2 cells and cells stably 
transduced with control or human RelA short hairpin RNA (shRNA) constructs. Nuclei were detected with 
Hoechst 33258 (blue). (B) Quantification of RelA/p65 levels in Wt, shControl and shRelA HepG2 cells by Western 
blot analysis. (C) Control shRNA and p65/hRelA shRNA transduced HepG2 cells transiently expressing a NF-
κB luciferase reporter, were treated with 10 ng/mL TNFα for 4 hours before measuring luciferase activity. The 
graph shows the average of five independent experiments +/- S.E.M. (C and D) Wt, control shRNA transduced 
and HepG2 cells stably knocked down for p65 (hRelA shRNA), were exposed to diclofenac for 24 hours without 
(C) or in the presence of TNFα (10 ng/mL; D). The graphs represent the percentage of apoptosis detected by 
cell cycle analysis and shows the means from three independent experiments +/- S.E.M. *** P < .001, * P < .05
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(Fig. 7 D). However, knockdown of p65/RelA sensitized HepG2 cells towards diclofenac/
TNFα-induced apoptosis (Fig. 7 E). Together, these data confirm the important role of 
functional NF-κB signalling and nuclear translocation in protecting hepatocytes from 
TNFα-enhanced diclofenac-induced apoptosis.  
DISCUSSION
Drug-induced liver injuries are a significant problem in clinical practice as well as during 
drug development. There is increasing evidence for a role of the innate immune system 
in the pathophysiology of drug-induced liver injury which seems to involve an interaction 
between reactive metabolite formation and cytokine signaling (2, 5, 6). Diclofenac can 
cause drug-induced liver injury in an idiosyncratic manner. Here we studied in detail 
the role and mechanism of diclofenac/cytokine-induced stress signaling on the onset of 
hepatocyte apoptotic cell death. Our data indicate that: 1) TNFα enhances diclofenac-
induced cell death of HepG2 cells; 2) this cell death involves the onset of apoptosis 
which is dependent on a caspase-8/Bid/APAF1 cascade and the activity of caspase-3; 
3) the diclofenac/TNFα synergy involves an inhibition of TNFα-induced NF-κB activity 
which is related to a disruption of IκBα phosphorylation and degradation and subsequent 
differential translocation of NF-κB to the nuclear compartment. Our results support a 
model in which diclofenac affects the TNFα signaling program, thereby preventing 
the anti-apoptotic actions of NF-κB and allowing a JNK- and death receptor-mediated 
mitochondrial onset of apoptosis. 
 Our data demonstrate that TNFα enhances the cytotoxicity of diclofenac in 
both human HepG2 and mouse Hepa1c1c7 cells. Our data fit with a model whereby 
activated Kupffer cells in the liver release TNFα and thereby aggravate liver injury (10-
12). Although a role for TNFα in diclofenac-induced liver injury has not previously been 
demonstrated, LPS treatment severely enhances liver failure induced by diclofenac (13). 
Since LPS induces direct activation of Kupffer cells with the subsequent release of high 
levels of TNFα (9), a direct interaction between diclofenac and TNFα in the liver can be 
anticipated. Importantly, oral administration of diclofenac can cause severe injury to the 
intestine (28), thus creating a condition for increased systemic levels of endotoxins and 
activation of liver macrophages with a subsequent deleterious interaction with diclofenac 
in the liver. A role of polymorphonuclear neutrophils (PMNs) infiltration in the above 
mentioned animal model of diclofenac/LPS-induced liver injury was demonstrated by 
PMN-depleting antiserum (13). We suggest that this observation does not exclude the 
importance of (LPS-induced) TNFα secretion in this model, as we simulate in our in vitro 
system. Thus, the PMN-depletion only provided partial protection against diclofenac/LPS 
liver injury, while the deleterious effect of the PMNs themselves could involve the release 
of TNFα by these cells within the liver (28). 
 The concentrations of diclofenac used to achieve diclofenac/TNFα synergy (>100 
µM) in this in vitro study exceed the maximal plasma concentration reached in humans after 
a single dose of 50 mg, 5-10 µM (29; with the potentially higher concentration in the liver 
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after oral intake). This is also expected since HepG2 cells are poor in drug metabolizing 
capacity, but do form identical relevant diclofenac metabolites (see Supporting Data S1). 
Indeed, using HepG2 cells that express GFP-Nrf2, we could demonstrate stabilization 
of Nrf2 upon diclofenac treatment in a time and concentration dependent manner 
supportive for drug reactive metabolite formation that has cell biological consequences 
(Herpers, Fredriksson and van de Water, unpublished observation). Although the 
observed patient concentrations are well below the concentration used in our studies, 
higher levels of drug metabolism in hepatocytes in the liver as well as chronic treatment 
of patients with diclofenac is likely to lead to equal levels of drug metabolite formation as 
well as accumulation of diclofenac metabolite covalent modification of cellular proteins 
in hepatocytes, in particular after overdosing, conditions of liver function insufficiency or 
reduced capacity of systemic diclofenac excretion. 
 Our data indicate that diclofenac/TNFα-induced apoptosis involves a mitochondrial 
pathway. This is in accordance with previous observations that diclofenac alone can 
induce apoptosis via the mitochondrial death route, which involves an increase in free 
cytosolic calcium and induction of the mitochondrial pore transition (mPT) (31) most likely 
through Bax-mediated mitochondrial outer membrane permeabilization (MOMP) (22). 
We used a small siRNA library that targets all individual components of the apoptotic 
machinery. Thereby, we identified two Bcl-2 family members that contribute to the control 
of diclofenac/TNFα-induced apoptosis, Bid and PUMA, two pro-apoptotic family members 
(32). Bid is activated through direct caspase-8-mediated cleavage, thereby inducing 
onset of the MOMP in mitochondria (33). Indeed, diclofenac/TNFα activates caspase-8 
and knockdown of caspase-8 as well as an inhibitor of caspase-8 effectively inhibited 
diclofenac/TNFα-induced apoptosis (Fig. 2 and Fig. 3 A). Furthermore, knockdown of 
c-FLIP, an endogenous inhibitor of caspase-8, strongly enhances the apoptosis (Fig. 3 
B). Diclofenac-induced permeabilization of the mitochondria is followed by release of 
pro-apoptotic factors which results in activation of caspase-9 and caspases-3 mediated 
apoptosis (22, 31, 34). In our hands only a weak activation of caspase-9 could be seen 
with diclofenac and diclofenac/TNFα exposure (Fig. 2 A), and in accordance with this, the 
specific caspase-9 inhibitor was not fully effective in inhibiting diclofenac/TNFα-induced 
apoptosis (Fig. 2 C-E). Nevertheless, knockdown of caspase-9 as well as of APAF1 
was confirmed as essential for the diclofenac/TNFα-induced apoptosis (Fig. 3 A and 
Supporting Data S3). Together this suggests a clear role for the apoptosome formation in 
this process..
 We show that diclofenac directly affected the efficient TNFα-induced activation of 
NF-κB. Diclofenac inhibited the TNFα-mediated phosphorylation and degradation of the 
inhibitor of NF-κB, IκBα. This was directly associated with a shift in the oscillatory NF-κB 
translocation pattern and a reduced TNFα-induced NF-κB transcriptional activity (Fig. 5 
and Fig. 6). In our model, NF-κB signalling is essential in the control of diclofenac/TNFα-
induced apoptosis. Thus, inhibition of the NF-κB activation using an IKKβ-inhibitor, BMS-
345541, or stable shRNA-based RelA knockdown increases the cell death induced by 
diclofenac/TNFα (Fig. 6 C and Fig. 7 E). The inhibition of NF-κB signaling by diclofenac 
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most likely affects the anti-apoptotic program typically induced by TNFα in normal cells 
(15). This would result in the reduced expression of anti-apoptotic molecules. Indeed, 
in cutaneous squamous cell carcinoma cells, diclofenac enhances death ligand-
induced apoptosis which was associated with downregulation of c-FLIP (35), an NF-κB 
target gene that inhibits caspase-8 (36). Knockdown of c-FLIP in our hands enhances 
diclofenac/TNFα induced apoptosis (Fig. 3 B). TNFα alone did not cause apoptosis when 
NF-κB signaling was inhibited by BMS-345541 or RelA knockdown (Fig. 6 C and Fig. 7 
E). This indicates that TNFα signaling itself is not the main contributor to the onset of 
apoptosis, further supporting a synergistic action between TNFα and the toxic properties 
of diclofenac, most likely involving formation of diclofenac reactive metabolites (2, 5, 6; 
Supporting Data S1).
 In summary, we show that TNFα enhances hepatocyte injury caused by 
diclofenac. We propose a mechanism by which diclofenac inhibits the TNFα-induced 
nuclear translocation of NF-κB thereby affecting the transcriptional activation of anti-
apoptotic molecules and allowing a caspase-8/Bid/APAF1 dependent onset of apoptosis 
(see Fig. 8). These results shed new light on the interaction of hepatotoxic drugs and 
pro-inflammatory cytokines in drug-induced liver cell injury.  
Figure 8. Working model for diclofenac-TNFα hepatotoxicity synergy. Reactive metabolites formed by diclofenac 
(DCF) metabolism inhibits IκBα phosphorylation in association with the NF-κB nuclear translocation oscillatory 
response and transcriptional activity. In the absence of the anti-apoptotic NF-κB signaling, the synergistic 
activation of both the death receptor pathway and JNK signaling pathway, mediate the onset of apoptotic 
cell death. This apoptosis is dependent on the caspase-8/Bid/Apaf-1/caspase-9/3 pathway with an additional 
involvement of the pro-apoptotic Bcl-2 family member PUMA. 
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SUPPORTING MATERIALS AND METHODS
Metabolite measurements
HepG2 cells were grown until confluency in TC-75 flasks and incubated with 500 µM 
diclofenac in 15 mL complete DMEM for 8, 16 or 24 hours. After incubation, 15 mL ice-
cold methanol (MeOH) was added and the total volume with cells was collected in 50 mL 
falcon tubes and stored at -80°C until analysis. The incubations were first centrifuged 
for 15 minutes at 4000 rpm to remove the cells. Solid phase extraction (SPE) was used 
for the isolation and purification of the metabolites. StrataTM-X C-18 SPE columns 
(Phenomenex, Torrance, CA, USA) were first conditioned according the manufacturer’s 
instructions. A 6 mL aliquot of the supernatant for each time point was then applied to the 
column and washed with 6 mL of water. Diclofenac and its metabolites were eluted using 
2 x 1 mL of MeOH. Samples were evaporated to dryness under a stream of nitrogen 
and reconstituted in 300 μL of methanol/water (1:1, v/v). Samples were analyzed using 
LC-MS/MS for identification and UV/VIS detector on 254 nm for quantification with the 
assumption that the extinction coefficients of the formed metabolites are equal to that 
of diclofenac. A SymmetryShieldTM RP18 3.5 μm column (100 mm x 4.6 mm i.d.) from 
Waters Corporation (Milford, Massachusetts, USA) was used as stationary phase using 
previously described HPLC conditions for diclofenac metabolites separation (1). An 
Agilent 1200 Series Rapid resolution LC system was connected to a hybrid quadrupole-
time-of-flight (Q-TOF) Agilent 6520 mass spectrometer (Agilent Technologies, Waldbronn, 
Germany), equipped with electrospray ionization (ESI) source and operating in the 
positive mode with the MS ion source parameters previously described (2).
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SUPPORTING DATA
Supporting Data S2. List of genes included in the primary apoptosis siRNA screen. The table 
presents all the short interfering RNAs (siRNAs) included in the screen, as well as the fold change 
in apoptosis endpoint that each individual siRNA resulted in after diclofenac/TNFα (500 µM/10 ng/
mL) treatment in HepG2 cells compared to siControl. The mean apoptosis endpoint of all three 
experiments, expressed as fold change over siControl, is given under “Average”. Blue indicates 
the genes that are identified as apoptosis inducers (≥ 2.0-fold reduction in endpoint compared to 
siControl) and in Red the genes that are identified as apoptosis suppressors (≥ 2.0-fold induction 





















Diclofenac acylglucuronidesC. Supporting Data S1. Diclofenac metabolites accumulate in 
HepG2 cells. (A) i) Chromatogram of diclofenac metabolite 
spectrum. Four different diclofenac acylglucuronides 
(D-O-G) were identified with retention times 21.18 minutes, 
21.99 minutes, 22.57 minutes and 22.89 minutes (a-d). The 
star (*) at 25.44 minutes indicates m/z 278, a diclofenac 
metabolite which results form intramolecular cyclization 
of the acylglucuronide. The arrow (e) points at 4’-OH-
diclofenac (m/z 312, 24.44 minutes). 5-OH-diclofenac (m/z 
312, 23.78 minutes) and 5-OH-Quinone-Imine-diclofenac 
(m/z 310, 23.13 minutes) are not indicated, as these are 
not UV-detectable. ii) Extracted Ion Chromatogram (EIC) of 
the hydroxy-metabolites. Red indicates 5-OH-QI-diclofenac, 
blue 5-OH (f) and 4’-OH-diclofenac (e). (B) MS/MS spectra 
that identifies the respective peaks from panel A. (C) 
Quantification of the different diclofenac acylglucuronide 
metabolites in HepG2 cells at 8 hours, 16 hours and 24 
hours of incubation. 
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 Exp. 1 Exp. 2 Exp. 3 Average 
CASP1 1.07 1.85 1.38 1.38 
CASP10 1.16 1.98 1.46 1.48 
CASP14 1.12 1.98 1.09 1.36 
CASP2 0.58 0.99 0.93 0.79 
CASP3 0.58 0.57 0.87 0.66 
CASP4 1.46 1.97 2.23 1.82 
CASP6 0.73 0.87 0.96 0.83 
CASP7 0.93 1.14 1.42 1.12 
CASP8 -0.02 0.08 0.19 0.07 
CASP9 0.43 0.90 0.58 0.60 
BCL10 1.87 4.29 3.53 3.02 
BCL2 0.60 0.72 0.94 0.72 
BCL2A1 0.73 0.94 0.72 0.79 
BCL2L1 0.75 0.95 1.00 0.87 
BCL2L10 1.60 2.71 2.50 2.17 
BCL2L11 0.62 0.71 0.53 0.62 
BCL2L14 0.60 1.07 0.95 0.83 
BCL2L2 1.06 1.61 1.39 1.31 
BAD 0.63 1.07 1.42 0.97 
BAG1 0.51 0.95 0.85 0.73 
BAG4 1.05 - 1.01 1.10 
BAG5 0.63 0.66 0.74 0.67 
BAK1 1.10 1.04 1.25 1.12 
BAX 0.70 0.94 1.57 1.00 
BBC3 0.38 0.56 0.63 0.50 
BMF 0.78 1.29 1.33 1.07 
BOK 0.74 2.13 1.73 1.41 
MCL1 0.68 1.32 1.64 1.13 
BID 0.22 0.40 0.42 0.32 
HRK 0.23 0.76 0.79 0.53 
PMAIP1 0.82 1.03 1.04 0.94 
BIK 1.08 1.93 1.14 1.34 
API5 0.84 0.70 0.96 0.83 
BIRC1 0.48 1.19 1.04 0.84 
BIRC2 1.07 1.82 2.09 1.56 
BIRC3 0.75 0.45 0.85 0.69 
BIRC5 0.29 1.06 1.07 0.72 
BIRC6 1.01 1.71 1.53 1.36 
DIABLO 1.50 2.32 1.79 1.82 
BIRC4 1.05 1.91 1.53 1.43 
PDCD8 0.40 0.34 0.55 0.42 
APAF1 0.30 0.34 0.55 0.38 
AVEN 1.17 2.28 1.73 1.64 
BFAR 0.55 1.06 1.30 0.90 
CFLAR 2.01 3.77 4.32 3.14 
CRADD 1.80 2.64 2.01 2.10 
CYCS 0.96 1.48 1.08 1.14 
DEDD 0.66 0.82 1.21 0.85 
TOSO 0.75 1.16 1.05 0.95 
MOAP1 0.80 1.92 1.11 1.21 
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Supporting Data S3. Graphical representation of hits from the secondary siRNA screen. (A) Confirmed 
inducers of diclofenac/TNFα-caused apoptosis in HepG2 cells for which knockdown could also be verified 
by western blotting. The knockdown confirmed by western blotting was achieved by transfection with 
siRNA smartpools as used in the primary screen. The fold change of protein expression after knockdown 
was determined by comparing tubulin normalized band intensities from the knockdown to the one of 
siControl transfected cells.  (B) Confirmed inducers and inhibitor of diclofenac/TNFα-caused apoptosis 
that were not verified by western blotting. (A and B) The constructs that caused >1.5 fold increase or 
decrease in apoptosis compared to siControl transfected cells after 24 h diclofenac/TNFα treatment 
were identified as confirmed hits from the primary screen. The individual apoptosis time curves from the 





































Supporting Data S4. Protein levels of 
JNK1/2 after JNK1 and JNK2 knockdown. 
HepG2 cells were transfected with cJun 
N-terminal kinase (JNK)-1, JNK2, JNK3 and 
Control siRNA before collecting lysates from 
those cells to confirm knockdown by Western 
blot analysis 96 hours after transfection. 
The data shown is representative of 3 
independent experiments corresponding to 
the results shown in Figure 4E.
3High content imaging of Nrf2 and NF-kB activation as markers for the prediction of drug-induced liver injury
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ABSTRACT
Drug-induced liver injury (DILI) is an important clinical problem, yet predicting human 
DILI for novel candidate drugs remains difficult. Current models indicate that in many 
cases DILI is linked to reactive metabolite formation and involves activation of innate 
immune responses.Here we systematically evaluated the combined application of high 
content live cell imaging-based analysis of 1) Nrf2 activation as a measure for reactive 
metabolite stress; 2) perturbations of the normal NF-κB activation mediated by TNFα; 
and 3) synergistic induction of apoptosis by DILI compounds and TNFα. Fifteen drugs 
associated with DILI were evaluated. Most DILI compounds induced Nrf2 stabilization-
dependent activation of the downstream target SRXN1 (11 out of 15). Various DILI 
compounds diminished the TNFα-induced activation of NF-κB (6 out of 15), which strongly 
correlated to the strength of Nrf2 activation. In particular for those compounds that show 
strong Nrf2 activation and perturbation of NF-κB signaling, a significant drug-cytokine 
synergy for apoptosis was observed, which included carbamazepine, diclofenac and 
ketoconazole, and to a lesser extent clozapine, nefazodone and amiodarone. Together, 
our data support that mechanism-based high content imaging strategies involving 
combined analyses of cellular stress responses contribute to DILI hazard identification. 
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INTRODUCTION
Adverse drug reactions are difficult to predict because of a lack in the understanding of 
the underlying mechanisms (1). Evidence points at the formation of chemically reactive 
metabolites being one of the initial causes of drug-induced liver injury (DILI) (1, 2), 
leading to oxidative stress and mitochondrial dysfunction (3). In addition, DILI involves an 
immune component (4) largely involving the innate immune system with the liver Kupffer 
cells as critical players (5-8). Activated immune cells release pro-inflammatory cytokines 
(9) which act on the hepatocytes undergoing reactive metabolite stress. This combination 
of toxicant and cytokine-induced stress signals may activate a pro-apoptotic response. 
Indeed, in mouse models non-hepatotoxic drugs (with DILI association in humans) can 
become hepatotoxic by co-treatment with lipopolysaccharide (LPS) which is dependent 
on the pro-inflammatory cytokine TNFα (10, 11). This critical role of TNFα in adverse 
drug-cytokine synergy can be reconstituted in an in vitro model by co-exposing liver 
epithelial cells to drugs linked to DILI in combination with TNFα (12, 13).
 Reactive drug metabolite-mediated intracellular perturbations of the cellular 
redox potential are counterbalanced by the anti-oxidant response under control of the 
transcription factor Nrf2 (14, 15). Under low oxidative stress conditions Nrf2 is degraded 
by the proteasome, due to ubiquitination by its inhibitory protein Keap1 (or INrf2) (14). 
During toxic stress the soft electrophilic reactive metabolites and/or increased levels of 
reactive oxygen species (ROS) target the cysteine residues in Keap1 (16, 17), allowing 
Nrf2 to evade the Keap1-mediated repression, and accumulates in the nucleus to activate 
a diversity of cytoprotective antioxidant target genes (18). Nrf2 is an essential transcription 
factor for defense against DILI (18), e.g. for the detoxification of acetaminophen (APAP) 
(19, 20). Interestingly, activation of Nrf2 is also influenced by the p53-p21 axis, autophagy, 
HSP90 and NF-κB signaling (21). This indicates that oxidative stress signaling, apoptosis 
regulation and immune signaling are tightly linked biological programs to accurately 
control the cell fate decision after toxicant exposure.
 TNFα binding to its receptor leads to activation of the tri-partite inhibitor of kappa-B 
kinase (IKK-) complex (IKKα, IKKβ and NEMO). This kinase complex phosphorylates the 
inhibitor of kappa B (IκBα), leading to rapid ubiquitination and degradation of this inhibitor 
directly followed by the release of NF-κB and nuclear translocation to activate its target 
genes. A primary early transcriptional target of NF-κB is IκBα (NFKBIA), which recruits NF-
κB back into the cytoplasm (resting state), creating an autoregulatory negative feedback 
loop (22). Hence, NF-κB activation follows an oscillating nuclear translocation pattern, 
dependent on the persistence of the cytokine signal and intracellular responses (23). 
Its periodicity is influenced by redox regulation and dictates the outcome of the genetic 
response (24). Importantly, we recently established that the hepatotoxicant diclofenac 
interferes with the NF-κB oscillatory response in association with a synergy between 
diclofenac and TNFα to induce apoptosis in liver cells (13). Whether this holds true for 
other DILI compounds is investigated here.
 We established a high content imaging-based strategy using HepG2 cells as 
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a model to quantitatively follow the onset of apoptosis, Nrf2-dependent activation of 
Sulfiredoxin (Srxn1) expression, and nuclear oscillation of NF-κB. These assays were 
used for concentration- and time-course experiments with a panel of fifteen drugs 
associated to human DILI: acetaminophen (APAP), 3’-hydroxyacetanilide (AMAP), 
amiodarone (AMI), carbamazepine (CBZ), clozapine (CLZ), diclofenac (DCF), isoniazid 
(INH), ketoconazole (KTZ), methotrexate (MTX), nefazodone (NFZ), naproxen (NPX), 
nitrofurantoin (NTF), ofloxacin (OFX), simvastatin (SN) and troglitazone (TGZ). We 
studied their effect on cell stress in relation to co-exposure with TNFα. Our results indicate 
that a strong correlation between Nrf2 activation and inhibition of TNFα-induced NF-κB 
nuclear translocation responses. When both of these response pathways are affected, 




All drugs were acquired from Sigma-Aldrich and freshly dissolved in DMSO, except for 
menadione and naproxen (in PBS). Human TNFα was purchased from R&D systems 
and stored as 10 μg/mL in 0.1% BSA in PBS aliquots.
 
Cell culture
Human hepatoma HepG2 cells were acquired from ATCC (clone HB8065) and maintained 
and exposed to drugs in DMEM high glucose supplemented with 10% (v/v) FBS, 25 U/
mL penicillin and 25 μg/mL streptomycin. The cells were used between passage 5 and 
20. For live cell imaging, the cells were seeded in Greiner black μ-clear 96-well plates, at 
20,000 cells per well.
Generation of GFP-tagged cell lines
HepG2 cells stably expressing human GFP-p65 as in (13). Mouse Sulfiredoxin (Srxn1) 
was tagged with GFP at the C-terminus using BAC recombineering (25) and stably 
introduced into HepG2 cells by transfection and 500 μg/ml G-418 selection. 
RNA interference
siRNAs against human NFE2L2 and KEAP1 were acquired from Dharmacon 
(ThermoFisher Scientific) as siGENOME SMARTpool reagents, as well as in the form of 
four individual siRNAs. HepG2 cells were transiently transfected with the siRNAs (50 nM) 
using INTERFERin (Polyplus). 
Western blotting
Samples were collected by direct cell lysis (including pelleted apoptotic cells) in 1x Sample 
Buffer supplemented with 5% v/v β-mercaptoethanol and heat-denatured at 95°C for 10 
minutes. The separated proteins were blotted onto PVDF membranes before antibody 
incubation in 1% BSA in TBS-Tween20. Antibodies: mouse-anti-GFP (Roche); rabbit-
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anti-IκBα (Cell Signaling); rabbit-anti-Nrf2 (H300, Santa-Cruz); mouse-anti-caspase-8 
(Cell Signaling); rabbit-anti-cleaved PARP (Cell Signaling); mouse-anti-Tubulin (Sigma).
Microscopy
Real-time apoptosis induction was determined by monitoring the accumulation of 
Annexin-V-Alexa633 labeled cells over a 24 hour time period (26). For this, transmission 
and Alexa633 images of the same area with cells were taken automatically every 30 
minutes using a BD Pathway™ 855 bioimager and a 10x Olympus PlanApo lens. 
 Stabilization of Srxn1-GFP or nuclear oscillation of GFP-p65 was monitored 
using a Nikon TiE2000 confocal laser microscope (lasers: 488nm and 408nm), equipped 
with an automated stage and perfect focus system. Prior to imaging at 20x magnification, 
HepG2 cells were loaded for 45 minutes with 100ng/mL Hoechst33342 to visualize the 
nuclei, upon which the Hoechst-containing medium was washed away to avoid Hoechst 
phototoxicity (27). Srxn1-GFP cells were imaged every 30 minutes across a 24 hour time 
span, GFP-p65 cells every 6 minutes for 6 hours.
Image quantification
To quantify the total pixel area occupied by cells or the number of cells per field imaged, 
transmission images and Hoechst images respectively were analyzed using ImagePro 
7.0 (Media Cybernetics). The accumulation of apoptotic cells or the appearance of 
Srxn1-GFP positive cells was quantified as the total number of pixels above background. 
The apoptotic pixel total was normalized for the total cell area. The number of adjacent 
fluorescent Srxn1-GFP pixels above background (with a minimum size of 45 pixels) 
was multiplied by the average density of those pixels as a measure for the GFP signal-
intensity increase and normalized for the amount of nuclei. 
 To quantify the nuclear translocation of GFP-p65, nuclei (Hoechst) masks are 
segmented and tracked in ImageJ to define the GFP-p65 nuclear intensity, followed by 
cytoplasm segmentation. The normalized nuclear / cytoplasmic intensity ratio for each 
cell is recorded and further analyzed for different oscillation features, also using ImageJ, 
including the number of translocations, time period of each individual peak, intensity of 
the peaks, delay between peaks, and nuclear entry and exit rates (Di Z., Herpers B., 
Fredriksson L., et al., submitted for publication).
Statistics
All experiments are performed at least in triplicate. Error bars indicate Standard Error, 
unless indicated otherwise. Statistical comparisons were done in a one-way ANOVA. 
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RESULTS
Drug-induced cell death of human HepG2 cells
To establish a strategy for a mechanism-based evaluation of adverse drug liver toxicities 
in in vitro models we assembled a list of 15 compounds linked to various types of adverse 
drug liver toxicity (Supporting Table 1). HepG2 cells were chosen as a model system since 
genetic manipulation allows the integration of fluorescent reporter constructs for live cell 
imaging approaches. First we incubated cells in presence of Alexa633-labeled AnnexinV 
and used live cell imaging to determine the concentration-dependent onset of apoptotic 
cell death. While none of the compounds induced an overwhelming amount of cell death, 
our sensitive and robust method allowed us to identify a concentration-dependent HepG2 
cell apoptosis for AMI, AMAP, APAP, CBZ, CLZ, DCF, KTZ, NFZ, NTF and SN. Little 
apoptosis was observed for INH, MTX, NPX, OFX and TGZ. For further experiments for 
each compounds we defined a concentration that is mildly cytotoxic (indicated in Fig. 1 A) 
to establish the effect on Nrf2 activation, NF-κB signaling and in relation to co-exposure 
to the pro-inflammatory cytokine TNFα.
A BAC-Srxn1-GFP HepG2 cell line reports xenobiotic-mediated Nrf2 activation
Rising levels of oxidative stress leads to activation of the antioxidant pathway, controlled 
by the transcription factor Nrf2. We first monitored the dynamics of Nrf2 stabilization 
in our HepG2 model. Menadione (20 μM, MEN), di-ethyl maleate (100 μM, DEM) and 
iodoacetamide (10 μM, IAA) are potent pro-oxidant xenobiotics that time-dependently 
stabilize Nrf2 in HepG2 cells (Fig. 1 B). Also KTZ and DCF for which phase I and II 
metabolism has been demonstrated in HepG2 cells (13, 28) caused stabilization of Nrf2.
To visualize the Nrf2 activation in real time, we generated HepG2 reporter cells expressing 
the Nrf2 target gene Sulfiredoxin (Srxn1) coupled to GFP, controlled by its own promoter, 
by BAC recombineering (25). Under normal conditions, the Srxn1-GFP reporter is not 
expressed, but exposure to MEN, DEM, IAA, H2O2, DCF and KTZ induced a strong time-
dependent expression of GFP-Srxn1 (Fig. 1 C) which was easily detected by confocal 
microscopy live-cell imaging (Fig. 1 D-E). Quantification of the Srxn1-GFP signal shows 
that activation of the Nrf2 response by the different Nrf2-inducing compounds follows 
differential activation patterns. All compounds activated the Srxn1-GFP expression within 
8 hours. However, while MEN, DEM, IAA and H2O2 induce acute Srxn1-GFP expression 
upon a lag-phase of 4 hours, the hepatotoxicants DCF and KTZ induce a gradual increase 
of the Nrf2 activity reporter over time (Fig. 1 E), possibly related to reactive metabolite 
formation. Importantly, the Srxn1-GFP expression in our model is Nrf2-dependent, since 
transfection with siRNA oligos targeting Nrf2 inhibits the expression of Srxn1-GFP after 
exposure to MEN, DEM, DCF and KTZ (Fig. 1 F). Moreover, also Keap1 knockdown 
which caused an expected stabilization of Nrf2, strongly induced Srxn1-GFP levels. 
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Figure 1. Drug-induced apoptosis and oxidative stress (A) Percentage of apoptotic HepG2 cells at 24 hours 
after exposure to fifteen different drugs. Concentrations are indicated in μM, except for AMAP, APAP and 
INH: in mM. “0”: 0.2% (v/v) DMSO. Shaded bars: concentration used in subsequent assays. (B) Western blot 
of Nrf2 expression in HepG2 cells exposed for 8 or 16 hours. (C) Western blot of GFP expression in HepG2 
Srxn1-GFP cells. (D) Stills of time-lapse image series of HepG2 Srxn1-GFP cells exposed to Nrf2 inducers. 
(E) Quantification of the Srxn1-GFP reporter response kinetics. (F) Knockdown of Nrf2 (siNFE2L2) and Keap1 
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DILI compounds activate the Nrf2 stress response independent of TNFR activation
Next, we systematically tested the panel of liver toxicants on the HepG2 Srxn1-GFP 
reporter cells and monitored the increase of the GFP signal by live-cell imaging (Fig. 2 
A-B). We observed that APAP and its regioisomer AMAP potently induce the oxidative 
stress reporter, as soon as 4 hours after compound exposure. The drugs CBZ, CLZ, DCF, 
KTZ, NFZ and NTF strongly induced the Srxn1-GFP reporter 8 hours after compound 
exposure. AMI, MTX and NPX are weak oxidative stress inducers, and Srxn1-GFP 
induction was observed with delayed kinetics, at 16 hours after compound exposure. 
The drugs INH, OFX, SN and TGZ did not lead to oxidative stress induction within the 
24-hour imaging period in our cell system. These results were confirmed by Western blot 
(Fig. 2 C-D).
 Next, we addressed the question whether TNFα (10 ng/ml) co-exposure increases 
the rate of Nrf2 stabilization. TNFα has been reported to induce ROS formation, which 
can be counterbalanced by NF-κB driven production of anti-oxidant genes (29). However, 
as an anti-oxidant transcription factor, Nrf2 is potentially involved in this process as well. 
We observed no significant rise in Nrf2 stabilization or Srxn1-GFP expression when the 
HepG2 Srxn1-GFP cells were exposed to TNFα alone (Fig. 2 C and D). Since most of 
our test drugs induced activation of the Nrf2 response 8 hours after drug exposure, we 
pre-incubated for 8 hours before addition of 10 ng/ml TNFα and assessed the effect 
of TNFα on the activity of the oxidative stress response 24 hours after the start of the 
exposure. No significant increase in Nrf2 responses by compound-TNFα combination 
was observed (Fig. 2 C and D).
Multiparametric analysis of HepG2/GFP-p65 cells to monitor spatio-temporal NF-
kB responses
TNFα promotes liver cell injury under hepatotoxicant treatment conditions. We previously 
demonstrated that this is related to perturbations of NF-κB signaling by TNFα (13). To 
monitor the effect of the hepatotoxicants on the execution of the NF-κB response, we used a 
previously established HepG2 cell line expressing GFP-tagged p65/RelA, a subunit of the 
dimeric transcription factor NF-κB. This GFP-p65 reporter allows us to follow and quantify 
the spatio-temporal nuclear translocation of NF-κB. TNFα promotes phosphorylation and 
subsequent degradation of the NF-κB inhibitor IκBα in an oscillatory manner (Fig. 3 A) 
which is followed by nuclear translocation of NF-κB that oscillates in time (Fig. 3 B: top 
panel). This activity is IKK-dependent, because an 8 hour pre-incubation with 2 μM BMS-
345541, a potent IKKβ inhibitor, resulted in inhibition of the NF-κB oscillation response 
(Fig. 3 B). Quantification of the nuclear/cytoplasmic ratio of the GFP-p65 NF-κB reporter 
construct (based on ~1000 individual cells per condition) revealed that BMS-345541 
not only inhibits the NF-κB response in relation to the number of nuclear translocation 
events at 0.5 μM, but also the translocation amplitude of the GFP-p65 signal (Fig. 3 
C). Extraction of multiple parameters from the oscillation pattern of all individual cells 
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Figure 2. Drug exposure induces dynamically divergent Nrf2 responses. (A) Stills of live-cell imaging on HepG2 
Srxn1-GFP cells upon drug exposure (shown are 4, 14 and 24 hours). (B) Quantification of the Srxn1-GFP 
signal appearing upon drug exposure. (C) Western-blots for Nrf2 and GFP expression after 24 hour drug 
exposure in HepG2 Srxn1-GFP cells, either with or without co-exposure to 10ng/ml TNFα. (D) Quantification of 
the Nrf2 and Srxn1-GFP protein levels, 24h after drug +/- TNFα exposure.
within the observed population revealed that the IKKβ inhibition caused a concentration-
dependent decrease in the number of cells oscillating upon TNFα stimulation, together 
with an increase in the time of the second nuclear translocation maximum (150 minutes 
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in control conditions, 186 minutes at low BMS-345541 concentrations, and 216 minutes 
at the highest concentration) (Fig. 3 D). These data indicate that this GFP-p65 HepG2 
reporter cell line in combination with high content imaging provides thorough insight in 
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Figure 3. TNFα stimulation induces IKKβ-dependent NF-κB oscillations. (A) 10 ng/ml TNFα stimulation induces 
IκBα phosphorylation and degradation, followed by IκBα re-synthesis and degradation. (B) HepG2 GFP-p65 
(NF-κB reporter) cells treated for 8 hours with the IKKβ-inhibitor BMS-345541 before TNFα exposure show 
impaired NF-κB nuclear translocation. (C) Quantification of the nuclear/cytoplasmic GFP-p65 intensity ratio 
in control (0.2% DMSO) and BMS-345541 treated cells upon TNFα stimulation. (D) Statistical analysis of the 
HepG2 GFP-p65 cell population under control versus BMS-345541 conditions.
DILI compounds cause a perturbation of NF-kB signaling
Next we tested the effect of DILI compound treatment on TNFα-induced NF-κB activation. 
We selected an 8-hour drug pre-incubation period before the addition of TNFα. As 
reported previously, DCF delayed the second translocation event (+20 min) (Fig. 4 A). 
AMI (+20 minutes), CBZ (+20 minutes) and NTF (+20 minutes) delayed the oscillation 
to a similar extent as DCF. Already at 25 μM KTZ strongly delayed the oscillation by 37 
minutes. NFZ delayed the oscillation by 30 minutes. Pretreatment with CLZ and MTX 
only weakly perturbed the appearance of the second translocation response with a delay 
of 10 and 16 min, respectively. Neither AMAP, APAP, INH, OFX, SN nor TGZ significantly 
influenced the translocation maximum of the second nuclear translocation event.
 Detailed cell population-based quantitative analysis of the translocation response 
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Figure 4. Drug-impaired NF-κB activation. (A) Time-lapse images of one representative cell showing NF-κB 
oscillation upon 10 ng/ml TNFα stimulation after an 8-hour drug pre-incubation period. Arrowheads point at 
the local nuclear translocation maxima. Quantified average of the GFP-p65 nuclear/cytoplasmic intensity ratio, 
normalized between 0 and 1 to focus on the appearance of the nuclear translocation maxima (peaks). (B) 
Analysis of the NF-κB response: time between peaks 1 and 2. (C) Analysis of the NF-κB response: assessment 
of the number of peaks. (D) Distribution of the TNFα-stimulated, drug pre-exposed cell population, classified for 
showing 0 to 5 peaks within the 6-hour imaging period.
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allows extraction of various parameters that describe the NF-κB oscillation response to 
TNFα. Indeed, pre-treatment with AMI, CBZ, DCF, KTZ, NFZ or NTF significantly affects 
the time between the translocation maxima 1 and 2 (Fig. 4 B) and thereby reduces the 
average number of translocation events within the 6-hour imaging window (Fig. 4 C). 
Importantly, by evaluating the cell distribution of on average ~1000 cells per condition, we 
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Figure 5. Drug pre-incubation followed by TNFα may induce adverse drug-cytokine synergy. (A) Still images 
of time-lapse movies of HepG2 cells exposed to the drugs in co-presence of Annexin-V-Alexa-633, taken at 8 
hours (before 10 ng/ml TNFα addition) and at 24 hours (16 hours TNFα). (B) Quantification of the percentage 
apoptotic cells appearing upon drug only exposure, or in combination with TNFα. (C) Western-blot for 
cleaved caspase-8 and the caspase substrate PARP induction by drug alone or drug-TNFα co-treatment. (D) 
Comparison of the quantified percentage apoptotic cells 24 hours after drug (+TNFα) exposure, the area under 
the curve (AUC) and cleaved caspase-8 protein levels. 
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of cells with only one or two nuclear translocation peaks, and thereby decreased the 
percentage of cells with three or more NF-κB nuclear translocation events (Fig. 4 D). 
DILI compound and TNFa synergy towards apoptosis  
Since TNFα drives a NF-κB-dependent pro-survival response we anticipated that the 
inhibitory effect of drug pre-exposure on the NF-κB response might sensitize HepG2 
cells towards apoptosis. To address this we systematically analyzed the compound-
TNFα apoptosis synergy upon 8-hour drug pre-treatment followed by TNFα treatment. 
We monitored the onset of apoptosis within a 24-hour time period by live-cell imaging of 
AnnexinV-Alexa633 (Fig. 5 A). TNFα clearly enhanced the cell killing for CBZ, DCF and 
KTZ compared to the drugs alone. The cell killing for the other compounds was low, yet 
a significant increase in apoptosis under drug/TNFα conditions could be observed for 
AMI, CLZ and NFZ (Fig. 5 B). To further evaluate the onset of apoptosis, we monitored 
caspase-8 activation and PARP cleavage as markers of death receptor mediated cell 
killing. In accordance with the live apoptosis assay, we found a marked increase in 
cleaved caspase-8 and caspase-cleaved PARP under DCF/TNFα and CBZ/TNFα co-
exposure conditions (Fig. 5 C and D).
Integrated analysis of Nrf2, NF-kB and apoptosis high content live cell imaging 
assays
Finally we evaluated the relationship between Nrf2 activation, NF-κB signaling 
perturbations and compound/TNFα synergy. For all markers we defined the response 
from absent to very strong and accordingly ranked the compounds based on their 
synergy response (Table 1). Firstly, the data indicate that there is not a necessary 
correlation between Nrf2 activation and NF-κB inhibition, since both AMAP and APAP 
have a strong Srxn1-GFP induction but hardly affect the NF-κB response. In this situation 
also no cytotoxic synergy is observed. Yet for almost all compounds that show some 
synergy response for apoptosis, a strong Srxn1-GFP induction as well as a delayed NF-
κB nuclear oscillation is observed. 
DISCUSSION
Whether a candidate drug in the development phase harbors an increased risk for liver 
failure remains difficult to predict due to the lack of adequate biomarkers and predictive in 
vitro and in vivo models. In this manuscript we propose the integration of three high content 
quantitative microscopy live cell imaging-based in vitro approaches to systematically 
analyze and classify the effect of drug exposure over time by addressing the biochemical 
mechanism (oxidative stress-based Nrf2 activation), the immune response mechanism 
(NF-κB signaling) and the cell death response (apoptosis). 
 Drug metabolism can create reactive soft electrophiles which are eradicated by 
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further phase 2 drug metabolism or scavenged by glutathione (GSH). GSH depletion 
is sensed by the Nrf2-Keap1 system, which responds by Nrf2-driven increases in GSH 
production. Alternatively, reactive metabolites may covalently modify free cysteine 
moieties in Keap1. To monitor activation of the Nrf2-Keap1 as a measure for reactive 
metabolite formation, we made advantage of a bacterial artificial chromosome-based 
Sulfiredoxin (Srxn1)-GFP reporter, driven by the endogenous promoter of Srxn1, which 
is fully dependent on Nrf2. Most DILI compounds showed activation of the Nrf2 response 
suggesting that reactive metabolites are formed by these compounds. Indeed in an 
earlier study we demonstrated metabolite formation for DCF (13). We observed for APAP 
and its regioisomer AMAP a fast Srxn1-GFP induction, similar to the GSH-depleting 
agents DEM and IAA, suggesting a direct effect for GSH depletion on the Nrf2 induction. 
Sustained Nrf2 stabilization, indicating persistent Nrf2 activation, was found for CLZ, 
DCF, KTZ, NFZ and NTF, possibly modifying Keap1 through reactive metabolites, which 
correlated with Srxn1-GFP induction. No effect was found on the Nrf2 response or the 
Nrf2 reporter in HepG2 cells for the drugs INH, NPX, OFX, SN and TGZ. This effect might 
be due to the low expression of cytochrome P450 enzymes in HepG2 cells, compared 
to primary hepatocytes (30), the FBS concentration (10 %) used (31), the duration of the 
experiments, or the chosen concentration (32). Since the redox-cycling agent MEN as 
well as H2O2 also activated Srxn1-GFP expression, at this moment we cannot entirely 
exclude that the observed effect for the DILI compounds is (partly) related to secondary 
oxidative stress, possibly derived from mitochondrial toxicity. Further research is required 
to identify the exact mechanism of Nrf2 activation for the different DILI compounds.  
 Stimulation of HepG2 cells with TNFα activates the IKK complex, which is 
essential for the activation of the downstream NF-κB response. We showed that a strong 



























CBZ 3.2 10 20 1.98 2.8 21.8 18.9 12 
DCF 5.7 10 20 1.91 3.8 13.6 9.8 12 
KTZ 7.3 8 37 1.75 4.1 6.7 2.7 12 
CLZ 3.6 11 10 2.07 3.3 5.3 2.0 22 
NFZ 3.8 10 20 1.66 2.8 4.4 1.6 23 
AMI 0.9 19 20 1.8 5.0 7.1 2.1 23 
NTF 3.6 8 30 1.67 1.5 1.8 0.3 >24 
AMAP 3.0 5 5 2.11 1.3 2.6 1.3 19 
APAP 3.0 5 6 2.04 2.1 2.4 0.4 >24 
MTX 2.3 17 16 2.11 1.0 1.4 0.5 >24 
NPX 0.8 20 0 2.1 1.0 1.9 0.9 >24 
TGZ 0.3 >24 0 2.22 0.7 1.8 1.1 19 
SN 0.1 >24 3 2.24 1.8 1.8 0 >24 
OFX 0.1 >24 6 2.14 1.1 2.1 1.0 24 
INH 0.0 >24 0 2.28 1.4 2.4 1.1 24 
DMSO 0.0 >24 0 2.28 0.8 1.3 0.5 >24 
 
Table 1. Overview of the test results derived from the Srxn1-GFP assay (Nrf2 response), the GFP-p65 assay 
(NF-κB response) and the Annexin-V apoptosis assay (TNFα-enhanced apoptosis).
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drug-induced Nrf2 activation for the drugs AMI, CBZ, DCF, KTZ, NFZ and NTF closely 
correlated with a delay in the timing of the nuclear translocation peaks of NF-κB. Yet, 
while APAP also caused Nrf2 activation, this was not associated to a delay in the NF-
κB oscillation. We speculate that the crosstalk between the Nrf2 and NF-κB signaling 
is apparently not mediated through Nrf2 activation per se. Alternatively, the reactive 
metabolites derived from AMI, CBZ, DCF, KTZ, NFZ and NTF likely affect a broader set 
of intracellular sensors and, thereby, affect alternative signaling pathways, including Nrf2 
and NF-κB signaling. APAP-derived metabolites presumably only affect the Nrf2 pathway. 
This difference in response is likely related to different reactivity of the metabolites and/
or the intracellular sites where they are generated. More work is required to identify the 
levels of metabolite formation and their cellular targets for the DILI compounds we used. 
Moreover, it will be highly relevant to determine which compounds directly affect the Nrf2 
activation through covalent modification of Keap1.  
 In case of combined Nrf2 activation and NF-κB suppression an increased risk for 
drug-cytokine cytotoxic synergy may be present. The working model for immune-related 
DILI suggests the imbalance between pro-inflammatory cytokine and anti-inflammatory 
cytokine signaling as a critical initiator of hepatocyte cell killing (11, 12). We observed the 
strongest TNFα-enhanced drug-induced apoptosis for CBZ, DCF and KTZ, and more 
weakly for NFZ, AMI and CLZ. These six drugs activate both the Srxn1-GFP reporter 
and induce a delay in the NF-κB response, albeit that the effect of CLZ at 50 μM on 
NF-κB oscillation was not significant (10-minute delay), yet at 75 μM the effect became 
significant (20 minutes). This suggests that monitoring the ability of drugs to activate the 
Nrf2 response and determining the drug effect on NF-κB oscillations can be indicative 
for sensitization towards pro-inflammatory cytokines during drug exposure, as a sign for 
increased risk of DILI potential. We are currently investigating the underlying molecular 
mechanisms through RNA-interference-based functional genomics strategies and our 
findings indicate a critical role for the translational control component EIF4A1 in close 
relationship to the expression of the pro-apoptotic unfolded protein response gene 
CHOP/DDIT3 (Fredriksson et al., submitted). 
 In conclusion, we have established a systems microscopy approach using 
high content confocal microscopy live-cell imaging in combination with automated 
multiparametric quantitative image analysis to monitor in parallel the kinetics of 
apoptosis, Nrf2 activation and the NF-κB oscillatory response. Our systems microscopy 
assays are more quantitative, robust, reliable and more informative than standard protein 
quantification, because single cells within a large population can be monitored across 
time. Furthermore, the approach can be multiplexed: the Srxn1-GFP reporter can be 
combined with Annexin-V or propidium-iodide to monitor oxidative stress simultaneously 
with apoptosis or necrosis induction, respectively. We are aware that our current 
strategy does not positively identify all DILI compounds. Given the diversity of molecular 
mechanisms for DILI, we would not expect this. Although the monolayer cultures of our 
HepG2 reporter cells provide greater speed and accuracy, we understand that their 
limited differentiation status is posing some limitations. Currently we are establishing 3D 
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spheroid cultures of HepG2 cells to increase their differentiation status and increase the 
levels of phase 1 and 2 metabolism. Preliminary results using 3D HepG2-Srxn1-GFP cells 
for high content imaging shows induction of Srxn1-GFP expression by TGZ. While we 
have limited ourselves to Nrf2 and NF-κB signaling in this study, further development of 
additional cell injury reporters (e.g. mitochondrial function, ER-stress and DNA damage) 
is ongoing. We anticipate that the application of such models in combination with DILI 
compound, cytokine and siRNA screening will greatly contribute to the mechanistic 
understanding of adverse drug reactions. 
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Supporting Table 1. Drugs used in this study and their reported adverse effects on the liver
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4Translation initiation factor EIF4A1 determines TNFa-mediated apoptosis in drug-induced liver injury through the stress protein CHOP
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ABSTRACT
Drug-induced liver injury (DILI) is an important clinical problem. Here we used a 
functional genomics approach to establish the critical drug-induced toxicity pathways 
that act in synergy with the pro-inflammatory cytokine tumor necrosis factor α (TNFα) 
to cause apoptosis of liver HepG2 cells. Transcriptomics-based analysis of the toxicity 
response pathways activated by diclofenac (DCF), carbamazepine (CBZ), ketoconazole 
and nefazodone revealed activation of death-receptor/apoptosis pathway signaling, 
nuclear factor-erythroid 2 (NF-E2)-related factor 2 (Nrf2) oxidative stress response, 
and endoplasmic reticulum (ER) stress/translational initiation signaling, independent 
of TNFα signaling. Systematic siRNA-mediated knockdown of the individual toxicity 
pathway determinants established the critical role of caspase-8, Bid, Bim and APAF1 for 
the drug/TNFα-induced apoptosis. Cell death involved an oxidative stress component 
since pre-induction of the Nrf2 pathway by knockdown of its negative regulator Kelch-
like ECH-associated protein 1 (Keap1) suppressed the drug/TNFα synergy and down-
regulation of the glutathione reductase and peroxidase enhanced cell killing independent 
of TNFα. While ER stress signaling through inositol-requiring enzyme 1-alpha (IRE1α) 
and activating transcription factor 6 (ATF6) acted cytoprotective, CBZ- and DCF-induced 
activation of  protein kinase R-like ER kinase (PERK) and subsequent expression of 
C/EBP-homologous protein (CHOP) was crucial in the onset of drug/TNFα-induced 
apoptosis independent of drug-induced oxidative stress. CBZ and DCF caused a strong 
expression of the translational initiation factor EIF4A1. Importantly, depletion of EIF4A1 
almost completely inhibited CHOP expression in association with protection against the 
drug/TNFα-mediated cell killing. Conclusion: We propose a model in which enhanced 
drug-induced translation initiates PERK-mediated CHOP signaling thereby sensitizing 
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INTRODUCTION
Drug-induced liver injuries (DILIs) constitute an important problem both in the clinic as 
well as during drug development (1). The underlying cellular mechanisms that determine 
the susceptibility towards developing DILI are incompletely understood. Recent data 
indicate that the crosstalk between drug reactive metabolite-mediated intracellular stress 
responses and cytokine-mediated pro-apoptotic signaling are important components in 
the pathophysiology of DILI (2,3). Tumor necrosis factor-α (TNFα) severely enhances 
liver damage caused by various xenobiotics (2,4-6) and it is the major cytokine to be 
excreted by the liver stationary macrophages (Kupffer cells) upon exposure to bacterial 
endotoxins or as a response to hepatocyte damage (7). In addition, reactive drug 
metabolites covalently modify cellular macromolecules leading to intracellular biochemical 
perturbations and the induction of various intracellular stress signaling pathways. It is 
likely that these stress pathways are causal for the sensitization of the crosstalk with the 
cytokine signaling. So far it remains unclear which toxicity pathways modulate the pro-
apoptotic activity of TNFα signaling.  
 The Kelch-like ECH-associated protein 1 (Keap1)/ nuclear factor-erythroid 2 (NF-
E2)-related factor 2 (Nrf2) pathway is important in the recognition of reactive metabolites 
and/or cellular oxidative stress (8). Under normal conditions Nrf2 is maintained in the 
cytoplasm and guided towards proteasomal degradation by Keap1 (9). Nucleophilic 
reactions with the redox-sensitive cysteine residues of Keap1 releases Nrf2 followed by 
its nuclear entry and transcriptional activation of antioxidant genes (8,10). Nrf2 signaling 
is critical in the cytoprotective response against reactive metabolites both in vitro and 
in vivo (11,12), but its role in regulating TNFα pro-apoptotic signaling relation to DILI is 
unclear.   
 The endoplasmic reticulum (ER) unfolded protein response is an adaptive 
stress response to ER protein overload due to enhanced translation and/or perturbed 
protein folding. It involves expression of molecular chaperones such as the heat shock 
family member HSPA5 (also known as BiP or Grp78) (13). When adaptation fails, a pro-
apoptotic program to eliminate the injured cell is initiated (14). The ER stress response 
contains three signaling arms: the protein kinase R-like ER kinase (PERK), the activating 
transcription factor 6 (ATF6) and the inositol-requiring enzyme 1α (IRE1α) (13). Activation 
of IRE1α and ATF6 initiates protective responses, while activation of PERK leads to 
attenuation of global protein synthesis and favored translation of activating transcription 
factor 4 (ATF4) by phosphorylation of eIF2α, resulting in expression of the ATF4 
downstream target gene DDIT3 encoding the C/EBP homologous protein (CHOP) (15). 
CHOP initiates a pro-apoptotic program by modulation of Bcl2-family proteins (13,14). 
The role and mechanism of ER stress in controlling DILI in relation to TNFα-induced 
apoptosis and its relation to drug-induced oxidative stress remains undefined. 
 We show that different hepatotoxic drugs including diclofenac, carbamazepine, 
and ketoconazole show a synergistic apoptotic response with the pro-inflammatory 
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related oxidative stress response, the ER stress response as well as the death receptor-
signaling pathway as critical cell toxicity pathways independent of, and preceding TNFα-
mediated cell killing. A systematic short interfering RNA (siRNA) mediated knockdown 
approach of genes related to these stress-induced pathways allowed a detailed functional 
evaluation of the mechanism by which oxidative stress, ER stress and translational 





Diclofenac sodium, carbamazepine, nefazodone and ketoconazole were obtained from 
Sigma (Zwijndrecht, the Netherlands). Methotrexate was from Acros Organics (Geel, 
Belgium). Human recombinant TNFα was acquired from R&D Systems (Abingdon, United 
Kingdom). AnnexinV-Alexa633 was made as previously described (16). The antibody 
against caspase-8, cleaved PARP, and CHOP were from Cell Signaling (Bioké, Leiden, 
Netherlands). The antibody against tubulin was from Sigma and the antibody against 
P-Thr 981-PERK was from Santa Cruz (Tebu-Bio, Heerhugowaard, the Netherlands). 
The antibody against Nrf2 was a kind gift from Dr. Goldring (Liverpool University, United 
Kingdom).
Cell line 
Human hepatoma HepG2 cells were obtained from American Type Culture Collection 
(ATCC, Wesel, Germany), cultured in DMEM supplemented with 10 % (v/v) FBS, 25 U/
mL penicillin and 25 µg/mL streptomycin and used for experiments between passage 5 
and 20. 
RNA isolation and cRNA microarrays
After drug exposure for 8, 14 or 8 hours followed by the addition of 10 ng/mL TNFα for 
6 hours, RNA was isolated from HepG2 cells using the RNeasy® Plus Mini Kit (Qiagen, 
Venlo, the Netherlands). RNA integrity and quality was assessed using the Agilent 
bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
 The synthesis of labeled cRNA and hybridization steps were performed by 
Service XS (Leiden, The Netherlands) using the Affymetrix 3’ IVT-Express Labeling Kit 
(#901229) and the Affymetrix Human Genome U133 plus PM arrays. Scanning of the 
Array Plates was performed using the Affymetrix GeneTitan scanner. BRB Array Tools 
software (developed by Dr. Richard Simon and BRB-ArrayTools Development Team) 
was used to normalize the .cel data using the Robust Multichip Average (RMA) method. 
Significantly differentially expressed genes (p-value < 0.001) between the various 
experimental conditions were identified with an ANOVA test followed by calculation of 
the false discovery rate according to Benjamini and Hochberg (17). Classification of the 
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using the Ingenuity Pathway Analysis (IPA®) software (Ingenuity® Systems, Redwood, 
CA, USA). Heatmap representations and hierarchical clustering (using Pearson 
correlation) were performed using the MultiExperiment Viewer software (18).
RNA interference
Transient knockdowns (72 hrs) of individual target genes were achieved using siGENOME 
SMARTpool siRNA reagents and siGENOME single siRNA sequences (50 nM; 
Dharmacon Thermo Fisher Scientific, Landsmeer, the Netherlands) with INTERFERin™ 
siRNA transfection reagent (Polyplus transfection, Leusden, the Netherlands). The 
negative controls were siGFP or mock transfection. The single siRNA sequences were 
used to exclude any off target effects of the SMARTpools resulting in a significant 
biological effect. The SMARTpool was considered on target when 2 or more of the 4 
singles showed a similar significant effect. All siRNA-targeted genes can be found in 
Supplemental Data S5.
Cell death analysis assays
Induction of apoptosis in real time was quantified using a live cell apoptosis assay 
previously described (16). Briefly, binding of Annexin V-Alexa633 conjugate to apoptotic 
cells was followed in time by imaging every 30 minutes after drug exposure with a BD 
PathwayTM 855 imager (Becton Dickinson). The relative fluorescence intensity per cell 
area was quantified using Image ProTM (Media Cybernetics, Bethesda, MD, USA). 
When siRNA-based knockdown resulted in a difference in the area under cell death 
curve (AUC) larger than 2 standard deviations from the negative control, the effect was 
considered biologically significant.
Western blot analysis 
Western blot analysis was essentially performed as previously described (2) using above-
mentioned antibodies. 
Live cell imaging of GFP-tagged proteins in HepG2 cells
Reporter HepG2 cells for Nrf2 activity (Srxn1 [mouse]) and ER-stress (HSPA5 [BiP/Grp78; 
human]) were generated by bacterial artificial chromosome (BAC) recombineering (19,20). 
Upon validation of correct C-terminal integration of the green fluorescent protein (GFP)-
cassette by PCR, the BAC-GFP constructs were transfected using LipofectamineTM 
2000 (Invitrogen, Breda, the Netherlands). Stable HepG2 BAC-GFP reporters were 
obtained by 500 µg/mL G418 selection. Prior to imaging, nuclei were stained with 100 
ng/ml Hoechst 33342 in complete DMEM. The induction of Srxn1-GFP and HSPA5-GFP 
expression was followed for a period of 24 hours, by automated confocal imaging (Nikon 
TiE2000, Nikon, Amstelveen, the Netherlands). Quantification of the GFP intensity in 
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Statistical analysis
All numerical results are expressed as the mean ± standard error of the mean (S.E.M.) 
and represent data from three independent experiments. The statistical analyses were 
made using GraphPad Prism 5.00 (GraphPad software, La Jolla, USA). Significance 
levels were calculated using 2-way ANOVA with Bonferroni post-test, * = P < .05, ** = P 
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Figure 1.  Synergy of hepatotoxic drugs 
with TNFα to induce apoptosis in HepG2 
cells. (A-E) The apoptosis after different 
drug exposure was followed in real time 
from 8 to 24 hours using automated imaging 
of AnnexinV (AnxV)-Alexa633 binding 
to apoptotic cells.  The concentration 
dependence is presented as end-point 
(24h) values of relative AnxV-Alexa633 
intensities presented as percentage of 
apoptosis (inserts). The data shown are 
means of three independent experiments 
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RESULTS
Hepatotoxic drug synergy with TNFa is preceded by oxidative stress, ER stress 
and death receptor signaling gene expression networks
We have previously shown that TNFα enhances the apoptosis induced by diclofenac 
(DCF) (2). To determine whether synergism with TNFα to induce apoptosis is a more 
general effect with compounds that cause drug-induced liver injury (DILI), we treated 
HepG2 cells for 8 hours with different compounds associated with unpredictable 
idiosyncratic DILI in humans, diclofenac (DCF), carbamazepine (CBZ), ketoconazole 
(KTZ), nefazodone (NFZ) and methotrexate (MTX), followed by an additional incubation 
with or without TNFα (10 ng/ml) for 16 hrs. DCF, CBZ and KTZ showed a significant 
enhanced apoptosis when combined with TNFα (Fig. 1 A-C). Only a trend to towards 
synergy was observed for NFZ (Fig. 1 D), while hardly any toxicity was observed for MTX 




































































































































































































Figure 2.  Differentially 
expressed genes after 
exposure to hepatotoxic 
drugs.  The gene expression 
after 8 (A), 14 (B) and 14 
hours including 6 hours of 
TNFα  (10 ng/mL; C) exposure 
to diclofenac (DCF; 500 μM), 
carbamazepine (CBZ; 500 
μM), ketoconazole (KTZ; 
75 μM), nefazodone (NFZ; 
30 μM) and methotrexate 
(MTX; 50 μM) is presented as 
number of genes differentially 
up- (black) or down-regulated 
(white) compared to control 
(p<0.001). The total number 
of genes overlapping among 
the TNFα-synergizing drugs 
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EIF2 Signaling
NRF2-mediated Oxidative Stress Response
Mismatch Repair in Eukaryotes
Cell Cycle Control of Chromosomal Replication





FLT3 Signaling in Hematopoietic Progenitor Cells
IGF-1 Signaling
Neurotrophin/TRK Signaling
Germ Cell-Sertoli Cell Junction Signaling
Polyamine Regultation in Colon Cancer
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Estrogen-Dependent Breast Cancer Signaling




Factors Promoting Cardiogenesis in Vertebrates




FcγRIIβ Signaling in B Lymphocytes
Estrogen Receptor Signaling
Endoplasmic Reticulum Stress Pathway
Cleavage and Polyadenylation of Pre-mRNA
IL-6 Signaling
IL-8 Signaling
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Figure 3.  Ingenuity Pathway Analysis (IPA) of common differentially expressed genes. (A) Using IPA® the 
canonical pathways being significantly affected following exposure to diclofenac (DCF; 500 μM), carbamazepine 
(CBZ; 500 μM), ketoconazole (KTZ; 75 μM), nefazodone (NFZ; 30 μM) and methotrexate (MTX; 50 μM) for 
8 hours were determined. The pathways are ranked by the criteria of being significantly regulated after DCF 
and CBZ, but not after MTX treatment. The most striking toxicity pathways are highlighted as follows: EIF2 
Signaling/Endoplasmic Reticulum Stress Pathways are marked in yellow, Nrf2-mediated Oxidative Stress 
response is marked in green and Apoptosis/Death Receptor Signalling is marked in blue.  (B) After hierarchical 
clustering using Pearson correlation and average linkage of the genes representing the pathways in A, the 
three clusters showing most genes up-regulated under DCF and CBZ conditions but not MTX are shown. The 
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To gain further insight into the toxicity pathways that may sensitize towards TNFα-
mediated cell killing, we first performed a gene expression analysis on HepG2 cells 
exposed to DCF, CBZ, KTZ, NFZ and MTX for 8 hours (Fig. 2 A). While MTX only mildly 
affected the gene expression (1121 differentially expressed genes [DEGs] at 8 hours), 
which was related to the mild cytotoxicity (Fig. 1 E), KTZ caused the strongest gene 
expression changes (9479 DEGs at 8 hours; Fig. 2 A) in association with greater onset 
of cell death (Fig. 1 C). Not many additional changes in DEGs were observed after 
treatment for an additional 6 hours with the compounds either in presence or absence of 
TNFα (Fig. 2 B and C).
 To identify likely candidate genes that contribute to this synergy we determined 
the overlap in DEGs for all synergizing drugs (DCF, CBZ and KTZ; see Venn-diagrams 
in Fig. 2). Since the most significant TNFα synergy was observed for CBZ (Fig. 1 A) we 
considered this a relevant model compound. DCF showed the highest overlap with CBZ 
in DEGs (Fig. 2 A-C). Due to this and the fact that KTZ showed marked cytotoxicity with 
the compound alone accompanied by only a slight, though significant, synergism with 
TNFα, we chose to focus on CBZ and DCF alone from here onwards. 
 Next we employed Ingenuity Pathway Analysis (IPA®) software to identify the 
signaling pathways that were affected by both CBZ and DCF (Fig. 3 A). Three prominent 
toxicity pathways were found: “EIF2-signaling/Endoplasmic reticulum stress pathway”, 
“Nrf2-mediated oxidative stress response”, and “Apoptosis/Death receptor signaling”. 
Subsequently we identified all the individual genes that determined these significant 
pathways (Supporting Data S1). Hierarchical clustering of these selected genes allowed 
identification of three main gene clusters that were up-regulated after 8 hours CBZ and/
or DCF but not MTX treatment (Supporting Data S2). Interestingly, these contained 
almost exclusively genes representing the above-mentioned significantly affected 
pathways (compare Fig. 3 A and Supporting Data S2).  For further gene selection we 
used a threshold of 1.5-fold change for any CBZ or DCF treatment time point (Fig. 3 B). 
Importantly, we confirmed the regulation of the Nrf2-mediated stress response and ER 
stress by DCF in primary hepatocytes (Supporting Data S3).
The death receptor pathway is critical in the drug/TNFa-induced apoptosis
Previously we showed that DCF/TNFα-induced apoptosis is dependent on the death 
receptor pathway (2). Next we systematically analyzed whether the CBZ/TNFα-induced 
apoptosis was using an identical apoptotic pathway. We observed the 41/43 kDa 
cleavage products of caspase-8, the most proximal initiator caspase downstream of the 
death receptor signaling complex, in CBZ/TNFα conditions already at 12 hours, but not 
for CBZ alone (Fig. 4 A). This correlated with the cleavage of caspase-3 substrate PARP 
(Fig. 4 A). Importantly, successful siRNA-mediated knockdown of caspase-8 (Supporting 
Data S4 A and S5) demonstrated that CBZ/TNFα-induced apoptosis was almost fully 
dependent on caspase-8 (Fig. 4 B).
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death receptor-related pathways that were up-regulated after both DCF and CBZ 
exposure conditions (see Fig. 3 B, blue highlight) using siRNA-mediated knockdowns 
of the individual genes. Knockdown of Bim/BCL2L11, a BH3 domain-containing Bcl2-
family member, significantly decreased CBZ/TNFα apoptosis (Fig. 4 C). In addition, 
knockdown of apoptotic protease activating factor 1 (APAF1), a critical component of the 
apoptosome formed upon mitochondrial release of cytochrome c, led to an inhibition of 
apoptosis (Fig. 4 C and Supporting Data S5). We anticipated that the onset of apoptosis 
followed a caspase-8/Bid/APAF1/caspase-9/caspase-3 route. Indeed, knockdown of 
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Figure 4. Carbamazepine (CBZ)/TNFα-induced apoptosis is dependent on the extrinsic apoptotic pathway.  (A) 
Caspase-8 and PARP cleavage after exposure to CBZ +/- TNFα after 8 hours of exposure was assessed by 
western blot analysis. “C”, controls exposed to vehicle for 12 hours.  (B)  Apoptosis was followed by AnnexinV 
(AnxV)-Alexa633 binding to apoptotic cells using automated microscopy after siRNA-mediated knockdown of 
caspase-8 and CBZ/TNFα-exposure. (C) AnxV-Alexa633 staining followed in time after knockdown of APAF1 
and Bim/BCL2L11 and CBZ/TNFα-exposure. (D) Schematic representation of the pro-apoptotic pathway 
activated by CBZ/TNFα-exposure. Identified inducers of apoptosis are shown in green and the arrows indicate 
an up-or down-regulation after DCF and/or CBZ exposure on a transcriptional level (p-value ≤ 0.001) after 8 
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(Supporting Data S4 B). Collectively, these data support the involvement of the death 
receptor/apoptotic pathway in the induction of CBZ/TNFα-induced apoptosis (Fig. 4 D) 
and is therefore similar to DCF/TNFα-mediated apoptosis (2). 
Oxidative stress sensitizes in the diclofenac and carbamazepine mediated apopto-
sis
The Nrf2-mediated oxidative stress response was significantly affected by CBZ and 
DCF treatment (Fig. 3), likely in relation to the formation of reactive metabolites of these 
compounds in our cell model (2). Modification of critical cysteine residues on Keap1, leads 
to the liberation of Nrf2 followed by its nuclear translocation and transcriptional activation 
of antioxidant genes (8,10,21). We first investigated the Nrf2 levels after CBZ and DCF 
treatment. DCF caused a stabilization of Nrf2, which was associated with increased 
levels of the Nrf2 target gene γGCSm (Fig. 5 A). Little effect of CBZ was observed on 
Nrf2 levels. Sulfiredoxin 1 (Srxn1) is a direct target of Nrf2 (22) and we monitored the 
activity of Nrf2 using live cell imaging of a BAC-Srnx1-GFP HepG2 reporter cell line. 
Srxn1-GFP expression was near absent under control conditions but increased over time 
following DCF and CBZ treatment independent of TNFα (Fig. 5 B and C). Importantly, 
siRNA-mediated knockdown of Nrf2 completely inhibited the Srnx1-GFP expression after 
CBZ, supporting Nrf2 activation (Fig. 5 C). 
 The antioxidant N,N’-diphenylbenzene-1,4-diamine (DPPD) drastically 
decreased both CBZ and CBZ/TNFα-mediated cell death (Fig. 5 D) as well as for DCF 
and DCF/TNFα treatment (Supporting Data S6 A), indicating a role for oxidative stress in 
drug/TNFα-induced apoptosis. The Nrf2 pathway and its related gene targets identified 
in the CBZ and DCF stress response (Fig. 3 B, green highlight) were also critically 
involved in the protection against drug/TNFα-mediated cell killing. Knockdown of Keap1 
led to enhanced protein levels of Nrf2 (Supporting Data S6 B), which was associated 
with a protection against CBZ/TNFα- and DCF/TNFα-induced cytotoxicity (CBZ: Fig. 
5 E and DCF: Supporting Data S7). Importantly, knockdown of Nrf2 itself (Supporting 
Data S6 B) led to enhancement of the apoptosis (Fig. 5 E and Supporting Data S7). In 
addition, depletion of two key antioxidant enzymes GSR and GPX4 that are involved 
in the detoxification of reactive oxygen species, led to enhancement of the cytotoxic 
response following drug/TNFα-exposure (Fig. 5 E). In contrast, depletion of a negative 
regulator of Nrf2-dependent transcription, BACH1 (23,24), which was found up-regulated 
following CBZ and DCF exposure in our gene array (Fig. 3 B), had a cytoprotective effect 
(Fig. 5 F and Supporting Data S7). Somewhat unexpected, knockdown of the multi-drug 
resistance protein MRP4, the glutathione S-transferase GSTO2 and the anti-oxidant gene 
inducer JUND also protected against the cell killing (Fig. 5 F and Supporting Data S7). 
All functionally relevant antioxidant components that we tested were validated by single 
siRNAs (Supporting data S 5). Altogether these data indicate the functional involvement 
of an Nrf2-dependent antioxidative stress pathway activation to protect against CBZ/
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Figure 5.  Carbamazepine (CBZ) and diclofenac (DCF) induces an Nrf2-response affecting the drug/TNFα-
induced apoptosis.  (A) Nrf2 and γ-GCSM protein levels were investigated by western blot analysis following 
DCF and CBZ exposure +/- TNFα addition. “C”, controls exposed to vehicle for 12 hours. (B and C) Nrf2-
responsive Srxn1-GFP levels were followed using automated confocal microscopy. Shown are representative 
images of Srxn1-GFP HepG2 cells exposed to vehicle (DMSO), DCF or CBZ (B) and the quantification of GFP-
intensity in time normalized to the area occupied by the nuclei (Hoechst; C). (D) AnxV-Alexa633 staining of 
HepG2 cells +/- pre-exposure to antioxidant DPPD (10 μM) followed by CBZ-exposure +/- addition of TNFα (10 
ng/mL) after 8 hours. (E) The effect on CBZ/TNFα induced apoptosis was investigated using live cell imaging 
of apoptosis after knockdown of crucial players in the oxidative stress response using siRNAs targeting Keap1, 
Nrf2, GSR and GPX4. Green indicates knockdown of inducers of oxidative stress and red protectors against 
oxidative stress. (F) The effect of knockdown of genes up-regulated in Fig. 3B and involved in an Nrf2-mediated 
oxidative stress response on the apoptosis induced by CBZ/TNFα measured by AnxV-Alexa633 staining 
and automated microscopy. (G) Schematic representation of the Nrf2-mediated oxidative stress response. 
Oxidative stress related protectors in E are shown in red, oxidative stress related inducers in F are shown in 
green and the arrows indicate an up-regulation on a transcriptional level (p-value ≤ 0.001) following DCF and/
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Figure 6.  Carbamazepine (CBZ) induces an ER stress-response affecting the drug/TNFα-induced apoptosis. 
(A and B) HepG2 cells were pre-treated with eIF2α phosphatase inhibitor salubrinal (Sal; 50 μM; A) or ER-
stressor tunicamycin (Tm; 10 μg/mL; B) for 16 hours before treatment with 500 μM CBZ. TNFα (10 ng/mL) 
was added 8 hours after drug exposure. (C) PERK activation was followed in time by western blotting for 
phosphorylated PERK (P-PERK). “C”, control exposed to vehicle for 12 hours. (D) HepG2 cells expressing 
HSPA5-GFP (BiP) were followed in time after exposure to diclofenac (DCF; 500 μM), carbamazepine (CBZ; 
500 μM), or Tm (10 μg/mL) using automated confocal microscopy. Shown are representative merged images 
of HSPA5-GFP (green) and Hoechst (blue) at 2, 8, 16 and 24 hours after drug exposure. (E) The effect of 
knockdown of the three arms of the UPR on the apoptosis induced by CBZ/TNFα was measured by AnxV-
Alexa633 staining and automated microscopy. An enhanced apoptosis response is shown in red and a reduced 
response in green. (F) The effect of knockdown of genes involved in translational initiation (found up-regulated 
on expression level in Fig. 3B) on the apoptosis induced by CBZ/TNFα was measured by AnxV-Alexa633 
staining and automated microscopy. (G) Schematic representation of the ER stress response. ER stress related 
protectors in E are shown in red, ER stress- and translation-related inducers in F are shown in green and the 
arrows indicate an up- or down-regulation on a transcriptional level (p-value ≤ 0.001) following DCF and/or CBZ 
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PERK activation determines ER stress-mediated hepatotoxicant/TNF synergistic 
cell death
EIF2-signaling in the context of translational initiation was identified as the most 
significantly affected pathway by CBZ and DCF, which was associated with endoplasmic 
reticulum (ER) stress or unfolded protein response (UPR) pathway regulation (Fig. 3, 
yellow highlight). First we pre-treated cells with an inhibitor of the de-phosphorylation of 
eIF2α, salubrinal, thereby prolonging the translational inhibition (25). This resulted in a 
protection against CBZ/TNF and DCF/TNF cell death (Fig. 6 A and Supporting Data S8 
A). Also pre-treatment of cells with an ER-stressor, tunicamycin, to induce a protective 
adaptive response (26), inhibited the apoptosis induced by CBZ/TNFα as well as DCF/
TNFα (Fig. 6 B and Supporting Data S8 B). ER stress/UPR induces the activation of 
PERK-ATF4, IRE1α-XBP1 and ATF6 target gene expression (13). Using IPA® pathway 
analysis of the DEGs after 8 hours of CBZ and DCF exposure, we investigated the 
expression of downstream targets of ATF4, XBP1 and ATF6. ATF4 showed the strongest 
upregulation of downstream targets indicating an important role for PERK/ATF4 signaling 
(Supporting Data S9). Indeed, PERK was activated after both CBZ and DCF treatment 
(Fig. 6 C and Supporting Data S10). Importantly, addition of TNFα did not enhance the 
levels of phosphorylated PERK. 
 Next we systematically analyzed the critical signaling components of the ER 
stress/UPR in regulation of the cytotoxicity. The UPR induces expression of BiP/HSPA5 
through the activation of IRE1α and ATF6 (13). Using a BAC-HSPA5-GFP reporter HepG2 
cell line we demonstrated a strong induction of HSPA5 after tunicamycin treatment. 
Although no obvious induction was observed after CBZ and DCF (Fig. 6 D), knockdown 
of IRE1α and ATF6 by siRNA, sensitized cells against apoptosis, indicating a role for 
the IRE1α/ATF6 adaptive response in the protection against cell death (Fig. 6 E and 
Supporting Data S11 A). In contrast, PERK knockdown led to reduction of apoptosis-
induction following CBZ/TNFα (Fig. 6 E) and DCF/TNFα (Supporting Data S11 A). 
 The protective effect of salubrinal suggested a central role for the translational 
program in the onset of apoptosis. To further test this hypothesis we performed a 
knockdown of the DEGs that determined the strong significance of the “EIF2 signaling” 
pathway (Fig. 3): the RNA helicase EIF4A1 and translation facilitator EIF4G3. Depletion 
of EIF4A1 and EIF4G3 provided an almost complete protection against both CBZ/TNF- 
and DCF/TNF-induced apoptosis (Fig. 6 F and Supporting Data S11 B). All functionally 
relevant ER stress-translation initiation components that we tested were validated by 
single siRNAs (Supporting Data S5).
 Together these data support a role for the ER stress/UPR pathway and 
translational control in the regulation of the observed cytotoxicity (Fig. 6 G).
EIF4A1 controls CHOP expression and thereby apoptosis onset
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mediated ATF4 activation leads to expression of the pro-apoptotic transcription factor 
CHOP (15). In line with this, both CBZ and DCF induced the expression of CHOP in 
parallel to the activation of PERK (compare Fig. 6 C and 7 A and Supporting Data S10). 
Importantly, knockdown of CHOP strongly protected against both CBZ/TNFα and DCF/
TNFα apoptosis (Fig. 7 B and Supplemental Data S11). 
 Since ER stress can activate the Nrf2 pathway (27) we wanted to determine 
the link between ER stress and oxidative stress. While PERK and CHOP knockdown 
protected against cell death (Fig. 6 E and 7 B), neither PERK nor CHOP knockdown 
inhibited the expression of the Nrf2 target gene Srxn1 (Fig.  7 C). Vice versa, knockdown 
of Keap1, causing stabilization of Nrf2 (Supporting Data S6 B), in association with strong 
A.
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Figure 7.  CHOP-expression and apoptosis is dependent on EIF4A1.  (A) CHOP protein levels were followed 
in time by western blotting after CBZ (500 μM) exposure +/- addition of TNFα (10 ng/mL) after 8 hours. 
“C”, control exposed to vehicle for 12 hours.  (B) The effect of CHOP siRNA mediated knockdown on CBZ/
TNFα-induced apoptosis was investigated using AnxV-labelling and automated microscopy. (C) The effect of 
PERK and CHOP siRNA mediated knockdown on Srxn1-GFP induction after CBZ exposure was investigated 
using automated confocal microscopy. GFP intensities were normalized to the area occupied by nuclei as 
determined by Hoechst33342 staining. (D)  Shown are representative images of GFP intensity (green) after 
KEAP1 knockdown in Srxn1-GFP expressing HepG2 cells 72 hours after transfection under non-exposed 
conditions. Nuclei are labelled with Hoechst33342 (blue) (E and F) ER-stress activation, as measured by 
protein expression of phosphorylated PERK and CHOP using western blot, was investigated after KEAP1 
(E) and EIF4A1 (F) knockdown and a time series of CBZ (500 μM) exposure +/- TNFα  (10 ng/mL) addition. 
Cleavage of caspase-8 is shown for assessment of extrinsic apoptosis induction.  Tubulin serves as loading 
control. “C”, control exposed to vehicle for 12 hours. The data are presented as means of three independent 
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Srxn1 expression (Fig. 7 D) and cytoprotection against CBZ/TNFα and DCF/TNFα (Fig. 5 
E and 7 E), did not block the activation of PERK and the expression of CHOP (Fig. 7 E). 
 Given the critical role of the RNA helicase EIF4A1 in the onset of apoptosis, 
we wondered whether the cytoprotection mediated by EIF4A1 knockdown was directly 
linked to the control of CHOP expression. Interestingly, EIF4A1 knockdown blocked 
CHOP protein expression after CBZ treatment, thereby also inhibiting activation of 
caspase-8 (Fig. 7 F), indicating a central role for the translational machinery in the ER 
stress signaling-mediated induction of CBZ/TNFα and DCF/TNFα synergy towards death 
receptor-mediated apoptosis. 
DISCUSSION
Here we studied in detail the underlying molecular mechanisms of the synergistic 
apoptotic response between hepatotoxic drugs and the pro-inflammatory cytokine 
TNFα using transcriptomics and siRNA-mediated knockdown approaches. Using gene 
expression analysis of HepG2 cells exposed to different hepatotoxic drugs we identified 
endoplasmic reticulum stress/EIF2 signaling, Nrf2-related oxidative stress and death 
receptor signaling as critically activated toxicity pathways. Further functional analysis 
of the role of critical determinants of these pathways using siRNA approaches support 
a model in which drug-induced PERK/CHOP-mediated ER-stress and oxidative stress 
sensitizes hepatocytes to TNFα-induced pro-apoptotic signaling resulting in caspase-8 
and subsequent mitochondria-dependent apoptosis (Fig. 8).
 Our current data support a general role for a death receptor-mediated apoptosis 
pathway that act together with Bid and Bim triggered mitochondrial-mediated apoptosome 
activation in the CBZ and DCF mediated synergy with TNFα to induce apoptosis. At the 
gene expression level the death receptor signaling/apoptosis pathway was significantly 
regulated in DCF and CBZ treated cells, but not in cells treated with the non-toxic MTX. 
This included induction of caspase-8, Bim and APAF1 expression, all of which are critical 
in the onset of apoptosis (Fig. 4). 
 The hepatotoxicant/TNFα synergy is for a major part dependent on the pro-
oxidant properties of both CBZ and DCF. Indeed, our gene expression profiling showed 
strong upregulation of Nrf2 target genes by both DCF and CBZ, which correlated with 
strong Nrf2-dependent induction of Srxn1. A role for DCF and/or CBZ induced oxidative 
stress induction is supported by gene expression data from mouse liver hepatocytes 
(Supplemental Data S2), and in vivo DCF treated rat liver (28) and DCF treated 
mouse liver (29). Importantly, both the anti-oxidant DPPD as well as knockdown of the 
endogenous Nrf2-inhibitor Keap1 led to protection against DCF/TNFα and CBZ/TNFα-
induced apoptosis. In addition, hepatocyte cell death induced by DCF and CBZ alone are 
oxidative stress dependent (30,31).  In our hands, the CBZ- and DCF-mediated oxidative 
stress was largely controlled by the glutathione peroxidase and reductase system, since 
knockdown of glutathione reductase (GSR) and glutathione peroxidase (GPX4) strongly 
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 Our data indicate that ER stress signaling through the PERK/CHOP pathway is 
a critical determinant for the hepatotoxicant/TNFα synergy response towards hepatocyte 
apoptosis. Endoplasmic reticulum (ER) stress and the UPR have been implicated in 
several different liver diseases including DILI (32). Here we present a more selective 
activation of the PERK-arm of the ER stress/UPR following DCF and CBZ exposure (Fig. 
6), which was directly related to expression of CHOP (Fig. 7), a downstream target of 































Figure 8. Working model for drug/TNFα-induced apoptosis. Reactive metabolites formed by diclofenac (DCF) 
and carbamazepine (CBZ) metabolism induce both oxidative and endoplasmic reticulum (ER) stress. The ER 
stress induced is solely dependent on the PERK-pathway, which results in the transcription of CHOP that in 
turn transcribes for example pro-apoptotic BIM. In the absence of translation less CHOP protein is expressed. 
Both PERK/CHOP-mediated ER stress and oxidative stress enhances the apoptotic effect of TNFα addition, an 
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fact that prior UPR-mediated upregulation of BiP protected against cell death. Given the 
critical role of CHOP in the onset of apoptosis, we propose that CHOP is a critical player in 
liver toxicity including sensitization for death receptor-mediated apoptosis. Upregulation 
of CHOP may lead to apoptosis via upregulation of pro-apoptotic Bcl-2 family members, 
including Bim (33). In our system Bim (BCL2L11) was up-regulated after DCF and CBZ 
exposure and siRNA mediated knockdown of this gene led to rescue of CBZ/TNFα and 
DCF/TNFα-induced cytotoxicity, thus supporting a link between ER stress-mediated 
CHOP induction followed by Bim expression and mitochondrial-mediated apoptosis 
induction.  
 The reduction of apoptosis after CBZ/TNFα and DCF/TNFα exposure by the use 
of siRNA mediated knockdown of translation initiation factors EIF4A1 and EIF4G3 and the 
use of an inhibitor of eIF2α dephosphorylation, salubrinal, highlight the need for translation 
in the hepatotoxicant-induced stress response. EIF4A1 and EIF4G3 together with cap-
binding protein EIF4E are part of the EIF4F complex that unwinds secondary structures 
of the 5’ untranslated region (UTR) of mRNA to allow ribosomal binding, scanning and 
thereby translation. The 5’ UTR of mRNA can be more or less structured, determining its 
translation efficiency (34). EIF4A and EIF4G have been implicated with cap-independent 
translation (34). Interestingly, the translation of several anti- and pro-apoptotic genes 
such as XIAP, and APAF1 can occur via cap-independent mechanisms (35,36). Since 
depletion of EIF4A1 reduced the expression of pro-apoptotic CHOP (Fig. 7C), CHOP 
protein expression could be regulated by EIF4A1 cap-independent translation. While our 
results emphasize a role of translational control in xenobiotic toxicity, more research is 
required in this area.
 In summary, we show that DCF and CBZ, drugs linked to idiosyncratic DILI 
with activation of the inflammatory system, sensitize HepG2 cells to TNFα-induced 
apoptosis in our in vitro system. We propose a mechanism where CBZ and DCF by 
inducing oxidative and PERK/CHOP-dependent ER stress, enhance the activation of the 
apoptotic signaling downstream of the TNF receptor, involving caspase-8, Bid, Bim and 
APAF1, possibly via translationally regulated induction of pro-apoptotic proteins (Fig. 8). 
This work sheds new light on the mechanism behind the - so far – unpredictable nature of 
idiosyncratic DILI. Possibly genetic polymorphisms in functionally critical determinants of 
the cytotoxic response are candidate susceptibility genes that predispose for idiosyncratic 
DILI.
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SUPPORTING MATERIALS AND METHODS
Isolation and culture of primary mouse hepatocytes
Primary mouse hepatocytes were isolated from 8-10 weeks old male C57BL/6 mice 
by a modified two-step collagenase perfusion technique (collagenase type IV, Sigma-
Aldrich, Zwijndrecht, The Netherlands), as described previously (1). In short, hepatocytes 
suspensions with at least 80 % viability were seeded onto plates coated with collagen gel 
and after attachment overlayed with a second layer of collagen gel, to form a sandwich 
configuration. Cells were kept in serum-free medium and the culture medium was 
changed daily until exposures were performed. 
Gene expression profiling
Forty-six hours after isolation, hepatocytes were exposed to either 300 µM DCF or the 
solvent DMSO. After 24 hours of exposure, cells were collected in 1 ml RNAprotect (QIAgen, 
Venlo, The Netherlands) and stored at -80˚C for RNA isolation. RNA was extracted using 
QIAzol and purified using the miRNeasy mini kit and the QIAcube (Qiagen), according to 
the manufacturer’s protocol. For both the DCF and vehicle-control groups, four biological 
replicates were used. RNA concentrations were measured using the NanoDrop ND-1000 
Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA) and RNA quality 
was assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies, Amstelveen, The 
Netherlands). Labeled RNA was prepared using the Affymetrix gene chip 3’IVT express 
kit and hybridized to the Affymetrix Mouse Genome 430 2.0 GeneChip arrays, according 
to the manufacturer’s instructions. After hybridization the array chips were washed and 
stained with a Genechip Fluidics Station 450 and scanned using the Affymetrix gene chip 
scanner 3000.
Data analysis 
Affymetrix CEL files were each checked on quality, including RNA degradation control, 
correlation and clustering. All quality checks were within acceptable limits, according to 
Affymetrix standards. After quality control the files were normalized with the Multichip 
Average (RMA) procedure (2), using the custom chip description files (CDFs) as 
previously described (3). For detecting significantly regulated genes, the microarray 
analysis of variance (MAANOVA) package in R was used (R version 2.9.2, www.r-project.
org). For the analyses on significantly regulated genes per compound between treated 
and control samples, an F1-test was used. Gene-specific P-values were corrected with 
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Supporting Data S2 (Not shown). Hierarchical clustering of significantly regulated genes. The genes listed 
in Supporting Data S1 were clustered using Pearson correlation and average linkage in the MultiExperiment 
Viewer software. Expression values, here presented as fold change of control, from all time points, 8 and 
14 hours +/- TNFα, and exposure conditions, diclofenac (DCF), carbamazepine (CBZ), ketoconazole (KTZ), 
nefazodone (NFZ) and methotrexate, (MTX) were used. The clusters identified as interesting (1-3) contained 
genes up-regulated after 8 hours DCF and CBZ exposure but down- or non-regulated after MTX treatment. 
The genes that could also be found to represent the interesting IPA®-defined canonical pathways presented in 
Figure 3 were labeled according to their respective pathways; yellow highlight = EIF2-signaling/Endoplasmic 
Reticulum Stress Pathway; green highlight = Nrf2-mediated Oxidative Stress Response; blue highlight = 
Apoptosis Signaling/Death receptor Signaling.
HepG2, 
DCF 8h
Human symbol Mouse symbol FC FDR FC
SQSTM1 Sqstm1 4.14 0.043 1.27
SRXN1 Srxn1 2.08 0.014 2.27
DDIT3 Ddit3 8.14 0.001 2.54
TNFRSF10B Tnfrsf10b 2.78 0.005 1.41
ATF4 A 4 1.7 0.086 1.15
XBP1 Xbp1 1.33 0.007 -1.22
DNAJB6 Dnajb6 1.55 0.064 1.35
ABCC4 Abcc4 1.54 0.014 3.15
DNAJB1 Dnajb1 1.67 0.022 1.22
HSPA5 Hspa5 -1.6 0.001 1.44
ATF6 A 6 1.42 0.043 1.20
SOD2 Sod2 3.16 0.054 -1.18
EIF4A1 Eif4a1 1.84 0.020 1.14
TRIB3 Trib3 5.6 0.002 2.02
PPP1R15A Ppp1r15a 2.53 0.004 2.06
Primary hepatocytes, 
mouse C57/BL6, DCF 24h
Supporting Data S3. Genes downstream of 
oxidative and endoplasmic reticulum stress 
are significantly regulated in primary mouse 
hepatocytes. Primary hepatocytes from C57BL/6 
mice were treated with 300 M diclofenac for 24 
h before mRNA collection and gene expression 
analysis. The expression of a selected number 
of genes, also regulated in HepG2 cells after 8 
hours of DCF, downstream of Nrf2-dependent 
oxidative stress signaling and endoplasmic 
reticulum stress signaling, was determined. 
Only the genes that were significantly regulated, 
false discovery rate (FDR) < 0.1, are presented. 
Genes related to ER/translational stress are 


















































Supporting Data S4. Knockdown of apoptosis related genes reduce CBZ/TNFα-induced apoptosis. (A) 
Knockdown using SMART-pool siRNA targeting caspase-8 was confirmed using western blotting. Tubulin was 
used as loading control. (B) The apoptosis induced by CBZ/TNFα was followed in time using live cell imaging 
of apoptosis after SMARTpool siRNA mediated knockdown of Bcl2-family member BID, executioner caspase-3 
and initiator caspase-9. TNFα (10 ng/mL) was added after 8 hours of drug exposure. Data presented are means 
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siRNA CBZ (p-value) DCF (p-value) Validation (CBZ)
HERPUD1 > 0.05 n.a. n.a.
DNAJB1 < 0.001 > 0.05 2/4
EIF4A2 > 0.05 n.a. n.a.
EIF4A1 < 0.001 < 0.001 4/4
ATF4 > 0.05 n.a. n.a.
Bim/BCL2L11 < 0.001 Fredriksson et al. 2/4
FOS > 0.05 n.a. n.a.
JUN > 0.05 n.a. n.a.
MCL1 > 0.05 n.a. n.a.
SQSTM1 > 0.05 n.a. n.a.
TNFRSF10B > 0.05 n.a. n.a.
XIAP > 0.05 n.a. n.a.
APAF1 < 0.001 Fredriksson et al. 3/4
JUND < 0.001 < 0.001 3/4
BACH1 < 0.05 < 0.05 3/4
KRAS > 0.05 n.a. n.a.
SOD2 > 0.05 n.a. n.a.
SOS1 > 0.05 n.a. n.a.
CASP10 < 0.001 1/4
DNAJB6 > 0.05 n.a. n.a.
EIF4G3 < 0.001 < 0.01 3/4
PIK3C2A > 0.05 n.a. n.a.
MRP4/ABCC4 < 0.001 < 0.001 3/4
GSTO2 < 0.01 < 0.001 2/4
CASP8 < 0.001 Fredriksson et al. 4/4
CASP3 < 0.001 Fredriksson et al. 4/4
CASP9 < 0.001 Fredriksson et al. 2/4
BID < 0.001 Fredriksson et al. 2/4
CHOP/DDIT3 < 0.001 < 0.05 2/4
PERK/EIF2AK3 < 0.01 < 0.05 4/4
IRE1α/ERN1 < 0.001 < 0.001 2/4
ATF6 < 0.001 < 0.001 2/4
SOD1 > 0.05 n.a. n.a.
GSR < 0.001 < 0.001 2/4
GPX4 < 0.001 < 0.001 3/4
KEAP1 < 0.001 < 0.001









Supporting Data S5.  List of siRNAs and their effect on apoptosis following CBZ and DCF exposure. HepG2 
cells were transfected with siRNAs targeting genes up-regulated after 8 hours of CBZ and/or DCF exposure 
and involved in apoptosis/death receptor signalling (blue highlights), Nrf2-mediated oxidative stress response 
(green highlights) or ER stress/translation initiation (yellow highlights), and hand-picked from the three 
respective pathways. 72 hours after transfection the cells were exposed to CBZ (500 μM) with 10 ng/mL TNFα 
added after 8 hours of drug exposure and the apoptosis was assessed using AnxV-labelling and automated 
microscopy. The siRNAs that gave a significant difference in apoptosis compared to siControl (using 2-way 
ANOVA) were also assessed under DCF (500 μM)/TNFα-exposure conditions. The effect of the siRNAs found 
significant after CBZ exposure was also validated using the 4 single siRNA sequences that consisted the initial 
SMART-pool. A knockdown effect that could be confirmed with ≥ 2 of the single sequences (AUC = siControl ± 
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Supporting Data S6.  Modulation of the oxidative stress response. (A) HepG2 cells were pre-treated with 
10 μM N,N’-diphenylbenzene-1,4- diamine (DPPD) before adding 500 μM DCF or vehicle. TNFα (10 ng/mL) 
was added after 8 hours of drug exposure. The apoptosis induction was followed in time using AnnexinV 
(AnxV)-Alexa633 and automated microscopy. Data presented are means of three independent experiments +/- 
S.E.M. (B) Effect of NRF2 and KEAP1 siRNA-mediated knockdown on Nrf2 protein levels was assessed using 
westernblotting. Tubulin served as loading control.
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Supporting Data S7.  Knock-
down of oxidative stress related 
genes affects apoptosis induced 
by DCF/TNFα. The apoptosis 
induced by DCF/TNFα was 
followed in time using live cell 
imaging of apoptosis after 
SMARTpool siRNA mediated 
knockdown of genes involved 
in oxidative stress and found to 
give a significant effect on CBZ/
TNFα-induced apoptosis. TNFα 
(10 ng/mL) was added after 8 
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Supporting Data S8.  Inhibition of endoplasmic reticulum stress reduces DCF/TNFα-induced apoptosis. HepG2 
cells were pre-treated with 50 μM Salubrinal (Sal; A) or 5 μg/mL tunicamycin (Tm; B) before replacing the 
medium with 500 μM DCF. Salubrinal was kept in the medium where indicated. After 8 hours of DCF exposure, 
TNFα (10 ng/mL) was added. The apoptosis was determined in time using AnnexinV (AnxV)-Alexa633 staining 
and automated imaging. Data presented are means of three independent experiments +/- S.E.M.





















































Supporting Data S9.  DCF and 
CBZ exposure induced mainly 
ATF4 mediated transcription. 
Using the IPA® software the genes 
up- or down-regulated by the 
transcription factors downstream 
of the three distinct unfolded 
protein response pathways, PERK 
(ATF4), IRE-1α (XBP1) and ATF6 
were determined after 8 hours 
DCF (A) or CBZ (B) exposure. Red 
colouring of the shapes indicate 
up-regulation of the target genes, 
while green indicated down-
regulation. The intensity reflects 
the fold-change gene expression 





ays regulate TNFa sensitivity
Diclofenac exposure 






Supporting Data S10. DCF 
induces PERK phosphorylation 
and CHOP expression. The 
expression of phosphorylated 
PERK (P-PERK) and CHOP 
were followed in time by 
western blot after DCF+/- TNFα 
(500 μM/10 ng/mL) exposure.
PERK

























































































Supporting Data S11. Knockdown of ER stress related genes affects apoptosis induced by DCF/TNFα. (A-C) 
The apoptosis induced by DCF/TNFα was followed in time using live cell imaging of apoptosis after SMARTpool 
siRNA mediated knockdown of genes involved in ER stress and found to give a significant effect on CBZ/TNFα-
induced apoptosis. TNFα (10 ng/mL) was added after 8 hours of drug exposure. Data presented are means of 
three independent experiments +/- S.E.M.
5A live-cell imaging-based NF-kB nuclear translocation RNAi screen identifies novel regulators of TNFa-induced apoptosis through control of the (de)ubiquitinase A20
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An NF-kB RNAi screen identifies novel regulators of A20
ABSTRACT
Stimulation of cells with the cytokine tumor necrosis factor alpha (TNFα) triggers 
cytoplasmic-to-nuclear oscillation of the dimeric transcription factor NF-kappaB (NF-κB). 
In the nucleus, NF-κB stimulates transcription of its own response inhibitors, IkappaBalpha 
(IκBα) and the (de)ubiquitinase A20. The concerted induction of IκBα and A20 functions 
to prevent over-activation of the response and the time-dependent inactivation is 
observed as a dampened NF-κB nuclear oscillation pattern. The number of nuclear 
oscillations dictates the transcription of downstream pro-inflammatory, anti-oxidant and 
anti-apoptotic genes. The number of nuclear translocation events is markedly reduced 
under hepatotoxic drug (diclofenac) exposure conditions in association with enhanced 
apoptosis. To understand the mechanism of the perturbed oscillatory response, we used 
a live-cell imaging-based siRNA screen to identify individual kinases, (de)ubiquitinases 
and sumoylases that control the NF-κB oscillatory response. We applied high content 
confocal laser scan microscopy in combination with multiparametric image analysis to 
follow the NF-κB oscillation in ~300 individual cells per condition simultaneously. Out 
of the ~1500 genes screened, we identified 115 that significantly affected the NF-κB 
oscillatory response. Using 4 individual siRNAs, we confirmed the action for 46 genes, 
which affected: (i) the amplitude or duration of nuclear oscillations; (ii) the time between 
oscillations, leading to an increase or decrease of the number of nuclear translocations; 
or (iii) an inhibition of the response altogether. In this last category we identified five 
genes, three novel, whose reduced expression protected against the diclofenac/TNFα-
induced apoptosis. Interestingly, the knockdown of four of these genes led to a basic 
up-regulation of A20 expression. In accordance, A20 knockdown promoted the NF-κB 
oscillation and enhanced apoptosis. Double knockdown experiments indicated a direct 
relationship between these four genes and A20 in the control of the NF-κB activation. 
These findings indicate that the (de)ubiquitinase A20 is a master regulator in the life-
death decision upon TNFα stimulation in drug-induced hepatotoxic responses, which, in 
turn, is kept under control by a network of genes that control its expression level.
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INTRODUCTION 
The dimeric transcription factor nuclear factor-κB (NF-κB) controls the expression of a 
wide array of genes that play an important role in many stages of both physiology and 
disease. The activity of NF-κB is crucial in the host-pathogen response by transcribing 
anti-oxidant and pro-inflammatory genes and thereby activating the innate and adaptive 
immune response (1). In addition, the activity of NF-κB has been associated with 
disease states such as cancer, chronic inflammatory diseases and atherosclerosis (2). 
The malignant role of NF-κB arises from improper regulation of its activation. Enhanced 
activation of NF-κB leads to over-expression of genes responsible for proliferation, 
angiogenesis, metastasis, tumor promotion, inflammation and suppression of apoptosis, 
which gives the transcription factor its tumorigenic properties (3,4). Yet on the other hand, 
inhibition of NF-κB activity has been associated to toxicity of drugs (5,6).
 NF-κB is activated by canonical and atypical signaling pathways. The canonical 
pathway is typically activated by pro-inflammatory stimuli such as the cytokines tumor 
necrosis factor-α (TNFα) and interleukin-1β (IL-1β) that bind to their respective receptors 
TNFR and IL-1R. Receptor activation is followed by the assembly of a signaling complex 
composed of several adaptor molecules, ubiquitin ligases and kinases to promote 
activation of the IKK-complex, the rate-limiting step of NF-κB pathway signaling. The 
IKK-complex consists of the catalytic subunits CHUK (IKKα) and IKBKB (IKKβ) and the 
regulatory subunit IKBKG (IKKγ or NEMO) (7). The active IKK complex phosphorylates 
the inhibitor of NF-κB, IκB, which is subsequently poly-ubiquitinated and degraded 
by the proteasome. This process unmasks the nuclear localization signal in NF-κB, 
allowing its nuclear translocation and initiation of NF-κB driven gene transcription (8). 
De-regulation of the IKK-complex is observed in different cancers, for example through 
activating mutations in NF-κB signaling promoting genes such as the NF-κB inducing 
kinase (NIK; MAP3K14) or inactivating mutations in NF-κB signaling repressors such 
as the deubiquitinase cylindromatosis (CYLD) (9), indicating that NF-κB activity requires 
tight regulation to control normal cellular physiology.
 To understand this regulatory control, the NF-κB pathway has been subject to 
different screening approaches to further decipher its intracellular signaling. Gain- and 
loss-of-function screens based on NF-κB luciferase reporter constructs (10,11) were 
performed using cDNA (10) or RNA-interference (siRNA) screens (11,12). These end-
point assay screens focused on the prolonged NF-κB activity, and were unable to unravel 
the complex regulatory mechanisms involved in NF-κB activity that determine the spatial 
and temporal behavior of NF-κB after receptor stimulation. 
 The nuclear translocation of NF-κB is an oscillatory response that is controlled 
by feedback control mechanisms and varies between individual cells. Importantly, these 
NF-κB oscillations determine the extent and levels of gene transcription (13-15). These 
oscillatory responses varies within a cell population and is dependent on regulation by post-
translational modifications such as phosphorylation, (de)ubiquitination and sumoylation 
(16). TNFα-induced activation requires K63 and linear (poly-)ubiquitination chains to 
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allow (auto-)phosphorylation of the IKK kinases to promote K48 linked poly-ubiquitination 
of IκB (8). Termination depends on deubiquitination as well as ubiquitination processes, 
as exemplified by the protein A20 (TNFAIP3). A20 deubiquitinates the activating K63 
chains from receptor-interacting protein 1 (RIP1), a TNFR associated kinase upstream 
of the IKK-complex, and replaces these by K48 chains, marking RIP1 for proteasomal 
degradation (17,18). As TNFAIP3 and NFKBIA (IκBα) are two of the principle early target 
genes of NF-κB, this provides a very important negative feedback loop to control NF-κB 
activation and constitutes the reason for the dampened oscillatory translocation pattern 
of NF-κB (19). Also drugs that cause liver failure in patients strongly affect the NF-κB 
oscillatory response (5).
 In the current manuscript we searched for novel regulatory components of the 
oscillatory nuclear translocation response of the canonical NF-κB subunit p65 (RelA) upon 
exposure to the pro-inflammatory cytokine TNFα. We studied this in the context of drug-
induced liver injury responses. By combining RNAi and using live high content confocal 
imaging of green fluorescent protein tagged p65 (GFP-p65), in a HepG2 cell background, 
we here present an advanced screening approach to quantitatively determine the effect 
of individual gene knockdowns on the temporal and spatial behavior of NF-κB in single 
cells as well as at the population level.  We identified several genes that are essential for 
the regulation of the A20 protein levels, which thereby not only control NF-κB oscillation, 




Human recombinant TNFα was acquired from R&D Systems (Abingdon, UK). Diclofenac 
sodium and the antibody against tubulin were from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). AnnexinV-Alexa633 and AnnexinV-Alexa561 were made as described 
(20). The antibody against phospho-specific IκBα was from Cell Signaling (Bioké, 
Leiden, The Netherlands). The antibody against A20 was from Santa Cruz (Tebu-Bio, 
Heerhugowaard, The Netherlands). The bromo phenol blue solution was from Merck 
(Merck Millipore, Amsterdam Zuidoost, The Netherlands).
Cell culture
Human hepatoma HepG2 cells were obtained from American Type Culture Collection 
(clone HB-8065, ATCC, Wesel, Germany). HepG2 cells stably expressing GFP-p65 (NF-
κB subunit) were created by 400 µg/ml G418 selection upon pEGFP-C1-p65 transfection 
using Lipofectamine™ 2000 (Invitrogen, Breda, Netherlands). HepG2 BAC IκBα-GFP 
cells were generated by bacterial artificial chromosome (BAC) recombineering (21,22). 
Upon validation of correct C-terminal integration of the GFP-cassette by PCR, the BAC-
GFP construct was transfected using Lipofectamine™ 2000. Stable HepG2 BAC IκBα-
GFP cells were obtained by 500 μg/ml G418 selection. For all experiments the cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
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(v/v) fetal bovine serum (FBS), 25 U/ml penicillin, and 25 µg/ml streptomycin between 
passages 5 and 20.
RNA interference
Transient knockdowns of individual target genes were achieved using siGENOME 
SMARTpool siRNA reagents in the primary screen or single siRNA sequences in 
the secondary deconvolution screen (50 nM; Dharmacon Thermo Fisher Scientific, 
Landsmeer, Netherlands). HepG2 cells were transfected using INTERFERin siRNA 
transfection reagent according to the manufacturer’s procedures (Polyplus transfection, 
Leusden, Netherlands) and left for 72 hours to achieve maximal knockdown before 
treatment. The negative controls were siGENOME non-targeting pool #1, caspase-8 and 
mock (INTERFERin only) transfection.
Exposures
Prior to imaging, nuclei were stained with 100 ng/ml Hoechst 33342 in complete DMEM 
for 45 minutes. The cells were then exposed to Diclofenac 500 µM or DMSO 0.2% for 8 
hours. The cells were then challenged with human TNFα (10 ng/ml).
Live Cell Imaging of GFPp65 and GFP-IkBa in HepG2 Cells
The GFP-p65 nuclear translocation response and IκBα-GFP level response upon 
10 ng/ml human TNFα challenge was followed for a period of 6 hours by automated 
confocal imaging every 6 minutes (Nikon TiE2000, Nikon, Amstelveen, Netherlands). 
Quantification of the nuclear/cytoplasmic ratio of GFPp65 intensity in individual cells was 
performed using an algorithm for ImageJ (Z. Di, B. Herpers, L. Fredriksson, K. Yan, B. 
van de Water, F.J. Verbeek and J.H.N. Meerman, submitted). 
Translocation response class definition and hit definition
For the primary screen, the amplitudes of the individual translocation response tracks 
were normalized to their intrinsic response maxima (=1) and minima (=0) to be able to 
compare the timing of the nuclear translocation events versus the plate average. For the 
secondary screen, non-normalized data were used. Four different classes were defined 
according to the type of nuclear p65 oscillation response: increased, no oscillation, 
decreased and different compared to the oscillation observed with control siRNA. Each 
class used a different set of five specific parameters (Fig. 1A). For each targeted gene, a 
Pearson’s chi-squared cumulative statistic was calculated from the set of five parameters 
of each class and p-values were obtained by comparing the value of the statistic to a 
chi-squared distribution. Targeted genes obtaining a p-value lower than or equal to 0.001 
were considered as hits.
Apoptosis measurements
Apoptosis was determined by the live cell apoptosis assay previously described (5,20). 
The relative Annexin V fluorescence intensity per image was quantified using Image Pro 
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(Media Cybernetics, Bethesda, MD) and normalized to the number of nuclei or cell area 
to obtain the estimated percentage of apoptosis.
Western Blot
Cells were harvested in sample buffer (6 times diluted bromo phenol blue solution 
with β-mercaptoethanol). The samples were subjected to protein separation, blotted 
on Immobilon-P (Millipore, Amsterdam, The Netherlands). Phosphorylated IκBα 
was detected using the Tropix Western-Star kit™ (Applied Biosystems) following 
manufacturer’s protocol. For tubulin and A20, the membranes were blocked for 1h at room 
temperature in milk powder 5% (w/v) in Tris-buffered saline/Tween 20 (TBS-T). Primary 
antibody incubation was done overnight at 4°C followed by incubation with cy5-labeled 
secondary or horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch, 
Newmarket, UK) in 1% BSA in TBS-T for 1 h at room temperature. Protein signals were 
detected with ECL (GE Healthcare) followed by film detection for A20 or by visualization 
on the Typhoon 9400 imager (GE Healthcare, Diegem, Belgium) for tubulin.
Statistical procedures
All numerical results are expressed as mean ± standard error of the mean (SEM). 
Statistical significance was determined by GraphPad Prism using an unpaired t-test,
* P≤0.05, ** P≤0.01, *** P≤0.001. Heatmap representations and hierarchical clustering 
(using Pearson correlation) were performed using the MultiArray Viewer software.
 
RESULTS
NF-kB nuclear oscillation phenotype siRNA screening in HepG2 cells
Stimulation of cells with TNFα initiates nuclear translocation oscillation of the NF-κB 
transcription factor. To follow the dynamics of this process, we created a stable GFP-
tagged HepG2 reporter line for the NF-κB subunit p65/RelA. Time-lapse confocal 
microscopy showed that the nuclear translocation of GFP-p65 is transient and follows a 
dampened oscillation at set time intervals, largely due to NF-κB-dependent transcription 
of IκBα (19). Under control conditions, the initial translocation peaks at 30 minutes after 
TNFα (10 ng/mL) stimulation, followed by a second and third peak at 120 minute intervals 
(Figure 1 A, top). In HepG2 cells this effect was maximal at 10 ng/mL (data not shown). 
Successful knockdown with siRNAs targeting A20 (Supporting Data S1) slightly decreased 
the time-interval between oscillations, leading to faster oscillation, whereas knockdown 
of IκBα (Supporting Data S1) almost completely inhibits NF-κB oscillation in association 
with enhanced levels of p65-GFP expression (Fig. 1 A, middle). Pre-incubation of HepG2 
cells with 500 μM diclofenac for 8 hours increased the time interval between peaks (Fig. 
1 A, bottom; (5)). To distinguish these four phenotypes (control, increased oscillation, 
decreased oscillation and no oscillation) from each another, we established a pipeline of 
automated image segmentation and GFP-p65 nuclear/cytoplasmic ratio quantification for 
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Figure 1. NF-κB oscillation phenotype siRNA screening in HepG2 cells. (A) Representative images of GFP-p65 
translocation after TNFα (10 ng/mL) challenge in HepG2 cells by automated confocal microscopy. Insets: zooms 
of single cells with an average response in respect to the imaged population. The nuclear translocation events 
are marked by yellow boxes and the numbers indicate the time in minutes after TNFα exposure. The nuclear 
translocation track of each cell was quantified and normalized to its own highest nuclear-to-cytoplasmic ratio 
(value of 1) and its lowest ratio (0). The average response of the total cell population is presented in the middle 
panel. The features and their directions that define the response classes (different, increased, decreased and 
no oscillation) compared to control are shown in the panel to the right. (B) Flowchart of the siRNA screen. 
(C) P-value distribution of the hits and the positive and negative controls. Under DMSO conditions the true 
discovery rate was 0.94 and 0.76 for siIκBα and siA20 respectively while the false discovery rate was 0.04. 
Under DCF conditions the corresponding values were, 1, 0.92 and 0 respectively. 4.5% of the screened genes 
were found to have an effect on the oscillation under DMSO conditions while 4.7% were determined to give a 
significant effect after DCF pre-exposure.
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all individual cells within one time-series, followed by extraction of 32 distinct oscillation 
features (Di et al., submitted). We classified the phenotypes based on the direction versus 
control for at least five oscillation features, e.g. number of peaks, time between peaks 
and amplitude of peaks (Fig. 1 A). If more than 5 of the 32 measured oscillation features 
were distinct from control and the oscillation phenotype did not match any of the other 
categories, the response was marked as “different oscillation”. 
 Having established an automated system to track, segment and categorize the 
NF-κB oscillation pattern in individual cells, we set out to identify the genes that are 
responsible for the timely activity of the NF-κB response by siRNA screening (Figure 
1 B). We screened 779 kinases, 107 de-ubiquitinases and sumoylases, 580 ubiquitin 
ligases and 123 pre-described players in the TNFR/TLR-driven NF-κB response, under 
DMSO (control) and diclofenac (DCF) conditions. 22 siRNAs were overlapping in 
either of the libraries. Annexin-V-Alexa633 labeling of the cells allowed us to omit the 
genes that induce apoptosis upon knockdown. For all target genes the oscillation of the 
GFP-p65 reporter was followed for 6 hours at 6 minute intervals, directly after TNFα 
stimulation. Because we were mainly interested in the time between oscillations under 
control and DCF conditions, we normalized the nuclear/cytoplasmic GFP intensity ratio 
and separated the analysis for both conditions. Within each condition, we considered 
genes a potential hit at a p-value below or equal to 0.001, a minimum of in total 35 cells 
analyzed (average number of cells was 184 per condition) and absence of apoptosis. 
Within this p-value cut-off we could trace back the effect of A20 knockdown under control 
and DCF conditions in 76% and 92% of the samples, respectively; and the effect of IκBα 
knockdown in 94% and 100% of the samples (Fig. 1 C). Another 42 genes were added 
from the “different” category, based on visual inspection of the translocation phenotype 
and taking the p-value into consideration (P ≤ 0.05). In total we re-screened 115 genes 
by using 4 single siRNAs targeting the same gene, of which 46 genes were confirmed 
to affect the GFP-p65 oscillation with 2 or more single siRNAs in addition to the pooled 
siRNAs in either or both DMSO and DCF conditions.
Functional and phenotypic classification of the siRNA screen hits that control 
NF-kB oscillation
Out of the 46 confirmed hits, 5 genes, including the known inhibitor of NF-κB activation, 
UCHL1 (23), decreased the oscillation after knockdown; 7 increased the oscillation, also 
confirming the inhibitory role for TNFAIP3 (A20) for the activation of NF-κB; 24 showed 
no oscillation, including the essential activators of NF-κB IKBKG (IKKγ) and ubiquitin 
ligase CUL1, needed for the polyubiquitination of IκBα (24), and 4 did not fall in the 
previous three categories, but were significantly different from the controls under DMSO 
conditions (Figure 2 A-B and Table 1). Despite the oscillation-decreasing effect of DCF, 
2 siRNAs targeting splicing factor PHF5A and th receptor TNFRSF18, led to a further 
decrease in oscillation under this condition. Twelve increased the oscillation, 22 stopped 
the oscillation, including knockdown of the cyclin-dependent kinase CDK12 that was 
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Figure 2. Functional and phenotypic profiling of the siRNA screen hits that control NF-κB oscillation. (A) 
Typical non-normalized NF-κB oscillation averages acquired in the deconvolution screen, including examples 
of knockdowns that led to a phenotype similar to the classification controls; siA20, diclofenac (DCF) and siIκBα. 
The “different” class is defined by having five or more features significantly different from the siControl. (B) 
Heatmap of the SMARTpool classification P-values for the hits confirmed by 2 or more single siRNAs in the 
deconvolution screen, clustered for their corresponding classification on the right.  The overlap of the hits under 
DMSO and DCF conditions are additionally presented in (C). (D) Most of the hits under both DMSO and DCF 
conditions are described as kinases, (ubiquitin) ligases and hydrolases (mostly deubiquitinases). (E) Knockdown 
of hydrolases led to a predominantly “increased” phenotype under both DMSO and DCF conditions, while 
knockdown of kinases and ligases in general lead to “no oscillation” phenotype. The “decreased” phenotype 
was predominantly detectable under DMSO conditions. The functionality of the target genes was evenly 
distributed. The “different” phenotype was evenly distributed over functionality as well as exposure condition.
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Table 1. Confirmed hits from the deconvolution screen arranged by classification. DCF = diclofenac.
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shown to only decrease the oscillation under DMSO conditions, and 4 had a different 
oscillation phenotype (Fig. 2 B and Table 1). Between the two conditions, 33 hits were 
overlapping, 7 were unique for DMSO and 6 for the diclofenac condition at a p-value cut-
off of p<0.001 (Fig. 2 B-C and Table 1). Most hits were kinases and (ubiquitin) ligases, 
which most often contributed to the “no oscillation” or “decreased” response phenotype 
(Fig. 2 D and 2 E).
 The strength of our siRNA screening approach is the analysis of the dynamics 
of the NF-κB response at the single cell level within an entire population of cells. This 
allows measurement of the population dynamics upon knockdown of our candidate 
genes (Fig. 3 A and 3 B). Under control conditions the majority of the cells showed three 
nuclear translocation events within the imaging period. Yet the siRNA conditions that 
blocked the oscillation led to profiles with either no, or one shallow oscillation event, 
as shown with our positive control IκBα and knockdown of the genes necessary for 
NF-κB activation, IKBKG (IKKγ) and TNFRSF1A (TNFR1)  (Fig. 3 Bi). The decreased 
phenotype exhibited mainly 2 or 3 oscillation events, as shown by knockdown of CDK12 
and PHF5A, whereas the increased class, best illustrated by knockdown of our positive 
control TNFAIP3 (A20), showed mostly cells with 3 or 4 oscillations (Fig. 3 Bii). Within 
the profile class of “no oscillation” the number of peaks was vastly reduced and any 
observable translocation event occurred later than in control cells, at lower amplitude 
and with a reduced nuclear entry slope. Within the remaining fraction of cells (~30%) that 
showed more than one nuclear translocation event, the peaks remained shallow, which 
leads to a reduced dampening between the peaks (Fig. 3 Ci). The group of siRNAs that 
decreased the oscillation also decreased the number of oscillations and increased the 
time of the first translocation event. Differently from the “no oscillation” class, the profiles 
within the “decreased” class that included CDK12, RBX1, PHF5A and USP8, all showed 
an increase in the duration of the initial translocation event including a delayed time for 
the maximum. This suggests a role in the regulation of the NF-κB nuclear export, which 
subsequently affects the timing of the second peak (Figure 3 Cii). Finally, the increased 
class, including our positive control TNFAIP3 (A20), the inhibitor of NF-κB activation 
MAPKAPK2 (25), AGTR2 and MAPK4, were hallmarked by an increase in the number of 
oscillations, with a decreased time interval between peaks, that exhibit an elevated NF-
κB nuclear translocation amplitude (Figure 3 Ciii). 
Genes that prevent the NF-kB oscillation protect against TNFa/hepatotoxicant-
induced cell death.
Diclofenac (DCF) and carbamazepine (CBZ) are two drugs that are associated with 
idiosyncratic liver injury in humans, in which the innate immune system-based TNFα is 
an important component. Indeed, we have previously reported that diclofenac sensitizes 
liver cells to apoptosis caused by an otherwise non-toxic dose of TNFα (5). Since this 
was directly linked to inhibition of NF-κB signaling (5), we questioned whether inhibition 
of the 22 candidate genes that showed a “no oscillation” phenotype after knockdown, 
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Figure 3. Population statistics. (A) The population distribution of NF-κB oscillations in HepG2 GFPp65 cells 
upon indicated siRNA treatments. (B) Examples of how each phenotypic class is distributed in relation to the 
number of translocation peaks. (C) The translocation features that define the different classes: “no oscillation” 
(Ci), “decreased” (Cii) and “increased”(Ciii) are exemplified by their representative siRNAs.
would affect the cytotoxic response upon DCF/TNFα and CBZ/TNFα exposure. Since 
knockdown of caspase-8 completely inhibited the apoptotic response induced by both 
DCF/TNFα and CBZ/TNFα, we further used this as a positive control (Fig. 4 A and B). 
The majority of the knockdowns that displayed a “no oscillation” phenotype significantly 
inhibited the drug/TNFα-induced apoptotic response (12 out of 21; including CDK12, 
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RNF126 and TNFRSF1A), while others did not significantly affect the response (7 out of 
21; including CUL1, USP8 and AATK); only IKBKG (IKKγ) and TNFRSF18 knockdowns 
slightly, but significantly, increased the sensitivity towards apoptosis (Fig. 4 B). 
Interestingly, knockdown of the important negative regulator of TNFα-induced apoptosis, 
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Figure 4. A “no oscillation” phenotype correlates to decreased drug/TNFα-induced apoptosis. (A) Live apoptosis 
imaging of wild type HepG2 cells with knockdowns resulting in a “no oscillation” phenotype in GFP-p65 cells 
after 500μM diclofenac (DCF) or 500μM carbamazepine (CBZ) pre-incubation for 8 hours followed by addition 
of TNFα (10 ng/mL) The amount of apoptosis is presented as a percentage after normalization to the number 
of Hoechst33342-positive cells. (B) The area under the curves (AUC) depicted in A was calculated and an 
average of the fold change (FC) compared to siControl for three independent experiments was determined. 
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Protection against apoptosis is correlated to A20 expression and not IkBa activa-
tion 
IκBα is a direct phosphorylation target for the IKK complex after TNF receptor activation 
and subsequently targeted for proteasomal degradation, a prerequisite for NF-κB nuclear 
translocation. In addition, IκBα constitutes the earliest induced negative feedback 
mechanism for the attenuation of NF-κB activity. We wondered whether genes showing 
the most significant reduction in drug/TNFα-induced apoptosis (p-value < 0.001 in Figure 
4B: including CDK12, RNF126, TNFRSF1A, TRIM8 and UFD1L) would affect IκBα 
levels. We used BAC-NFKBIA-GFP (IκBα-GFP) HepG2 cells that phosphorylate and 
degrade IκBα-GFP with the same kinetics as non-tagged IκBα (Supporting Data S2). 
We knocked down above genes individually and followed the IκBα-GFP levels by live 
cell imaging. Depletion of the TNFRSF1A, UFD1L, and RNF126 strongly increased the 
initial levels of IκBα-GFP compared to mock treatment (Fig. 5 A), which was associated 
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Figure 5. IκBα levels are elevated and the re-expression is delayed while phosphorylation status remains the 
same after knockdown of the candidate genes. (A) Quantification of GFP expression in HepG2 cells expressing a 
BAC-NFKBIA-GFP construct. TNFα stimulation induces degradation and re-synthesis of the IκBα-GFP protein, 
which is altered after knockdown of the indicated candidate genes. (B) The amount of IκBα phosphorylation (P) 
after knockdown of the indicated candidate genes in HepG2 GFP-p65 cells followed by TNFα exposure for 0, 5, 
120 and 210 minutes was determined by western blotting. The tubulin-normalized intensities of P-IκBα for the 
same knockdowns after 5 minutes of TNFα exposure is shown in the right panel. 
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with an essential complete inhibition of the NF-κB translocation response (see Fig. 2 
B). Importantly, TNFα treatment caused an oscillatory response of IκBα-GFP at the 
population level, corresponding to the western blot data. As expected, depletion of the 
TNF receptor inhibited an IκBα-GFP oscillatory expression. Yet, CDK12, TRIM8 and 
RNF126 did not affect the initial breakdown of IκBα-GFP, but slightly delayed the newly 
translated IκBα-GFP. In line with this CDK12, TRIM8 and RNF126 did not inhibit the early 
phosphorylation of IκBα upon TNFα stimulation; as expected, TNFRSF1A knockdown 
prevented this phosphorylation event (Fig. 5 B). Knockdown of UFD1L showed a different 
response: despite the fact that TNFα could initiate a phosphorylation of IκBα, the 
degradation of IκBα-GFP was reduced, suggesting a role for UFD1L in the degradation 
of this protein (Fig. 5 A and B).
 As differences in IκBα phosphorylation and breakdown were not the major 
contributors to the effect of CDK12, RNF126, TRIM8 and UFD1L, we turned our attention 
to a second important negative feedback mechanism for NF-κB activity, A20 (TNFAIP3) 
(17,18). Intriguingly, the A20 levels after knockdown of CDK12, RNF126, TRIM8 or UFD1L 
were increased at control situation, prior to TNFα treatment (Fig. 6 A and B). Regardless, 
TNFα was still capable to further induce A20 after TNFα exposure (Fig. 6 A) most likely 
since the first NF-κB nuclear entry peak is not affected by these knockdowns. Again, as 
expected, depletion of the TNFα-receptor (TNFRSF1A) did not affect A20 levels under 
control or TFNα treatment. 
 A20 was an important regulator of the oscillatory NF-κB response in HepG2 
cells. The above data suggested that the effects of CDK12, RNF126, TRIM8 and UFD1L 
depletion on the reduced NF-κB oscillation was a direct result of the increased A20 levels. 
Therefore, we performed double knockdown experiments by combining A20 siRNAs with 
the siRNA against CDK12, RNF126, TRIM8 or UFD1L, again using TNFRSF1A as a 
siRNF126
0 5 120 210C
siTRIM8
0 5 120 210C
Mock
0 5 120 210C
siTNFRSF1A
0 5 120 210C
siCDK12
0 5 120 210C
siUFD1L


























































Figure 6. Knockdown of the 
candidate genes leads to 
basic upregulation of (de)
ubiquitinase A20. (A) Western 
blot for the A20 expression 
levels after knockdown of the 
indicated candidate genes 
in HepG2 GFP-p65 cells 
exposed to 10ng/ml TNFα for 
0, 5, 120 and 210 minutes. 
(B) Quantification of the A20 
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positive control. Importantly, depletion of TNF receptor together with A20 did not induce 
any oscillatory response, indicative for the effectiveness of our double knockdown. Yet, 
simultaneous knockdown of A20 with either CDK12, RNF126, UFD1L or TRIM8, (partially) 
recovered the NF-κB oscillatory response (Fig. 7 A), which was further quantified with 
respect to the average number of nuclear entry peaks at the cell population level (Fig. 7 
B).
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Figure 7. Double knockdown 
with candidate genes and 
siA20 leads to restoration 
of the translocation 
response. (A) The average 
oscillatory response in 
HepG2 GFP-p65 cells 
upon TNFα addition under 
double candidate gene and 
A20 knockdown conditions. 
Increased oscillation could 
be observed compared 
to knockdown of the 
candidate genes alone. 
(B) Quantification of the 
average number of peaks 
with and without A20 double 
knockdown. The data 
represent the average of 3 
independent experiments 
+/- S.E.M. The difference 
in the number of peaks 
compared to mock was 
defined using Student’s 
t-test where *** P≤0.001.
DISCUSSION
The transcription factor NF-κB is an important player in both physiology and disease, 
and its (enhanced) activity has been implicated in cancer as well as chronic inflammatory 
diseases (2). In addition, inhibition of NF-κB signaling has been implicated in the toxicity 
of drugs (5). The NF-κB translocation response is tightly controlled by different types of 
posttranslational modifications such as phosphorylation and especially (de)ubiquitination, 
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which has received much attention in recent years (16,17). In the current manuscript we 
have investigated the role of individual kinases, (de)ubiquitinases and sumoylases in the 
nuclear translocation of the transcription factor NF-κB following TNFα stimulation using 
siRNA-mediated knockdowns. For accuracy to determine the dynamics of the response, 
we employed a high content imaging method including a recently developed image 
analysis technique to quantify 32 different parameters describing the NF-κB oscillatory 
response. Using at least 5 of these features we could distinguish and classify siRNA 
knockdowns that result in a “no oscillation”, “decreased”, “increased” and significantly 
“different” translocation phenotype. An siRNA deconvolution screen confirmed 46 of 
the 115 hits from the primary screen of which the majority showed a “no oscillation” 
phenotype, and are thus likely to be positive regulators of NF-κB oscillation (Fig. 2). Many 
of these positive regulators also control the apoptotic outcome after hepatotoxicant/
TNFα-exposure, by regulating the expression levels of the (de)ubiquitinase A20.
 We successfully applied an advanced high content imaging approach to identify 
novel regulators of NF-κB signaling. So far RNA interference screens for NF-κB signaling 
mainly involved endpoint assays that mimic NF-κB transcriptional activity using luciferase 
reporter assays (11,12), precluding mechanistic insight in the dynamics of the NF-κB 
activation response. Our method allowed us to identify candidate genes that regulate 
the oscillatory response of NF-κB. Some of the 46 candidate genes have already been 
implicated in the regulation of NF-κB signaling (Table 1). This overlap was primarily 
observed in the target genes that upon knockdown increased or inhibited an NF-κB 
oscillatory response: genes with an “increased” phenotype were previously described as 
inhibitors of the NF-κB signaling response, and genes with “no oscillation” phenotypes 
are associated with promoters of NF-κB signaling (Table 1). 
 There is increasing evidence for a role of the oscillatory response of NF-κB in 
the control of gene expression. The total duration of nuclear localization and promoter 
association is likely to define the spatiotemporal control of epigenetic modulation of 
genes, and thereby their expression. Indeed, the differential expression of early, mid and 
late NF-κB target genes seems proportional to the strength and duration of the NF-κB 
nuclear occupancy (14,15). IκBα and A20 are classical early NF-κB target genes that 
are also regulated tightly in our model systems and provide early feedback control of 
NF-κB activation. At this point we do not know whether our candidate genes that affect 
the oscillatory response of NF-κB will also affect the overall target gene expression. We 
anticipate that such a dynamic transcriptional activity of NF-κB is likely to differ within 
the cell population. Indeed, we observed a differential response of the NF-κB oscillation 
in our cell population, with around 80% of the cells demonstrating 3 to 4 oscillations in 
control situations, and only 10% demonstrating one single peak. Depletion of for example 
TRIM27 completely shifted this response with 80% showing either 0 or 1 oscillation peak. 
Reversely, MAPKAPK2, AGTR2 and MAPK4 increased the percentage of cells with 4 
peaks. These effects will likely determine NF-κB mediated gene transcription. 
 Various novel candidates that regulate NF-κB signaling were identified. We 
described the splicing factor PHF5A as a promoter of the NF-κB oscillatory response. 
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PHF5A is implicated in processing of pre-mRNA (26). We suggest that this gene is 
required for proper processing of the mRNA of the protein needed for nuclear export of 
NF-κB, i.e. IκBα, after transcriptional activation. Furthermore we implicated the atypical 
mitogen activated protein kinase (MAPK) 4 (also known as ERK4), in the attenuation 
of the NF-κB signaling, since knockdown of this protein resulted in an “increased” 
translocation phenotype. ERK4 acts as a kinase for the substrate MAPKAPK5 (MK5) 
(27). We identified MAPKAPK2 (MK2), another protein in the same family as MK5 as an 
inhibitor of NF-κB translocation. MK2 is known to inhibit the nuclear export of NF-κB by 
reducing the levels of IκBα (25). MK5 has a similar role as MK2 and both phosphorylate 
HSP27 (28). Interestingly, HSP27 was previously implicated in the regulation of IKK 
activity as well as IκBα function (25,29,30). More research is required to investigate this 
link.
 Previously we reported that inhibition of the NF-κB translocation is linked to 
enhanced cytotoxicity following exposure to the hepatotoxicant diclofenac in combination 
with TNFα (5). Therefore, we focused on the knockdowns that resulted in a “no oscillation” 
phenotype. As expected, knockdown of known activators of the NF-κB signaling response, 
such as IKBKG (IKKγ; NEMO) and TNFRSF18 (GITR) (Table 1) enhanced the apoptotic 
response under diclofenac/TNFα and carbamazepine/TNFα exposure conditions (Fig. 
4). In addition, knockdown of known inhibitors of the NF-κB response such as FBXW5 
and TRIM27 (RFP) as well as the TNF receptor itself (TNFRSF1A) (Table 1) reduced the 
apoptotic response (Fig. 4). However, surprisingly, most of the knockdowns that lead to a 
reduced or no oscillatory response, reduced the drug/TNFα-induced apoptosis, including 
the known activators of NF-κB signaling, MAP3K14 (NIK) and TRIM8. Here we report 
for the first time that this observation is most likely due to the basal induction of the (de)
ubiquitinase A20. Higher A20 levels at the start of TNFα exposure would indeed reduce 
the induction of NF-κB translocation, as A20 is the most important negative regulator of 
RIP1 activity (17,18).  Furthermore, since A20 also controls apoptosis by deubiquitinating 
caspase-8 to reduce the activation of this protease (31), the elevated A20 levels might 
provide cellular protection against drug/TNFα-induced cell death. To our knowledge none 
of the candidate genes have been previously reported to affect A20 expression. 
 Since both IκBα as well as A20 levels were enhanced under control conditions 
(Fig. 5 A and 6), and both are important target genes of NF-κB, it seems likely that 
the enhanced expression of these proteins results from some initial activity of p65 after 
knockdown of the candidate genes. Especially in UFD1L knockdowns, the A20 and 
IκBα levels were exceptionally high. UFD1L is described as part of a complex regulating 
the proteasomal degradation of polyubiquitinated proteins from the endoplasmic 
reticulum and implicated in the closure of the nuclear envelope (32). Potentially, lack 
of UFD1L dismantles the boundary between inactive (cytoplasmic) and active (nuclear) 
p65, allowing a rise in nuclear p65 presence and thereby transcription of the negative 
feedback genes A20 and IκBα, an effect similar to IκBα knockdown itself (Supporting 
Data S1). In addition, the higher expression of A20 together with potential upregulation of 
NF-κB transcribed anti-apoptotic genes could result in the decreased apoptotic response 
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observed. 
 To our knowledge nothing is known about the functions and substrates of the E3 
ubiquitin ligase RNF126. However, as discussed earlier, many regulatory steps leading 
to the translocation of NF-κB involves ubiquitination of RIP1 and therefore RNF126 
knockdown possibly prolongs RIP1 polyubiquitination and thereby NF-κB activity, leading 
to the “no oscillation” phenotype by up-regulation of A20 as well as IκBα (Fig. 5 A and 
6). To determine whether the elevated IκBα and A20 expression is indeed caused by 
enhanced NF-κB activity before TNFα stimulation, the basal transcriptional activation of 
NF-κB should be addressed during the pre-stimulation knockdown period.
 Similar to PHF5A described earlier, cyclin dependent kinases such as CDK12 
have been implicated in the processing of pre-mRNA (33). Although not yet described, 
knockdown of CDK12 could have a similar effect on the processing of IκBα pre-mRNA as 
suggested for PHF5A above, resulting in the “delayed” phenotype (Fig. 2 A), and delayed 
re-expression of IκBα protein (Fig. 5 A). The delay of IκBα pre-mRNA processing and 
thus prolonged nuclear p65 presence would also explain the enhanced expression of 
A20.
 TRIM8 is an E3 ubiquitin ligase that has been reported to activate the NF-κB 
pathway by ubiquitinating the activating kinase TAK1 (34) as well as SOCS-1, a negative 
regulator of transcriptionally active NF-κB (35,36). Reduction of TRIM8 thereby resulted 
in a non-responsive, “no oscillation” phenotype with basic enhanced levels of A20 protein 
(Fig. 6). Of all candidate gene knockdowns leading to the “no oscillation” phenotype, 
the effect of TRIM8 knockdown seems to rely most on A20 upregulation as double 
knockdown for TRIM8 and A20 completely restored and even increased the NF-κB 
oscillatory response (Fig. 7).
 In summary, using an advanced  systems microscopy approach involving high 
content imaging and RNA interference screening, we identified novel regulators of NF-
κB signaling. Some of these regulators were essential to control the TNFα-dependent 
cell death by controlling the expression levels of A20, a negative feedback regulator of 
TNF receptor signaling. Besides in cytotoxicity, our candidate genes are likely to have 
important functions in inflammation and in the development or progression of different 
diseases including cancer, rheumatoid arthritis and pathogen infection. This needs further 
exploration. 
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Supporting Data S1. siRNA-mediated 
knockdown is successful in wildtype and 
GFP-p65 HepG2 cells. 50 nM siRNA 
SMARTpool transfection on positive controls, 
siA20 and siIκBα results in successful 
knockdown using INTERFERin tranfection 
reagent, as determined by western blotting. 
In GFP-p65 cells the siIκBα results in higher 
IκBα levels after 72 hours of knockdown, 
since knockdown of this inhibitor leads to 
enhanced p65 activity during this period and 
thereby increased IκBα transcription.
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Supporting Data S2. Expression 
of IκBα-GFP does not enhance 
the levels of the protein. Stable 
expression of BAC-IκBα-GFP does 
not result in overexpression of this 
protein. Furthermore, the GFP-tagged 
version of this protein behaves as the 
endogenous protein following TNFα 








The occurrence of adverse drug reactions (ADRs) is a significant problem both for 
society and for the drug-industry.  A few decades ago, the biggest challenge during 
drug development was poor bioavailability and pharmacokinetics. This has now shifted 
towards issues related to ADRs, of which idiosyncratic drug-induced liver injury (iDILI) is 
the most common.
 To tackle the ADR problems in drug development, there is need to better 
understand the underlying molecular mechanisms of ADRs. An improved mechanistic 
foundation of iDILI would open doors to establish new pre-clinical in vitro and in vivo 
tests that represent the most important programs that underlie iDILI. These would allow 
the removal of candidate drugs with a high likelihood of iDILI-inducing potential from 
further development at an early stage. In addition, such mechanistic insight could allow 
individualization of drug therapy by avoiding certain drug therapies for susceptible 
individuals, while maintaining access of these same drugs for patients that benefit from 
its actions without any demonstration of ADR. Finally, such a mechanistic understanding 
could help patients already suffering from ADRs, by providing candidate therapeutic 
strategies for protection, adaption or recovery.
 In this thesis I have investigated the involvement of the pro-inflammatory cytokine 
tumor necrosis factor-alpha (TNFα), in the toxicity of drugs that are known to cause iDILI 
in humans. I have given special attention to the non-steroidal anti-inflammatory drug 
diclofenac (DCF) and the anticonvulsant carbamazepine (CBZ). A variety of techniques 
including high content imaging of cell toxicity, cell based fluorescent reporters of drug-
induced and inflammatory stress, and toxicogenomics, allowed me to present in depth 
understanding of the mechanisms that could be involved in iDILI.
The role of TNFa-signaling in DILI
The immune system is known to play a major role in the development of adverse drug 
reactions, and especially of DILI. In relation to this, both the innate and the adaptive 
immune system have been shown to play an important role.  However, irrespective of 
which part of the immune system gets activated, the main mediators of their activity are 
cytokines. 
 The role of inflammatory stress in iDILI has been most extensively studied in 
the group of Patricia Ganey and Robert Roth. They have developed an animal model 
in which the severity of human iDILI has been replicated the best thus far (1). In this 
model, non-toxic doses of drugs like diclofenac, sulindac, trovafloxacin and amiodarone 
have been rendered toxic by the addition of a non-toxic dose of the bacterial endotoxin 
lipopolysaccharide (LPS). Although LPS, when absorbed from the intestines to the 
circulation, and thereby reaching the liver, causes activation of the liver stationary 
macrophages (Kupffer cells), the main source of injury in this model is infiltrating 
neutrophils (2-4). However, importantly, TNFα, a cytokine secreted by both macrophages 
and neutrophils, has been shown to be indispensible for the liver injury seen in these 




enhance the toxicity of diclofenac in an in vitro model using HepG2 cells, providing a good 
cell system for the study of the detailed mechanism(s) behind the role of inflammatory 
stress in DILI.
The unique role of the TNF receptor in the decision between life and death
The TNF receptor 1 (TNFR1) is unique among other cytokine receptors in the sense that 
it can induce both pro-survival and pro-apoptotic signaling. In chapter 2, I demonstrated 
that diclofenac and TNFα co-exposure leads to an enhanced amount of apoptosis, 
compared to exposure to the drug or the cytokine alone. Next, I showed that this apoptosis 
is strictly dependent on caspase-8 activity. This suggests that diclofenac is sensitizing the 
cells to TNFα-induced apoptosis rather than the other way around. Necroptosis is a novel 
mechanism by which TNFα can induce cell killing in a caspase independent manner 
(7). However, I show that the DCF/TNFα-induced cytotoxicity, in these cells, is solely 
dependent on apoptosis and seems not to involve necroptosis, since z-VAD-fmk, a pan-
caspase inhibitor, could completely inhibit the cytotoxicity induced. 
 In chapter 2, I also show an important role for c-Jun N-terminal kinase (JNK) 
in the induction of DCF/TNFα-induced apoptosis. JNK is known to induce apoptotic 
signaling after prolonged activation by the disruption of mitochondrial membrane integrity. 
Since the apoptosis is completely caspase-8 dependent, I propose that the pro-apoptotic 
role of JNK most likely occurs upstream of the mitochondria by controlling proteins at 
the proximity of casaspe-8 activity control. Indeed, JNK regulates the expression of 
cellular FLICE-like inhibitory protein (c-FLIP), the endogenous inhibitor of caspase-8, by 
phosphorylation of the E3 ubiquitin ligase Itch (8). Furthermore, more recently, TRAF7 
was described as an inducer of JNK activity downstream of the TNFR1 and additionally 
as a regulator of c-FLIP by inducing its degradation (9). This provides another common 
factor between the stress kinase JNK and the anti-apoptotic protein c-FLIP. Interestingly, 
the gene encoding the c-FLIP protein (CFLAR), was down-regulated after DCF and CBZ 
exposure of HepG2 cells (chapter 4), further supporting the potential role for c-FLIP in 
the survival of drug/TNFα co-exposed cells. Additionally, siRNA-mediated knockdown 
of CFLAR led to induction of DCF/TNFα-induced apoptosis, as shown in chapter 2. 
Recently, a mouse model with a conditional liver specific c-FLIP deletion was described 
(10). This mouse presented enhanced liver injury upon exposure to D-galactosamine 
and LPS, which induces liver cell death by activation of TNFR1. The cell death was also 
dependent of JNK activity, which suggests a bidirectional regulation of JNK and c-FLIP. A 
role for c-FLIP expression levels in regulating DILI under in vivo conditions needs further 
investigation.
 CFLAR is one of the anti-apoptotic target genes of nuclear factor kappaB (NF-
κB), the most important transcription factor induced down-stream of the TNFR1 upon 
TNFα exposure. In chapter 2 I described how diclofenac pre-exposure leads to a delay 
in the cytosol-to-nuclear translocation pattern of NF-κB using high content imaging of 




of oscillatory pattern of NF-κB determines the set of NF-κB target genes that will be 
transcribed after TNFR1 activation (11-13). Thus, a delay in the NF-κB translocation 
response may very well lead to a differential regulation of the crucial target genes and 
thereby affect the activation of the pro-apoptotic pathway downstream of TNFR1. This 
provides a potential explanation to why pre-exposure to certain drugs result in a greater 
sensitivity to TNFα; however it needs further detailed investigations. 
 A shift in the NF-κB translocation response upon drug exposure does not per 
se result in enhanced apoptosis by any hepatotoxicant. This was observed in chapter 
3, where three different high content imaging methods were used to assess apoptotic 
synergism with TNFα, induction of oxidative stress and ability to cause a shift in the TNFα-
induced NF-κB nuclear translocation response. A panel of 15 drugs, including several 
iDILI-inducing compounds, was used. Interestingly, the majority of the compounds that 
were able to induce an oxidative stress response as monitored by the Nrf2-dependent 
expression of Srxn1, also caused an inhibition of NF-κB activation. This is in agreement 
with other reports (14,15). Yet, a conclusive link between oxidative stress induction, NF-
κB nuclear translocation shift and TNFα apoptotic synergism could not be made for all 
compounds. 
Translation initiation and mRNA processing - crucial determinants of TNFa-
signaling
The lack of a direct link between oxidative stress-induction and increased sensitivity to 
TNFα calls for an alternative mechanism.  Glutathione depletion (especially mitochondrial) 
also causes sensitization to TNFα-induced apoptosis (16,17). In this thesis I did not 
assess (mitochondrial) GSH after drug exposure, which could be an explanation for the 
differences in the TNFα-synergism. However, to explain the DCF/TNF and CBZ/TNF 
synergism, in chapter 4 we applied a toxicogenomics approach and determined the 
gene transcription profiles after exposure to synergizing drugs DCF and CBZ compared 
to the hepatotoxicants ketoconazole, nefazodone and the far less toxic methotrexate. 
For the first time, I in this chapter describe translation initiation as a crucial process 
for the control of TNFα-induced hepatocyte-toxicity. The translation initiation factor 
EIF4A1 was selectively up-regulated after diclofenac and carbamazepine exposure. 
Intriguingly, knockdown of this RNA helicase using transient siRNA gene silencing led 
to a marked protection against drug/TNFα-induced apoptosis. Also the transcription 
of other translation initiation factors was affected, including a close family member of 
EIF4A1, EIF4A2. Yet, knockdown of EIF4A2 did not affect apoptosis. Only until recently, 
there was no difference in action described between EIF4A1 and EIF4A2 and they were 
presumed to have redundant functions. However, interestingly, selective knockdown of 
EIF4A1 can apparently increase the expression of EIF4A2. Yet, this did not completely 
compensate for the loss of EIF4A1, possibly due to differences in enzymatic activity or 
substrate specificity (18). This could also form the basis for the discrepancy between the 




 Inhibition of EIF4A in general (without isoform specificity) using the pharmacological 
inhibitor hippuristanol, has been described to result in selective inhibition of translation of 
injurious proteins, while translation of protective proteins remained intact (19). A similar 
scenario could be set in our case, where selective inhibition of EIF4A1 by knockdown, 
would result in decreased translation of crucial apoptotic proteins including CHOP, as 
was described in chapter 4, while translation of essential anti-apoptotic proteins would 
remain intact or even enhanced, due to increased activity of EIF4A2 upon EIF4A1 
inhibition. The role for translation initiation in drug-induced liver injury is an unexplored 
area. My data indicate that this clearly deserves more attention both in the context of DILI 
but also in relation to other liver pathological conditions.
 I searched for novel regulators of NF-κB nuclear translocation in chapter 5. 
Interestingly, two of the candidate genes whose knockdown had a significant effect on 
the TNFα-induced nuclear translocation of NF-κB are involved in mRNA splicing: splicing 
factor PHF5A and the cyclin dependent kinase CDK12 (20,21). Despite the fact that CDK12 
has also been implicated in gene-set specific transcription by its phosphorylation of RNA 
polymerase II (22), this further emphasizes the important role for post-transcriptional 
regulation of protein expression in a situation of cellular stress.  Interestingly, depletion 
PHF5A or CDK12 led to a “delayed” translocation phenotype under DMSO conditions, 
much like the one seen by diclofenac pre-treatment. Additionally, knockdown of PHF5A 
led to a slight enhancement of apoptosis induced by TNFα under DMSO conditions 
(observation not shown). This suggests aberrant mRNA splicing as a mechanism for 
diclofenac-induced inhibition of NF-κB translocation as well as induction of apoptosis 
after TNFα exposure. The description of similar substrate specificity between EIF4A1 
initiated translation and PHF5A and CDK12 mediated mRNA splicing, would provide 
further mechanistic insight to how certain drugs can sensitize towards TNFα-induced 
apoptosis and thereby induce DILI. It would be relevant to investigate the expression of 
c-FLIP after knockdown of EIF4A1, PHF5A and CDK12.
A central role for A20 in regulating cell death and survival in TNFa-signaling
I demonstrated that perturbations in NF-κB signaling are critical in drug-induced 
hepatocyte cell death. NF-κB is well known for its involvement in the transcription of genes 
involved in for example inflammation, survival and proliferation. However, inappropriate 
activity of NF-κB signaling has been linked to the development of (liver) cancer, but also 
of autoimmune and inflammatory diseases (23). Therefore, the identification of novel 
regulators of the NF-κB signaling would provide improved insight for both hepatotoxicity 
as well as (liver) carcinogenesis. We focused on the NF-κB translocation response for 
our siRNA screen. Interestingly, most of our hits from the screen inhibited the NF-κB 
translocation response (described as “no oscillation”). Additionally, we were able to 
link this “no oscillation” phenotype to inhibition of drug/TNFα-induced apoptosis. “No 
oscillation” could be explained by inhibition of TNFR1 activation, which would also result 




candidate genes would affect the assembly of TNFR1 downstream signaling complexes, 
thereby preventing the pro-survival NF-κB signaling, but also preventing the pro-apoptotic 
caspase-8 activation. We showed that a common denominator for the knockdowns that 
inhibited both processes was the expression of the protein A20.
 A20, or TNFAIP3, is a target gene of NF-κB and constitutes, together with IκBα 
(NFKBIA), the most important transcriptionally regulated feedback mechanisms to down-
regulate NF-κB activation (24). A20 inhibits NF-κB signaling by deubiquitinating receptor-
interacting protein 1 (RIP1) and subsequently targeting this protein for proteasomal 
degradation by ubiquitin ligation (25).  However, apart from its role in terminating the 
NF-κB signaling, A20 has a crucial role in regulating the apoptotic response after TNFα 
exposure as demonstrated in an A20-deficient mouse model (26). The inhibition of 
apoptosis has been shown to occur via deubiquitination of caspase-8 downstream of the 
death receptor 4 and 5 (27). Further research in this topic is however needed to clarify the 
exact role of A20 in repression of the pro-apoptotic signaling downstream of the TNFR1. 
One possibility is that A20 is involved in the direct switching from anti-apoptotic complex 
I formation, to pro-apoptotic complex II initiation, and thereby regulating the apoptosis 
induced by TFNα.
 Because of its dual role in the regulation of TNFα and other immune-mediated 
signaling, A20 has been thoroughly investigated as a key mediator in cancer and chronic- 
as well as autoimmune disease. Moreover this gene has been described as a susceptibility 
locus for the development of such diseases (28). Together with its protecting role in drug/
TNFα-induced liver cell death, further studies on the regulation of A20 expression in DILI is 
needed. In chapter 5 I describe four novel regulators of A20 expression, CDK12, UFD1L, 
TRIM8 and RNF126. Importantly, knockdown of these genes resulted in an enhanced 
expression of A20 leading to the inhibition of TNFα-induced NF-κB nuclear translocation, 
as well as apoptosis under drug pre-exposure conditions. Further investigation on how 
this regulation occurs is relevant to exploit this pathway to treat chronic inflammatory 
and autoimmune diseases as well as cancer, in which A20 has been shown to play an 
important role (28).
The future for in vitro hepatotoxicity assessment
A golden standard for human liver toxicity testing in a pre-clinical setting is the use of 
primary or cryo-preserved human hepatocytes. However, this cell system has been 
proven difficult to work with, as the batch-to-batch variability in the cellular responses 
is large, and as the cells go through rapid dedifferentiation. The use of HepG2 cells is 
then an attractive option since these cells, as an immortal cell line, show low variability in 
between experiments and allow detailed mechanistic research using techniques such as 
the functional genomics screening in this thesis. Granted an important drawback of using 
a transformed cell line such as HepG2 is its low drug-metabolizing capacity. Yet, while 
HepG2 cells show low phase I metabolizing activity (29), its phase II metabolism is more 




induced by certain drug-metabolites (30). Furthermore, and critically importantly for our 
research, the acyl-glucuronide metabolite for the induction of idiosyncratic diclofenac-
mediated liver injury, could be readily identified in our culture system (chapter 2). 
 An additional advantage of the HepG2 cells is that they can be easily engineered 
to express for example GFP-tagged proteins as reporters for different types of intracellular 
stress. This was first introduced in chapter 2 using a GFP-p65 reporter cell line, and further 
expanded in more detail in chapter 3. Here it is nicely illustrated how the combination of 
a few different cellular assays, can be used to estimate the toxicity potential of novel drug 
candidates. Although in the end not proven to result in apoptosis in our cellular system, 
the capability of a drug to induce oxidative stress as detected by the Srxn1-GFP reporter, 
or its ability to inhibit the nuclear translocation response of NF-κB, can provide enough 
information from a toxicological perspective. Especially since both these events have 
been linked to enhanced drug toxicity in vivo (see chapter 1).
 Multi-parametric analysis of cells stained with different dyes to assess different 
drugs’ hepatotoxic potential has recently been described as a high throughput method 
for fast assessment of (mode of) toxicity (31). However, such a method involves different 
sample preparation steps as well as the limitation of a fixed-time-point. Instead an 
extended panel of in vitro reporters of different types of cellular stresses known to be 
involved in drug-induced liver injury, similar to the stress reporters described in chapter 
3, would constitute an important asset to the pharmaceutical safety assessment. These 
would provide minimal amount of wet-work, resulting in reduced variability. Since GFP-
based reporter systems allow live cell imaging of stress responses, kinetic information 
about the toxicity onset on a cell-to-cell basis provides additional valuable information. 
In addition, different GFP stress reporter cell lines would provide important mechanistic 
information about the pathways of toxicity that are induced by drug exposure. When 
considering the results from chapter 4, I would additionally suggest reporters for CHOP 
and EIF4A1-induction, as a part of the pre-clinical in vitro tox-screening panel. These 
proteins were both up-regulated after liver-toxic drug exposure and functionally critical 
for the drug/TNFα-induced synergistic toxicity. 
 The use of induced pluripotent stem cells (iPSCs) that are later differentiated into 
hepatocytes is becoming an increasingly attractive alternative for in vitro toxicity testing. 
These newly differentiated cells seem more “hepatocyte-like” than HepG2 cells when 
it comes to for example drug metabolism capacity (32). In an ideal world, these could 
also be used for stress reporter construction, as this background would be even more 
relevant to the human situation compared to the HepG2 cells. Interestingly, considering 
the individual variances in drug responses, projects are underway to generate iPSCs, 
and subsequently hepatocytes, from patients experiencing iDILI (33). This would provide 
very important information on the hepatocyte-based molecular mechanisms underlying 






In this thesis I used an in vitro model to study the role of inflammatory stress in idiosyncratic 
DILI. I have described in detail the interplay between hepatotoxicant- and cytokine-
induced signaling in liver cell death. Two drugs, diclofenac and carbamazepine, which 
have been associated with inflammatory DILI in humans, showed an exceptionally strong 
synergistic response with the pro-inflammatory cytokine TNFα. This response was linked 
to the inhibition of NF-κB signaling (chapter 2 and 3) and the induction of oxidative as well 
as to onset of endoplasmic reticulum and translation-dependent stress (chapter 3 and 
4). Finally in chapter 5, I described novel regulators of A20 expression and indirectly of 
NF-κB signaling as well as apoptosis induction. Potentially these genes could be used as 
markers for inflammatory diseases as well as susceptibility markers for the development 
of DILI. Moreover, I anticipate that more detailed studies of post-transcriptional regulation 
will provide further important information about the mechanisms behind drug-induced 
liver injury.
 The findings reported in this thesis provide important contributions to the 
understanding of the mechanisms behind drug-induced liver-injury. This deeper 
understanding may aid in the development of advanced pre-clinical drug safety 
assessment models for novel candidate drugs. Furthermore, I anticipate that the novel 
findings regarding the regulation of NF-κB activation can contribute to areas beyond 
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Bijwerkingen van medicijnen zijn een groot probleem voor zowel de maatschappij als 
voor de farmaceutische industrie. Bij ernstige bijwerkingen zijn de kosten hoog; voor 
de farma-bedrijven in de financiële zin omdat hun product (vroegtijdig) van de markt 
gehaald moet worden en voor de maatschappij omdat de betrokken individuen mogelijk 
additionele behandelingsmethodes moeten ondergaan. Dit is nog afgezien van de last 
voor de patiënten in kwestie.
 Leverschade door medicijngebruik is de meest voorkomende bijwerking en zo 
ook onderliggende reden voor het verwijderen van een medicijn. Dit type bijwerking, in 
het engels afgekort tot DILI (drug-induced liver injury), schaadt de lever in die zin dat de 
lever ophoudt met functioneren, met mogelijk dodelijke gevolgen. De lever is één van 
de meest kwetsbare organen bij medicijngebruik vanwege diens functie: het bloed, dat 
langs de darmen stroomde, ontdoen van lichaamsvreemde stoffen, inclusief medicijnen. 
Daarbij worden deze stoffen omgezet naar makkelijk af te voeren stofjes die uitgescheiden 
kunnen worden via de urine of de gal. Dit omzetten gaat vaak goed en het medicijn wordt 
navenant afgevoerd. Echter, soms worden ook schadelijke nevenproducten gevormd die 
de lever kunnen schaden. Of en waarom ernstige leverschade optreedt lijkt af te hangen 
van het individu.
 Voor een aantal medicijnen kan DILI worden verklaard. Paracetamol bijvoorbeeld 
wordt gedeeltelijk omgezet tot een reactief bijproduct, wat normaliter efficiënt wordt 
weggevangen door de verdedigingsmechanismen in de lever zolang de inname niet 
overmatig is, anders leidt het tot leverfalen met dodelijke afloop. Het bijproduct kan 
worden weggevangen en daarom is de ernstige schade relatief makkelijk te voorkomen. 
Echter, de oorzaak en het mechanisme van DILI door andere medicijnen is vaak nog 
niet bekend. Omdat DILI niet vaak voorkomt maar wel zeer ernstig kan zijn, is het 
wenselijk om te weten te komen hoe dit proces zich ontwikkelt om het uiteindelijk te 
kunnen voorkomen. Een beter inzicht in de toedracht leidt mogelijk tot testsystemen die 
gebruikt kunnen worden door de farmaceutische industrie om te voorkomen dat dit type 
schadelijke medicijnen nooit op de markt gebracht worden. Mijn proefschrift gaat over dit 
belangrijke probleem; waarom treden deze onverklaarbare bijwerkingen op in de lever en 
welke testsystemen kunnen we opzetten om nieuwe kandidaat-medicijnen op veiligheid 
te testen?
 Het is al bekend dat niet alleen het omzetten van of het metabolisme van een 
stof de lever kan beschadigen, maar ook dat het immuunsysteem een belangrijke rol 
speelt in dit proces. Met deze kennis hebben we in Hoofdstuk 2 de synergie-hypothese 
getest: het tegelijkertijd blootstellen van gekweekte levercellen aan een stof die DILI 
veroorzaakt en een cytokine die ontstekingen bevordert, leidt tot meer celdood dan beide 
componenten an sich. We testten deze hypothese voor de modelstof diclofenac, de niet-
schadelijke controlestof naproxen en de cytokine TNFα: tumor necrosis factor α. Met 
dit model ontdekten we dat TNFα inderdaad de celdood bevordert in aanwezigheid van 




te worden gezet door diclofenac, dat de levercellen gevoelig maakt voor de schaduwzijde 
van TNFα, en niet andersom. TNFα stimuleert namelijk overlevingsmechanismen binnen 
een cel, maar tegelijkertijd ook celdood. De balans tussen deze tegenovergestelde 
signaalcascades helt normaliter over naar overleving, maar deze wordt dusdanig verstoord 
door diclofenac dat de celdood-respons de overhand krijgt, met meer leverschade tot 
gevolg.
 Als medicijnen worden omgezet tot metabolieten leidt dit tot stress in levercellen. 
In Hoofdstuk 3 laten we een combinatie van drie microscopie-gebaseerde benaderingen 
zien om medicijnen op leverschade potentie te testen. Blootstelling aan medicijnen kan 
oxidatieve stress induceren. Daarom testten we eerst een aantal stoffen, inclusief die 
medicijnen die onverklaarbare leverschade kunnen veroorzaken, in een reporter systeem 
voor oxidatieve stress. Hiermee konden we aantonen dat het gros van de stoffen, zo ook 
diclofenac, oxidative stress veroorzaakt. Dit drukt mogelijk de overlevingsmechanismen 
die normaliter aangezet worden na TNFα. Daarom onderzochten we de dynamiek van de 
signaal-cascade volgend op TNFα stimulatie in een toegewijde assay. De mate waarop 
oxidatieve stress werd geïnduceerd voorspelde echter niet of een medicijn de respons 
op TNFα negatief zou beïnvloeden. Desalniettemin, zodra we de verkregen informatie 
combineerden met een derde assay die de celdood meet door toedoen van een 
combinatie van cytokine en medicijn, vonden we dat de stoffen die zowel oxidatieve stress 
induceerden en de TNFα-afhankelijke overlevingsresponsen negatief beïnvloedden juist 
degenen zijn die tot meer celdood leiden in combinatie-condities. Hiermee konden we 
aantonen dat een combinatie van meetmethodes ingezet kan worden om het lever-
schadelijke potentiëel van medicijnen te indexeren.
 Omdat het optreden van oxidatieve stress niet voorspellend was voor het optreden 
van leverschade na medicijn en cytokine, is het aannemelijk dat ook andere stress-
routes een belangrijke rol spelen. In Hoofdstuk 4 hebben we dit aangepakt door te kijken 
naar het genexpressie patroon dat door blootstelling aan DILI-gerelateerde medicijnen 
wordt geïnduceerd. De focus lag op twee medicijnen waarvan de celdood flink versterkt 
wordt door TNFα: diclofenac en carbamazepine. Met software die signaalcascades 
helpt analyseren hebben we de verschillende typen celstress nagelopen. We konden 
bevestigen dat deze twee stoffen oxidatieve stress induceren en vonden vervolgens 
ook dat beide de eiwitproductie beïnvloeden. Vooral een specifiek gen, EIF4A1, werd 
sterk aangezet na blootstelling aan diclofenac en carbamazepine, maar minder door 
stoffen waarbij TNFα de celdood niet specifiek verergerde. Wat verder interessant 
is, is dat het specifiek voorkomen dat dit eiwit aangemaakt kan worden voorkomt de 
celdood. Dit toont aan dat dit eiwit zeer belangrijk is bij de versterking van de celdood na 
medicijn-blootstelling door TNFα. Mogelijkerwijs kan dit eiwit dienen als merker voor het 
leverschadelijk effect van stoffen. Anders zou het ook kunnen dienen als een additionele 
merker voor translationele stress in een microscopische setup vergelijkbaar met het 
oxidatieve stress reporter-systeem zoals beschreven in hoofdstuk 3, om medicijnen te 
kunnen monitoren op ernstig DILI-potentiëel.




overlevingsrespons na TNFα om uit te monden in celdood. Diclofenac voorkomt namelijk 
de gerichte activiteit van de transcriptie-factor NF-κB waarmee de stof voorkomt dat de 
genen die voor overleving zorgen niet (goed) aangezet worden. In Hoofdstuk 5 hebben 
we systematisch de rol van individuele genen getest in de dynamiek van NF-κB. NF-
κB dient in een voorgeprogrammeerde cyclus de kern in en uit te gaan om de juiste 
genetische respons aan te zetten. We konden enkele nieuwe eiwitten identificeren die 
deze locatie-wisseling beïnvloeden en ook aantonen dat dit direct invloed heeft op de 
celdood. Het uitbreiden van de kennis rondom NF-κB regulatie is niet alleen van belang bij 
het begrijpen van bijwerkingen, maar ook op gebied van celgroei en ontstekingsreacties, 
processen waarbij NF-κB een belangrijke rol speelt en kennis bijdraagt bij het begrijpen 
van kanker en chronische ontstekingsziekte.
 Samenvattend, het werk dat in dit proefschrift is gepresenteerd is dieper ingegaan 
op hoe bijwerkingen optreden in de lever en focuste op de rol van ontstekingsreacties in 
dit proces. De kennis die we hebben verzameld kan mogelijk ingezet worden om nieuwe 
en betere testmethodes voor toxiciteit te ontwerpen en ontwikkelen om in te zetten voor 
medicijn-ontwikkeling. Verder denk ik dat het werk dat in hoofdstuk 5 staat, aangaande 






Adverse drug reactions, more commonly called side effects, are very problematic 
for both society and pharmaceutical industry. The costs are high in severe cases: for 
pharmaceutical companies due to the loss of intended income if a drug needs to be 
removed from the market; for society due to the extra healthcare that is required to treat 
the affected individuals. And, not to be forgotten, the burden to the patient in question.
Liver damage upon drug intake is the most common type of adverse drug reaction and 
reason for drug withdrawal. Drug-induced liver injury (DILI) may affect the liver to such an 
extent that the liver fails to function, which is potentially fatal. One of the major functions of 
the liver is drug clearance, meaning that it monitors the blood coming from the intestines 
for foreign substances, including drugs, takes these up and modifies them to species 
(metabolites) that can be removed via the urine or bile. Often this drug clearance process 
runs without trouble; however, sometimes drug metabolites are formed that actively 
damage the liver. Whether and why severe liver damage occurs seems to depend on the 
individual.
 Sometimes DILI can be explained. For example, paracetamol is partially modified 
to form a harmful side product. Under normal circumstances this is detoxified by the 
liver’s own defense systems, but upon overdose the concentrations exceed the defense 
potential, resulting in acute liver failure. This process can be counteracted and by that 
avoided. However, the cause and mechanism of DILI by various other drugs is not (yet) 
known. Although infrequent, but severe, it is of major interest to prevent unexplainable 
DILI. Understanding how and why will therefore be very important. The knowledge could 
result in creating tests for drug safety that can be used by the pharmaceutical industry, to 
prevent the marketing of harmful drugs. My thesis dealt with this important problem: why 
does DILI occur and would it be possible to create tests to screen new drug-candidates 
for (liver) safety?
 For some time it is known that not only the drug transformation or metabolism 
can damage the liver, but there is also a role for the immune system in DILI. Based on 
this knowledge, we tested in Chapter 2 the synergy hypothesis: simultaneous exposure 
to a drug that can cause DILI and a cytokine that promotes inflammation is more harmful 
to liver cells that are grown in a culture dish, than either of the two components alone. 
We tested this hypothesis for the model-drug diclofenac, the safe control drug naproxen 
and combined these with the cytokine TNFα: tumor necrosis factor α. Using this model 
we could confirm our hypothesis, TNFα indeed enhanced the cell-death response when 
combined diclofenac, but not by itself or when combined with naproxen. In this chapter we 
further show that this effect occurs because diclofenac sensitizes the liver cells to the dark 
side of TNFα, rather than the other way around. TNFα namely stimulates both pro-death 
as well as pro-survival signals in a cell. Under normal conditions, the balance between 
these opposites is favored towards survival. However, diclofenac shifts this balance by 
inhibiting the pro-survival signaling and thus promotes the cell-death response, resulting 




 The formation of drug metabolites induces stress in liver cells. In Chapter 3 
we demonstrate the combination of three imaging methods to address the liver-injury 
potential of drugs. First, drug exposure may cause so called oxidative stress. Several 
drugs, including those that can cause unexplainable DILI, were tested in a imaging-based 
system to be able to detect this type of stress. This showed that many drugs, including 
diclofenac, cause oxidative stress. It is known that this might affect the survival-response 
to TNFα and therefore the activation of this response was monitored. The induction of 
oxidative stress by itself did not accurately predict the effect on the survival response. 
However, when this information was combined with the third assay, the cell-death assay 
to investigate the potential of TNFα to enhance the drug-induced liver cell death, we 
found that the drugs that both induced oxidative stress and inhibited the TNFα-induced 
survival signaling, caused more cell death. This demonstrated that a combination of 
readouts can be used to indicate the liver injury-inducing potential of drugs.
 Since the induction of oxidative stress by drugs alone does not fully predict the 
enhancement of liver cell injury when combined with TNFα, other stress pathways must 
be involved. In Chapter 4 we took a gene expression approach to identify the types 
of signaling that are induced upon drug exposure. For the analysis we focused on two 
drugs whose toxicity is exceptionally enhanced when combined with TNFα: diclofenac 
and carbamazepine. Using signaling pathway analysis software we investigated the 
stress types that are induced by these drugs. This confirmed our earlier findings that 
these two drugs induce oxidative stress, but additionally indicated that they both affect 
genes controlling the protein synthesis machinery. Especially one gene, EIF4A1, was 
enhanced in expression under diclofenac and carbamazepine conditions, but not by 
drugs whose toxicity is not enhanced by TNFα. Interestingly, preventing this protein from 
being expressed reduced the amount of dying cells under these conditions. This shows 
its vital importance in the TNFα-enhanced drug-induced cell death response. Potentially, 
this gene could be used as a marker for the liver injury potential of drugs. Additionally, it 
might serve as a marker that can be used in an imaging setup, next to the oxidative stress 
reporter presented in chapter 3, to identify drugs that cause severe DILI.
 In chapter 2 we reported that diclofenac leads to a shift in the survival response 
to TNFα to favor cell death. Diclofenac does this by inhibiting the activity of the TNFα-
responsive transcription factor NF-κB, and thereby prevents the induction of pro-survival 
genes. In Chapter 5 we systematically investigated the role of individual proteins in the 
response dynamics of NF-κB. NF-κB needs to move in and out of the nucleus in a pre-
determined manner in order to induce the appropriate genetic response. We identified 
several novel proteins as being important in controlling this movement, and were 
able to show that this had a direct impact on the cell death response under drug and 
TNFα conditions. This expansion of the knowledge about NF-κB regulation is not only 
important for understanding adverse drug reactions, but also in relation to cell growth 






 In summary, the work presented in this thesis provides a deeper understanding of 
how adverse drug reactions occur in the liver and emphasized on the role of inflammation 
in this process. The knowledge we gathered can be used to design and develop novel 
and better tests for toxicity assessment during drug development and I think that the work 







Läkemedelsbiverkningar utgör ett stort problem både för samhället och för 
läkemedelsindustrin. Om biverkningarna som uppstår är mycket allvarliga blir kostnaderna 
höga: för läkemedelsbolagen på grund av förlorad inkomst om läkemedlet i fråga måste 
tas bort från marknaden; för samhället i form av sjukvårdskostnader om biverkningarna 
leder till sjukhusintagning. Biverkningar medför också mycket lidande för patienten i 
fråga, vilket inte får glömmas.
 Leverskada till följd av läkemedelsanvändning är den vanligaste formen av 
läkemedelsbiverkan och det är också den vanligaste orsaken till att ett läkemedel måste 
tas bort från marknaden. Läkemedelsorsakad leverskada kan påverka levern till en 
sådan grad att den slutar att fungera, kallat leversvikt, något som kan leda till döden. 
En av leverns viktigaste funktioner är att rena blodet från främmande ämnen, också 
läkemedel, genom att modifiera dem på ett sådant sätt att de lätt kan utsöndras från 
kroppen, antingen med urinen eller gallan. Oftast fungerar den här oskadliggörande 
utsöndringsprocessen som den ska, men ibland kan skadliga biprodukter bildas. Om 
och varför en allvarlig leverskada inträffar eller inte tros bero på omständigheter rörande 
individen.
 Ibland kan den läkemedelsorsakade leverskadan förklaras, givet att man vet 
vad som vållar den. Till exempel paracetamol är ett läkemedel som delvis omvandlas 
till en skadlig biprodukt i levern. Normalt sett kan leverns eget försvarssystem ta hand 
om den här biprodukten men vid överdosering resulterar detta i att försvarssystemet 
överhettas, vilket i sin tur leder till akut leversvikt. Detta är i många fall dödligt om den 
överdoserade inte behandlas snabbt. För andra läkemedel finns det däremot (ännu) ingen 
förklaring till varför vissa individer får leverskador vid en normal dosering. Leverskadorna 
uppkommer sällan, men det är mycket allvarligt när de väl inträffar, vilket gör att det 
är väldigt eftertraktat att försöka undvika dem. Att förstå ”varför?” och ”hur?” är därför 
väldigt angeläget, och den kunskapen skulle kunna användas för att designa tester som 
kan användas inom läkemedelsindustrin för att undvika att skadliga mediciner kommer 
till försäljning. Min doktorsavhandling handlar just om detta viktiga problem: varför 
uppkommer läkemedelsrelaterad leverskada och är det möjligt att ta fram tester som kan 
användas för att se om ett potentiellt läkemedel riskerar att orsaka detta?
 Sedan en tid tillbaka vet man att inte bara läkemedelsmetabolism/-modifikation 
kan skada levern, men också immunsystemet har visat sig spela en viktig roll. Med 
denna kunskap i åtanke testade vi i Kapitel 2 hypotesen att samtidig exponering för ett 
läkemedel som orsakar oförklarlig leverskada, och en cytokin som orsakar inflammation, 
leder till mer skada av isolerade leverceller än exponering för de två komponenterna var 
för sig. Vi testade den här hypotesen med hjälp av det sällan leverskadande läkemedlet 
diklofenak, det ”säkra” läkemedlet naproxen och den inflammationsorsakande cytokinen 
TNFα. Med hjälp av den här modellen kunde vi bevisa vår hypotes. Samtidig exponering av 
leverceller för diklofenak och TNFα ledde till fler döda leverceller jämfört med exponering 




heller i förhöjd celldöd. I samma kapitel presenterar vi också att den ökade celldöden 
beror på att diklofenak gör levercellerna mer känsliga för TNFα, snarare än det motsatta: 
att TNFα gör levercellerna mer känsliga för den skadliga effekten av diklofenak. TNFα 
är intressant på så sätt att den både kan skicka både överlevnads- och dödssignaler till 
den cell som är utsatt. Normalt sett väger överlevnadssignalerna över, men diklofenak 
hämmar dem på ett sådant sett att dödssignalerna tar över istället, vilket leder till ökad 
leverskada.
 Då levern bryter ner läkemedel i sitt försök att oskadliggöra och utsöndra dem, 
kan som redan sagts, skadliga biprodukter bildas. Dessa orsakar stress inne i cellerna. 
I Kapitel 3 beskriver vi att kombinationen av tre olika mikroskoperingsmetoder kan 
användas för att förutspå om ett läkemedel kommer att ha en leverskadande effekt 
eller inte. Läkemedel kan orsaka så kallad oxidativ stress. Flera läkemedel, inklusive 
de som kan medföra oförklarlig leverskada, testades för att se om de kunde orsaka 
sådan typ av stress med hjälp av ett mikroskop. Det visade sig att många läkemedel, 
inklusive diklofenak, orsakar just oxidativ stress. Det har redan bevisats av andra att 
detta kan hämma överlevnadssignalerna som skickas av den inflammatoriska cytokinen 
TNFα, så därför valde vi att också följa aktiveringen av det här svaret med hjälp av 
ett mikroskop. Det visade sig att bildandet av oxidativ stress i sig själv inte kunde 
förutspå om överlevnadssignalerna skulle hämmas. Däremot märkte vi att om de här 
två metoderna kombinerades med en tredje mikroskoperingsmetod som gör det möjligt 
att övervaka framkallandet av celldöd, så var det möjligt att säga att de läkemedel som 
båda orsakade oxidativ stress och hämmade TNFαs överlevnadssignaler, orsakade mer 
celldöd. Detta demonstrerar att en kombination av olika metoder kan användas för att 
förutspå möjligheten för ett läkemedel att orsaka leverskada.
 Eftersom metoden att övervaka uppkomsten av oxidativ stress själv inte kunde 
förutspå om mer celldöd skulle bli resultatet av samtidig exponering för läkemedel och 
TNFα, undersökte vi i Kapitel 4 om läkemedel också kan orsaka annan typ av stress. 
För att kunna svara på denna fråga använde vi oss av en metod som mäter genuttrycket 
hos celler vid en given tidpunkt och ett givet tillstånd. För denna analys använde vi oss 
återigen av diklofenak, men också av karbamazepin som också orsakar mycket celldöd 
om det kombineras med TNFα, och som också visats vara allvarligt leverskadande i 
sällsynta fall. Genom att använda en programvarubaserad analysmetod kunde vi 
bestämma vilken typ av stress som de här två läkemedlen orsakade i levercellerna. Vi 
kunde därmed bekräfta att både diklofenak och karbamazepin orsakar oxidativ stress, 
men det visade sig också att de påverkar uttrycket av gener som är involverade i cellens 
förmåga att producera nya proteiner. Speciellt en gen, EIF4A1, nådde högre nivåer i 
levercellerna efter behandling med diklofenak och karbamazepin. Om vi förhindrade 
uttrycket av den här genen kunde vi intressant nog förhindra de förhöjda nivåerna av 
celldöd som vi såg vid exponering för diklofenak/TNFα och karbamazepin/TNFα. Detta 
betyder att uttrycket av den här genen är ytterst viktigt för att cellerna ska dö under dessa 
förhållanden. EIF4A1 skulle möjligtvis kunna användas som en markör för ett läkemedels 
möjlighet att orsaka leverskada. Alternativt skulle en mikroskoperingsmetod, liknande 




ytterligare ett test för att förutspå blivande läkemedels förmåga att orsaka leverskada.
 I kapitel 2 beskrev vi att diklofenak hämmar överlevnadssignalerna från TNFα så 
att dödssignalerna väger över. Sättet som diklofenak gör detta på är genom att hämma 
transkriptionsfaktorn NF-κB som aktiveras till följd av TNFα-exponering, och på så sätt 
förhindrar uttrycket av de gener som är ansvariga för överlevnadssignalerna. I Kapitel 
5 undersökte vi systematiskt vilka gener som är ansvariga för att aktiveringen av NF-κB 
fungerar som den ska. NF-κB måste röra sig in och ut från kärnan av cellen för att se till 
att rätt sorts gener uttrycks vid rätt tidpunkt. Genom vår systematiska undersökning fann 
vi flera nya gener som är involverade i NF-κBs rörelsemönster och vi kunde också visa 
att de påverkar överlevnadssignalerna som skickas från TNFα vid samtidig exponering 
för läkemedel. Den utökade kunskapen som vi därmed fått om hur NF-κB regleras, är 
inte bara viktig för att förstå varför läkemedelsbiverkningar i levern uppstår, men den är 
också viktig i relation till tillväxt av celler och inflammation, vilka är två processer som är 
betydande i uppkomst av cancer och kroniskt inflammatoriska sjukdomar, till exempel 
reumatism.
 Sammanfattningsvis presenteras i den här avhandlingen, data som ger en djupare 
förståelse för varför läkemedelsbiverkningar uppstår i levern, med betoning på den roll 
inflammation har i processen. Kunskapen som vi har fått kan användas för att designa 
nya tester som läkemedelsföretag kan använda sig av för att bedöma nya läkemedels 
förmåga att orsaka leverskada. Dessutom tror jag att de data som presenteras i kapitel 5 






ADR   Adverse drug reaction
AIF   Apoptosis-inducing factor
AMAP   3’-hydroxyacetanilide
AMI   Amiodarone
AnxV   Annexin V
APAF1   Apoptosis protease-activating factor 1 
APAP   Acetaminophen; paracetamol
ATF4   Activating transcription factor 4
ATF6   Activating transcription factor 6
AUC   Area under curve
BAC    Bacterial artificial chromosome
CBZ   Carbamazepine
cFLIP   Cellular FLICE inhibitory protein
CHOP   C/EBP-homologous protein
CLZ   Clozapine
CYLD   Cylidromatosis
CYP450  Cytochrome P450
DCF   Diclofenac
DILI   Drug-induced liver injury
DMSO   Dimethyl sulfoxide
EIF   Eukaryotic translation initiation factor
ESI   Electrospray ionization
ER   Endoplasmic reticulum
FADD   Fas-associated death domain
GFP   Green fluorescent protein
GPX   Glutathione peroxidase
GRP   Glucose-regulated protein
GSH   Glutathione
GST   Glutathione S-transferase
HLA   Human leukocyte antigen
HMGB1  High mobility group box 1
HSP   Heatshock protein
IAP   Inhibitor of apoptosis protein
iDILI   idiosyncratic drug-induced liver injury
IFN-γ   Interferon-γ
IκB   Inhibitor of κB
IKK   IκB kinase
IL-1β   Interleukin-1β
IL-6   Interleukin-6
INH   Isoniazid
IPA®   Ingenuity Pathway Analysis
IRE-1α   Inositol-requiring enzyme 1α
JNK   c-Jun N-terminal kinase
Keap1   Kelch-like ECH-associated protein 1
KTZ   Ketoconazol
LDH   Lactate dehydrogenase
LPS   Lipopolysaccharide
MAPK   Mitogen activated protein kinases
MHC   Major histocompatibility complex
MOMP   Mitochondrial outer membrane permeabilization
mPT   Mitochondrial membrane permeability transition
MTX   Methotrexate
NEMO   NF-κB essential modifier
NF-κB   Nuclear factor κB
NFZ   Nefazodone
NIK   NF-κB inducing kinase
NPX   Naproxen
Nrf2   Nuclear factor-erythroid 2 (NF-E2)-related factor 2
NSAID   Non-steroidal anti-inflammatory drug
NTF   Nitrofurantoin
OFX   Ofloxacin
PARP   Poly (ADP)-ribose) polymerase
PERK   Protein kinase R-like ER kinase
PUMA   p53 up-regulated modulator of apoptosis
RAIDD   RIP-associated protein with a death domain
RIP   Receptor-interacting protein
RNAi   RNA interference
ROS   Reactive oxygen species
shRNA   short hairpin RNA
siRNA   short interfering RNA
SN   Simvastatin
SOD   Superoxide dismutase
SRXN1   Sulfiredoxin 1
TAK1   TGFβ-activated kinase 1
TGZ   Troglitazone
TNFα   Tumor necrosis factor α
TNFR   TNF receptor
TRADD   TNF receptor-associated death domain
TRAF   TNF receptor associated factor
UGT   Uridine diphosphate glucuronosyl-transferase
UPR   Unfolded protein response
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